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ABSTRACT 
 
MenD, a thiamin diphosphate (ThDP)-dependent enzyme, catalyzes the reaction from 
isochorismate (ISC) to 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate   
(SEPHCHC), and thus is also called SEPHCHC synthase. This conversion is the first 
committed step in the classical menaquinone (Vitamin K2) biosynthetic pathway, 
requiring 2-ketoglutarate (2-KG), ThDP and Mg
2+
. Since the biosynthesis of 
menaquinone is essential in some bacterial pathogens, for example Mycobacterium 
tuberculosis, MenD or the menaquinone pathway could be a target for drug development. 
The method for the kinetic assay of the MenD-catalyzed reaction was evaluated by 
comparing UV spectrophotomeric measurements and HPLC analysis. It was validated 
that the steady-state kinetics of the MenD-catalyzed reaction can be determined by 
monitoring UV absorbance of ISC at 278 nm and 300 nm. 
Phosphonate analogues of 2-KG were synthesized and assayed as inhibitors of the 
MenD reaction. It was found that the phosphonate analogues of 2-KG are competitive 
inhibitors with varied affinity for MenD. Of the inhibitors, monomethyl succinyl 
phosphonate (MMSP) was the most effective, with a Ki of 700 nM. However, the potent 
MenD inhibitors show no effectiveness against mycobacterial growth. 
An analogue of isochorismate, trans-(±)-5-carboxymethoxy-6-hydroxy-1,3-
cyclohexadiene-1-carboxylate ((±)-CHCD), was synthesized. The (+)-CHCD was found 
to be an alternative substrate for the MenD-catalyzed reaction. When CHCD was utilized 
in the MenD reaction, 5-carboxymethoxy-2-(3-carboxy-propionyl)-6-hydroxy-cyclohex-
2-enecarboxylate (CCHC) was isolated and characterized, which was believed to be the 
product of spontaneous isomerization of the SEPHCHC-like analogue. The kinetic study 
iii 
of MenD reaction using (±)-CHCD, in association with the kinetics pattern probed by 
MMSP, demonstrated for the first time that the MenD-catalyzed reaction has a Ping Pong 
bi bi kinetic mechanism. 
The analysis of sequence and structure of MenD from E. coli allowed the 
investigation of the active site residues and their catalytic functions by mutation of the 
individual residues. S32A, S32D, R33K, R33Q, E55D, R107K, Q118E, K292Q, R293K, 
S391A, R395A, R395K, R413K and I418L were prepared and assayed kinetically with 
respect to 2-KG, ISC, (±)-CHCD, ThDP and Mg
2+
. The values of 
a
mK  and 
a
m
a
cat Kk /  for 
the mutants, in comparison with that of wild type MenD, provide valuable insight into the 
catalytic mechanism of MenD. 
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1. INTRODUCTION 
 
1.1 Menaquinone biosynthesis 
 
      “Vitamin K” refers to a group of lipid-soluble compounds which have a 2-methyl-
1,4-naphthoquinone core structure containing a polyisoprene side chain at position 3 
(Figure 1.1). Vitamin K consists of a naturally occurring phylloquinone (vitamin K1), 
menaquinone (vitamin K2) and the synthetic menadione (vitamin K3). Phylloquinone is 
found in cyanobacteria and plants, whereas menaquinone is principally present in 
bacteria. In mammals, menaquinone is normally produced by the intestinal bacteria and 
acquired from nutrients. Vitamin K is a critical participant in the functionaliztion of some 
proteins. For instance, vitamin K is the cofactor of -glutamyl carboxylase, which 
catalyzes the posttranslational conversion of glutamate residues in certain proteins to -
carboxyglutamate. -Carboxyglutamate residues are good Ca2+ chelators with the 
essential involvement in various physiological processes such as blood coagulation and 
calcium metabolism
1
.  
 
Figure 1.1: Structures of Vitamin K. 
2 
 
Figure 1.2: Classical menaquinone biosynthetic pathway. 
 
After the extensive reviews on menaquinone biosynthesis by Bentley and 
Meganathan
2,3
, the exploration of the biosynthetic pathway and the enzymatic catalysis of 
individual steps are still of great interest. Studies on menaquinone biosynthesis have been 
carried out mainly on the pathway in E. coli, as well as in B. subtilis and M. tuberculosis. 
The menaquinone biosynthesis pathway starts with chorismate (Figure 1.2), an 
intermediate from the shikimate pathway. Chorismate is first isomerized to isochorismate 
(ISC) by MenF. Then upon the catalysis of MenD, isochorismate reacts with 2-
3 
ketoglutarate (2-KG) to form 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-
carboxylate (SEPHCHC). Over the steps catalyzed by a series of enzymes named from 
MenA to MenG, SEPHCHC is finally converted to menaquinone (vitamin K) through the 
intermediate 1,4-dihydroxy-2-naphthoate
3,4,5,6
.  
Recently, an alternative biosynthetic pathway of menaquinone was revealed in some 
microorganisms such as H. pylori and C. jejuni
7,8,9
. Compared with the classical pathway 
of menaquinone mentioned above, the alternative pathway branches at chorismate and 
proceeds through the intermediate 1,4-dihydroxy-6-naphthoate, unlike the 1,4-
dihydroxyl-2-naphthoate in classical pathway (Figure 1.2), to menaquinone (Figure 1.3).  
 
 
Figure 1.3: Alternative menaquinone biosynthetic pathway. 
 
Although a new biosynthetic pathway for production of menaquinone was identified 
in some microorganisms, the search for a microorganism which has both the classical 
pathway and the alternative pathway was unsuccessful
8
. Therefore, those microorganisms 
which were known to have the classical pathway, such as E. coli, B. subtilis and M. 
tuberculosis, will solely rely on the classical pathway. Especially for the pathogenic 
organism M. tuberculosis, in light of the fact that the biosynthesis of menaquinone in the 
human body does not exist, the classical pathway is an attractive target for anti-
tuberculosis drug development
4,10
. Some compounds aimed at the inhibition of 
4 
menaquinone biosynthesis have been synthesized and tested against the enzymes in the 
pathway
10,11,12
. For instance, an inhibitor of MenA showed significant growth inhibition 
against some drug-resistant Gram-positive bacteria
10
.  
 
1.2 The MenD-catalyzed reaction  
 
The conversion of isochorismate to 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclo- 
hexadiene-1-carboxylate (SEPHCHC) in the classical menaquinone pathway is catalyzed 
by the enzyme MenD. This enzyme hence is also called 2-succinyl-5-enolpyruvyl-6- 
hydroxy-3-cyclohexene-1-carboxylate (SEPHCHC) synthase. The reaction catalyzed by 
MenD is the first committed step in the biosynthetic route. As shown in Figure 1.4, the 
MenD-catalyzed reaction, requiring thiamine diphosphate (ThDP) and metal ion Mg
2+
 as 
cofactors, converts isochorismate (ISC) and 2-ketoglutarate (2-KG) to SEPHCHC and 
CO2.  
 
 
Figure 1.4: The overall MenD-catalyzed reaction. 
 
MenD has been long annotated  as SHCHC synthase
13,14
, but recently Guo and his 
coworkers revealed that MenD actually catalyzes the production of SEPHCHC, which 
was previously proposed to be an intermediate precursor of SHCHC, but was isolated and 
characterized in terms of the structure and stereochemistry
15
. The conversion to SHCHC 
5 
from SEPHCHC was then attributed to the catalysis of the known enzyme MenH, 
although a spontaneous non-enzymatic 2,5-elimination to form SHCHC can occur readily 
under mild conditions (Fig. 1.5)
5,6,15
.  
 
1.3 Mechanism of the MenD-catalyzed reaction  
 
 
Figure 1.5: Proposed mechanism of MenD-catalyzed reaction. 
 
Initially, MenD was postulated to undergo the ThDP-dependent 2-ketoglutarate 
decarboxylation with a mechanism identical to that in the 2-ketoglutarate decarboxylase 
6 
reaction
16,17
. With the determination of the complete sequence of the gene menD and the 
characterization of the expressed enzyme, it was found that the enzyme actually has both 
activities of decarboxylation and subsequent addition to isochorismate. A mechanism for 
the MenD-catalzyed reaction was later proposed by Bentley and Meganathan on the basis 
of the ThDP-dependent decarboxylation in 2-ketoglutarate decarboxylase reaction and 
subsequent Michael addition to isochorismate (see Figure 1.5. Ref. 3 and references cited 
therein).     
 
1.3.1 Activation of enzyme-bound thiamin diphosphate (ThDP)  
 
MenD belongs to the pyruvate oxidase (POX) family of ThDP-dependent enzymes, 
including the E1 subunit of E.coli pyruvate dehydrogenase (PDH-E1), yeast pyruvate 
decarboxylase (YPD), POX, acetohydroxyacid synthase (AHAS), benzoylformate 
decarboxylase (BFDC), and others. In the proposed mechanism of the MenD reaction 
(Figure 1.5), the catalytic sequence is initiated by the binding and activation of ThDP in 
the same way as other ThDP-dependent enzymes
18
. In this widely accepted mechanism, 
published for over 50 years, the C2-H of the thiazolium ring is abstracted and the 
resulting nucleophilic carbene attacks eletrophilic species such as the carbonyl of 2-
ketoacid
19,20
. The studies on the molecule ThDP and its role in enzymatic catalysis were 
extensively reviewed by Kluger and Tittmann
21
. More recently, a series of mini reviews 
about several different aspects of ThDP chemistry were published
22
. With the 
accumulation of the understanding on the chemistry of ThDP-dependent enzymes, 
especially the reports of many X-ray crystallographic structures for these types of 
enzymes, it was found that the activation of ThDP within the enzymatic environment is a 
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highly efficient and sophisticated process
18,21
. The aminopyrimidine moiety of ThDP 
(AP) substantially contributes the C2-H abstraction by taking two preliminary actions: (1) 
adopting a V-conformation between the pyrimidine and thiazolium rings over the 
bridging methylene so as to achieve the proximity of the C2-H and the 4'-NH2 (< 3.5 Å); 
(2) formation of the iminopyrimidine tautomer (IP) with the assistance from enzymes 
(Figure 1.6)
23
. Actually, the tautomerization not only enables production of the 
nucleophile, but also participates in the protonation of the incipient adduct of ThDP and 
2-ketoacid
23,24,25
.  
 
 
Figure 1.6: Tautomerization of enzyme-bound ThDP. 
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1.3.2 Post-decarboxylation intermediate and carboligation  
 
 
Figure 1.7: Stetter reaction and mechanism. 
 
The highly conserved mechanism in ThDP-dependent enzymes utilizing 2-
ketoacids involves formation of an “active aldehyde” by decarboxylation. The active 
species is now known as a conjugate pair of enamine and C2-carbanion (Figure 1.5). 
The delocalization of negative charge into the thiazolium ring reduces the energy of the 
resulting acyl carbanion in analogy to the non-enzymatic aldehyde-utilizing reactions 
catalyzed by cyanide or thiazolium, such as the Stetter reaction, in which the acyl 
carbanion undergoes 1,4-addition to a Michael acceptor (Figure 1.7)
26,27
. Putatively, in 
the MenD reaction, the carboligation step was achieved by the reaction between the post-
decarboxylation intermediate from 2-ketoacid and the Michael acceptor (here it is the 
,-unsaturated carboxylate moiety of isochorismate, Figure 1.5). Actually, this unusual 
9 
type of chemical reaction, with 2-ketoacid rather than aldehyde as the acyl anion donor, is 
not only present in enzymatic reactions. A closely analogous non-enzymatic reaction in 
aqueous solution was realized with thiamin catalysis (Figure 1.8)
28
. This is an interesting 
example of the inspiration for organic chemists from enzyme-catalyzed reactions. This 
Stetter-like reaction catalyzed by MenD has not yet been reported for other ThDP-
dependent enzymes.  
 
Figure 1.8: Non-enzymatic analogous Michael reaction of acyl carbanion
28
. 
 
1.3.3 Cleavage of ThDP  
 
Tautomerization and ionization in ThDP seem to be the central mechanism in the 
ThDP-dependent enzyme reactions. Nemeria et al. concluded, from the data of several 
enzymes extensively studied, that the post-decarboxylation ThDP-bound intermediates 
with tetrahedral structure of C2 atom exist in 1',4'-iminopyrimidinyl (IP) tautomeric 
forms, while the enamine intermediate may be in 4'-aminopyrimidinylAP or APH+) 
form because of the hybridization of C2 atom29. Furthermore, it was observed from 
many structural data that there are no residues identified as general acid-base catalysts to 
facilitate the proton transfer for the C2 oxygen and the structures show close proximity 
10 
of the 4'-N and C2 oxygen. This leads to a suggestion that ThDP itself, or more 
specifically, the 4'-N is responsible for the intramolecular proton shuttle as the only 
general acid-base in the entire catalytic cycle for ThDP enzymes
30
. Accordingly, in the 
MenD-catalyzed reaction mechanism, it is plausible that the cleavage of ThDP after the 
carboligation step with isochorismate proceeds by transferring a proton from the IP to 
regenerate the AP form of ThDP (Figure 1.9)
31
.  
 
 
Figure 1.9: Regeneration of ThDP from carboligation product. 
 
Although we can reasonably assume that the MenD reaction would share the 
mechanism for the pre-decarboxylation and some post-decarboxylation steps with other 
ThDP-dependent enzymes as noted above, we know little about how this fascinating 
enzyme works effectively. The elucidation of the catalytic details on the basis of the 
hypothetical mechanism above is a challenging task and will certainly add interesting and 
useful findings to the expanding database of ThDP-dependent enzyme reactions.  
 
1.4 The structural analysis of MenD  
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1.4.1 The overall structure of MenD  
 
Structurally, MenD belongs to the pyruvate oxidase (POX) family within the ThDP-
dependent superfamily. The enzymes of this family all catalyze the decarboxylation of 2-
ketoacids, therefore Duggleby named them as the “DC family”32. The first solved X-ray 
structure of ThDP-bound MenD from E. coli was reported by Hunter et al from Scotland 
in 2008
31
. Soon after, the structure of holo-MenD was published by Priyadarshi et al from 
Korea
33
.  
      
Figure 1.10: Diagram of EcMenD monomer (PDB: 2jla).  Domain in blue,  domain in green and  
domain in cyan, ThDP was shown in stick, and links between domains in red. Prepared using Pymol. 
 
      MenD from E. coli K12 (EcMenD) is composed of 556 amino acids and has a 
molecular mass of ~61.4 kDa. In practice, the overexpressed and purified EcMenD in our 
lab was shown in SDS-PAGE as a single band at around 64 kDa (with a fragment 
containing histidine-6 tag), reasonably consistent with the molecular mass of the 
12 
monomer. The gel filtration experiment demonstrated that the EcMenD exists mainly as a 
dimer with a predominant peak of 138 ± 4 kDa. Most other ThDP-dependent enzymes 
exist in dimeric or tetrameric forms
14,31,34
.  
Sequence alignments predict that the monomer of EcMenD consists of 3 domains 
with comparable sizes, typical of DC family enzymes
32
: the  domain, residues 1-180; 
the  domain, residues 181-341; and the  domain, residues 342-556. Furthermore, it was 
found that the central domain shows fewer conserved residues than the  and  domain14. 
The solved X-ray structure provided clear evidence in agreement with the sequence 
alignment-derived prediction of domains, albeit there is some modification and correction 
(the  domain: residues 1-~200, the  domain: residues 210-335, and the  domain: 340-
556). In general, the solved structure of EcMenD fully conforms to the secondary and 
tertiary features summarized by Duggleby for DC family enzymes
32
: (1) ThDP is bound 
at the interface of two subunits; (2) the N-terminal domain, also called the Pyr domain, 
binds to the pyrimidine ring of ThDP, while the C-terminal domain, also called the PP 
domain, from the partner subunit binds to the diphosphate of ThDP; (3) the shorter  
domain connects  the  domain and the  domain (Figure 1.10). 
The apo-EcMenD X-ray crystal structure, along with the CD and ITC measurements, 
demonstrate a more flexible conformation than holo-enzyme and that the thermal as well 
as structural stability are enhanced by the binding of ThDP
33
.  
 
1.4.2 Cofactor binding of MenD  
 
13 
As noted above, MenD was identified structurally as a member of DC family, the 
largest of five families of ThDP-dependent enzymes. The analysis and comparison with 
other structurally characterized enzymes will be highly instructive to recognize how the 
ligands bind to MenD. First of all, it is not surprising for MenD to have a highly 
conserved ThDP-binding motif in Pyr domain, which was long revealed as GDGX25-
30NN motif before the appearance of X-ray structures
35
. In EcMenD, this motif is present 
as Gly441-Asp442-X25-Asn468-Asn469, where a polar pocket is formed to coordinate to 
divalent metal ion (Mg
2+
 or Mn
2+
 in MenD), along with the diphosphate moiety of ThDP. 
Secondly, the ThDP was oriented to adopt the conserved "V conformation" in the active 
site (Figure 1.11).  
A structure of substrate-bound MenD has not been reported thus far, however Hunter 
et al. have built a model accommodating the putative post-decarboxylation intermediate 
of ThDP and 2-KG and the second substrate ISC
31
. It was predicted by the model that the 
carboxylate anions of the post-decarboxylation intermediate and ISC are balanced with 
basic residues such as arginines and lysines. The lack of the residues involved in 
removing the pyruvate side chain of ISC, as shown in the model, provides the structural 
evidence to support the assignment of MenD as SEPHCHC synthase. Although the model 
remains hypothetical, it is the foundation available at this time to guide mutagenesis of 
active-site residues. 
 
1.5 Analysis of active-site residues of MenD  
 
The crystal structures of MenD and comparison with other ThDP-depedent enzymes 
revealed certain active-site residues which are potentially implicated in subtrate and 
14 
cofactor binding. As shown in Figure 1.11, residues such as S32, R33, E55, R107, Q118, 
K292, R293, S391, R395, R413 and I418, surround the catalytic center where ThDP is 
located. Conceivably, these residues, all bearing active side chain functional groups, may 
play catalytically important roles in MenD catalysis.  
 
 
 
Figure 1.11: The stereo view of ThDP binding site (created from PDB file 2jla using Pymol). ThDP is 
bound at the interface of chain A and B. The ThDP is depicted as in chain B and surrounded by Ser32, 
Arg33, Glu55, Arg107, Gln118, Lys292, Arg293, Ser391, Arg395, Arg413 and Ile418. The residues and 
ThDP are colored as blue (N), red (O), orange (S), cyan (P). Carbons are colored differently as chain A 
(green), chain B (yellow) and ThDP (gray ). 
 
1.5.1 I418 residue and V conformation of ThDP  
 
In ThDP-dependent enzymes, the large hydrophobic side chain of highly conserved 
isoleucine is important to help the V conformation of ThDP when bound to enzymes, 
Glu55 A 
Ile418 B 
ThDP B Ser391 B 
Arg413 B 
Arg395 B 
Lys292 B 
Arg293 B 
Gln118 A 
Ser32 A 
Arg107 A 
Arg33 A 
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which is however not favored for ThDP in solution (Figure 1.12)
18
. In MenD, the highly 
conserved residue I418, as the I415 in PDC from S. cerevisiae
36
, points between 
thiazolium and pyrimidine ring of ThDP with its hydrophobic side chain (Figure 1.11). 
The V conformation and the resulting close contact of C2 and 4'-NH2 are essential to the 
activation of ThDP and the viability of the entire catalytic cycle, therefore the substitution 
of the residue I418 was expected to affect the reaction, maybe by the interference with 
the binding of ThDP. As a result, the mutation and kinetic measurement would 
demonstrate the effect and importance of this residue. 
 
 
Figure 1.12: V-conformation of ThDP bound to MenD (PDB: 2jla). 
 
1.5.2 E55 residue and tautomerization of ThDP  
 
The glutamate-aided tautomerization of ThDP seems to be a universal mechanism for 
all the ThDP enzymes so far
37
. The only exception was recently reported about the 
16 
enzyme glyoxylate carboligase (GCL)
38
. In the MenD structure, as observed for many 
other ThDP enzymes, a highly conserved glutamate residue was found with the 
carboxylate side chain in hydrogen bond distance to N1' of the AP ring in ThDP (Figure 
1.11). The protonation/deprotonation of N1' by glutamate presumably assists the 
tautomerization of AP (Figure 1.6 & Figure 1.9). As discussed earlier, it was recently 
recognized that the tautomerization and ionization of the AP plays a pivotal role in 
ThDP-dependent enzyme catalysis, and this glutamate residue is apparently critical in the 
process. The mutation of the glutamate to other residues, e.g. glutamine, invariably 
results in the reduction of catalytic activity for many ThDP-enzymes
37
. In our lab, the 
abolished activity of E55Q mutants of EcMenD was reported
14
.   
 
1.5.3 Thiazolium-proximal Q118 residue 
 
In the MenD structure as shown in Figure 1.11, glutamine 118 is located close to the 
thiazolium C2. Similarly, benzaldehyde lyase (BAL)
39
, AHAS, POX and N2-(2-
carboxyethyl)arginine synthase (CEAS)
40
 possess a similar thiazolium-proximal 
glutamine, whereas some other ThDP-dependent enzymes such as PDH-E1 and pyruvate 
decarboxylase (PDC) have histidine in the position. It was proposed that the polar 
glutamine residue serves to stabilize the enamine intermediate or transition state by 
electrostatic interaction rather than as a proton donor
30
. Therefore, the replacement of 
glutamine with glutamate was speculated to disrupt the interaction because of the 
incompatibility of the carboxylate anion of Glu and the negative charge-bearing -
carbanion/enamine intermediate. 
17 
 
1.5.4 S32 and S391 residues 
 
Alignment of the EcMenD sequence with benzoylformate decarboxylase (BFDC) 
demonstrated the S32 of MenD aligns with S26 of BFDC
41
. In the X-ray structure, S26 of 
BFD forms two hydrogen bonds with the carboxylate of the inhibitor (R)-mandelate, one 
by the hydroxyl of the side chain, the other one by the amidic nitrogen of the main chain. 
According to the kinetic study of mutant S26A, S26 was thought to be implicated in 
benzoylformate binding by interaction with the carboxylate anion and possibly also 
involved in other steps of the reaction pathway
42
. When BFDC was incubated with 
benzoylphosphonic acid, the enzyme was irreversibly inactivated. The X-ray structure 
clearly demonstrates that S26 is phosphorylated by accepting the phosphono group of 
benzoylphosphonic acid
43
. In the X-ray structure of EcMenD, S32 is in a position 
pointing to the putative substrate binding pocket (Figure 1.11), suggesting the S32 
residue may play a similar role in catalysis as the S26 residue in BFDC. 
Serine 391 in EcMenD is in close contact with the diphosphate tail (2.8 Å) and the 
thiazolium sulfur (2.8 Å) of ThDP, suggesting the hydrogen bonds form between them. 
Therefore, serine 391 was speculated to mainly contribute to the binding and orientation 
of ThDP. 
 
1.5.5 Basic residues in the active site 
 
In Hunter’s model simulating the substrate binding cavity, one striking feature is the 
presence of a series of basic residues (R33, R107, K292, R293, R395 and R413) 
18 
surrounding the substrates (Figure 1.11 and Figure 1.13)
31
. MenD's substrates, 2-KG and 
ISC, each bear two carboxylate anions, requiring a basic environment within MenD to 
accommodate these substrates. Among these 7 residues, K292 and R293 appear to be not 
close to the C2 of thiazolium, the presumed catalytic center. What roles these basic 
residues likely play in substrate binding and catalysis is of interest and kinetic assays of 
site-directed mutants will be informative to probe the active site of MenD. 
 
 
Figure 1.13: Hunter's model for substrates binding to EcMenD. The post-decarboxylation product of 2-KG-
ThDP covalent adduct and ISC are shown
44
. 
 
1.6 Analogues of ThDP 
 
In order to investigate binding and catalytic activity of ThDP, many ThDP analogues 
have been synthesized
45
. Because these analogues usually lack the functional ability of 
ThDP but still possess high affinity with ThDP-dependent enzymes, many of them are 
able to incapacitate ThDP-dependent reaction efficiently. Therefore in kinetic and 
19 
structural studies they are powerful mechanistic tools to probe substrate binding and 
snapshots of the elementary catalytic steps along the reaction sequences.  
 
 
Figure 1.14: ThDP and some analogues. 
 
Analogues of ThDP comprise the modifications to aminopyrimidine (AP) and 
thiazolium ring (Figure 1.14). For example, the 1'-deaza-ThDP and 3'-deaza-ThDP were 
used to test the role of N1' and N3' on AP ring on several enzymes. The results suggested 
that the N3' was not crucial for function. However, the replacement of N1' with carbon 
abolished the activity of catalysis, supporting the now widely accepted glutamate-aided 
tautomerization mechanism
46
. 3-Deaza-ThDP, synthesized by Hawksley et al
47
, is 
representative of the thiazolium-modified analogues. It demonstrated much tighter 
binding affinity to several ThDP-dependent enzymes including PDC and 2-KG 
dehydrogenase than ThDP and the binding is faster and irreversible
48
. The absence of 
positive charge in the ring makes 3-deaza-ThDP a good mimic of the neutral carbene 
20 
intermediate (Figure 1.5), probably accounting for the tighter binding in enzymes
45
. 3-
Deaza-ThDP has been applied mainly by Leeper’s group to obtain the co-crystallization 
of ThDP-dependent enzymes bound with substrates to provide the information of the 
active sites and catalysis
49
. Recently, a report about inhibition studies of oxythiamin and 
derivatives against MenD from S. aureus appeared
50
.  
 
1.7 Analogues of 2-ketoglutarate (2-KG) and isochorismate (ISC)  
 
1.7.1 Succinyl phosphonate analogues of 2-KG  
 
Since methyl acetylphosphonate (MAP), the first phosphonate analogue of pyruvate, 
was synthesized and used as inhibitor against pyruvate dehydrogenase (PDH-E1)
51
, 
phosphonate analogues of 2-ketoacids continue to be perhaps the most powerful 
mechanistic probe rather than as inhibitors in the studies of ThDP-dependent enzymes 
which utilize 2-ketoacids as substrates (Figure 1.15)
52,53
. The phosphonate moiety bearing 
one negative charge is an isoelectric mimic of the 1-carboxylate of 2-ketoacid, therefore 
phosphonate analogues of 2-ketoacids are able to bind to the enzymes and even form the 
covalent adducts with ThDP by following the enzymatic mechanism. Covalent adducts 
with phosphonate analogues are presumably inactive to subsequent steps because the 2-
ketophosphonate cannot undergo the decarboxylation-like dephosphorylation reaction to 
yield carbanion/enamine, which is the central intermediate for these types of reactions. 
As a result, the phosphonate analogues generally behave as dead-end inhibitors with 
respect to the ThDP-dependent enzymes utilizing decarboxylation step in catalysis. C2-
21 
phosphonolactylThDP (PLThDP) and C2-phosphonolmandelylThDP (PMThDP) were 
also chemically synthesized to simulate lactyl-ThDP (LThDP) and mandelyl-ThDP 
(MThDP), which are the tetrahedral intermediates formed by condensation of pyruvate or 
benzoylformate with ThDP in enzymes
54
.  
 
 
Figure 1.15: The intermediates and analogues of 2-KG and 2-KG-ThDP adduct. 
 
The phosphonate analogues of 2-ketoacids (pyruvate or benzoylformate) and their 
pre-decarboxylation intermediates (PLThDP or PMThDP) have been widely used in 
kinetic and structural studies of ThDP-utilizing enzymes such as pyruvate decarboxylase 
(PDC), pyruvate dehydrogenase E1 subunit (PDH-E1), pyruvate oxidase (POX), 
benzaldehyde lyase (BAL) or benzoylformate decarboxylase (BFDC).  
It was observed spectroscopically that the PLThDP exists in the form of the 1',4'-
iminopyrimidine (IP) tautomer when bound in the active sites of yeast PDC and E. coli 
PDH-E1, as does the tetrahedral intermediate C2-hydroxyethylThDP (HEThDP), 
suggesting that all the tetrahedral ThDP-bound covalent complex would prefer IP 
22 
tautomer
24,29
. At almost the same time, the structures of PLThDP-bound E. coli PDH-
E1
55
 and L. plantarum POX
56
 were solved and published. Several common structural 
features can be summarized from the two cases, and may be applicable for other ThDP-
dependent enzymes: (1) similar to the carboxylate of LThDP, the phosphonate moiety of 
PLThDP is perpendicular to its thiazolium ring in enzymes; (2) the C2-C bond of 
PLThDP, slightly distorted from the aromatic plane of thiazolium, may facilitate the 
subsequent decarboxylation; (3) the hydroxyl of C is in close contact with the 4'-N of 
pyrimidine, strongly supporting the existence of 1',4'-iminopyrimidine form and putative 
proton transfer between them; (4) the methoxy moiety of the phosphonate points towards 
the exit of the active site with no steric clash. That is to say, PLThDP is not only a good 
structural mimic of LThDP, but also a good functional analog in the catalytic steps prior 
to decarboxylation. 
Unlike the benzoylphosphonic acid that irreversibly inactivates BFDC by 
phosphorylation of the S26 residue
43
, methyl benzoylphosphonate (MBP) is a 
mechanism-based, competitive and reversible inhibitor of BFDC. MBP forms stable 
PMThDP with ThDP in BFDC in analogy to the covalent tetrahedral intermediate, as 
evidenced by circular dichroism, mass spectrometry and X-ray analysis
52,53
. Compared 
with the PLThDP in POX and PDH-E1, PMThDP shows almost the same structural 
features in the active site of BFDC. Benzaldehyde lyase (BAL) catalyzes the reversible 
conversion of (R)-benzoin to benzaldehyde. Interestingly, BAL was found to be able to 
catalyze the decarboxylation of benzoylformate and phenylpyruvic acid too
57
. This 
BFDC-like activity was thus used to incorporate MBP into the active site of BAL
39
. MBP 
was found to be a time- and concentration-dependent inactivator of BAL and indeed form 
23 
the pre-decarboxylation intermediate PMThDP in BAL as revealed in the X-ray structure. 
The PMThDP-bound structure in BAL allows the interpretation of the binding mode in 
BAL: Ala28, His29, Gln113, and Thr73 likely form the network of hydrogen bonds with 
PMThDP. The comparison of the binding mode of PMThDP in BAL and BFDC 
suggested low active-site residues conservation
52
.  
In studies of multienzyme 2-ketoglutarate dehydrogenase complex (KGDHC), several 
2-KG phosphonate analogues were synthesized (Figure 1.16)
58,59,60
. Because KGDHC 
catalyzes the ThDP-dependent decarboxylation of 2-KG, the 2-KG phosphonate analogue 
should form the pre-decarboxylation intermediate that cannot yield the critical 
carbanion/enamine conjugate. The inhibition studies with these phosphonates were 
carried out using KGDHC (isolated and in intact cells). The results indicated that the 
succinyl phosphonate (SP), monoethyl succinyl phosphonate (MESP) and carboxy ethyl 
ester succinyl phosphonate (CESP) are inhibitory to isolated brain KGDHC, whereas 
ethyl monoethyl succinyl phosphonate (EMSP) is ineffective. In cell system containing 
KGDHC, it was found that EMSP needs hydrolysis of the ester to obtain the inhibitory 
ability as SP and its monoethyl esters (MESP and CESP). Also, SP and its monoethyl 
esters were not effective inhibitors of other enzymes utilizing 2-KG or 2-ketoacids such 
as some aminotransferases and pyruvate dehydrogenase (PDH-E1), probably because 
those aminotransferases tested are not ThDP-dependent and PDH-E1 does not recognize 
2-KG as alternative substrate. In short, the SP and its derivatives demonstrated the 
inhibition against KGDHC in vitro and in vivo with specificity for KGDHC and 
preference over SP diethyl esters (EMSP). The results are apparently encouraging for the 
24 
further investigation of 2-KG-specific ThDP enzymes using 2-KG phosphonate 
analogues. 
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Figure 1.16: Some phosphonate analogues of 2-KG. 
 
1.7.2 Analogues of isochorismate  
 
Isochorismate (ISC) is known as an unstable intermediate compound in biosynthetic 
pathways
61
, such as in enterobactin biosynthesis. ISC can be prepared enzymatically from 
chorismate, although chemical synthesis of the racemic mixture was reported
62
. The 
absolute configuration of naturally occurring isochorismate was determined to be trans-
(+)-5S,6S-5-[(1-carboxyethenyl)oxy]-6-hydroxy-1,3-cyclohexadiene-1-carboxylic acid
63
. 
In studies of chorismate or isochorismate-utilizing enzymes, such as isochorismate 
synthase (IS) and isochorismatase, many analogues of isochorismate were prepared and 
used to investigate the catalysis
64
.  
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Among the analogues of isochorismate, the molecules with the core of the 1,3-
cyclohexadiene-1-carboxylate or benzoate are of greater interest due to the resemblance 
of the planar 1,3-cyclohexadiene conformation of isochorismate. Among 5,6-
dihydrobenzoate, (2S,3S)-2-amino-3-hydroxy-2,3-dihydrobenzoate and (2S,3S)-2,3-
dihydroxy-2,3-dihydrobenzoate (Figure 1.17), only (2S,3S)-2,3-dihydroxy-2,3-dihydro-
benzoate was accepted by MenD to undertake 1,4-addition reaction as isochorismate
65
. 
(2S,3S)-2,3-dihydroxy-2,3-dihydrobenzoic acid is the product from hydrolytic cleavage 
of isochorismate catalyzed by isochorismatase, therefore possessing the relative and 
absolute configuration of isochorismate. In that study, results suggested that the MenD-
catalyzed 1,4-addition is limited to 1,3-cyclohexadiene-1-carboxylate scaffold, and is 
tolerant of even lacking the enolpyruvyl side chain. 
 
 
Figure 1.17: Isochorismate and analogues. 
 
       In studies of salicylate synthase and isochorismatase, aromatic analogues of 
isochorismate were designed and found them to be potent inhibitors of the enzymes 
(Figure 1.18)
64,66
.  
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Figure 1.18: Aromatic analogues of isochorismate. 
 
In the MenD reaction, isochorismate is actually playing a pivotal role since it 
provides the structural core for the product SEPHCHC and presumably isochorismate 
gets involved in all mechanistic steps after decarboxylation in the catalytic mechanism 
(Figure 1.5). Substrate analogues bearing a cyclohexadiene or benzoate moieties might 
get involved in or inhibit the MenD reaction, adding to the toolbox of the mechanistic 
probes which are useful for elucidation of the MenD reaction mechanism. 
 
1.8 Steady-state kinetics and inhibition studies of enzymes 
 
Although X-ray crystallography and NMR structural analysis of proteins in solution 
became powerful recently and demonstrates advantages in some aspects, kinetic analysis 
of enzyme-catalyzed reaction represents the most common method of elucidating enzyme 
mechanism.  In an enzyme-catalyzed reaction, a progress curve (i.e. depletion of substrate 
or accumulation of product over time) usually has an early linear phase, ranging from 
seconds to several hundred seconds typically. Initial rate refers to the reaction rate at this 
linear phase when a steady state or quasi-equilibrium is reached. During the steady state, 
the concentrations of various enzymatic intermediates are in equilibrium and essentially 
constant. In classic textbooks of enzyme kinetics, for the simplest one substrate-one 
product reaction, the well-known Henri-Michaelis-Menten equation is introduced based 
on rapid equilibrium or steady-state approaches as equation 1.1:  
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where [S] is concentration of substrate, Vm is the maximal rate at very high (or 
"saturating") concentrations of substrate, and Km, refered to as Michaelis constant in the 
literature, is the substrate concentration when initial rate is half the Vm.  
Derivation of equation 1.1 gives some linear forms of the Henri-Michaelis-Menten 
equation which are especially useful under certain circumstances, for example the 
Lineweaver-Burk equation (also called double reciprocal equation, equation 1.2) and 
Hanes-Woolf equation (equation 1.3): 
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Among enzyme-catalyzed reactions, multisubstrate and multiproduct reactions are 
actually more common in biochemistry. In kinetic analysis of a multisubstrate system, if 
other substrate concentrations stay unchanged or are at the saturating level, the reaction 
canbe treated as a one-substrate reaction with respect to the substrate with the 
concentration varied.  Thus the principle, and the terms Vm and Km, as discussed above 
are still applicable in the case of a more complex enzyme reaction. 
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Inhibitors are small molecules able to reduce enzyme activity by interfering with 
turnover in different ways. The study of enzyme inhibition is always one of the most 
important topics in enzymology, and in the pharmaceutical industry. Inhibitors can 
interact with enzymes reversibly or irreversibly. According to different binding modes 
(Figure 1.19), reversible inhibitors are generally categorized as competitive, 
noncompetitive, uncompetitive and mixed (thorough discussion was presented in the 
book by Segel
67
): 
 1) Reversible competitive inhibitors can bind to the active sites of enzymes and thus 
block the binding of substrate in competitive manner;  
2) Noncompetitive inhibitors bind with equal affinity to both the free enzyme and the 
enzyme-substrate complex at a site distinct from substrate binding site; 
3) Uncompetitive inhibitors bind only to the enzyme-substrate complex at a site 
distinct from the substrate binding site, but not to free enzyme; 
4) Mixed inhibitors are less commonly encountered compared with the three types of 
inhibition above. Similar to noncompetitive inhibition, mixed inhibitors bind to both free 
enzyme and the enzyme-substrate complex at a site distinct from substrate binding site, 
but with different affinity. Thus noncompetitive inhibitor can be considered as a special 
case of mixed inhibitor.  
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Figure 1.19: Equilibrium scheme of substrate, inhibitor and enzyme. Ks is the dissociation constant of 
substrate (S) and enzyme (E); Kic is the dissociation constant of competitive inhibitor (I) and enzyme (E); 
Kiu is the dissociation constant of uncompetitive inhibitor (I) and enzyme-substrate complex (ES). 
 
The type of inhibition can be determined graphically by a number of methods. A 
Lineweaver-Burk plot is a commonly encountered means of diagnosing inhibition type. 
At several fixed inhibitor concentrations, the double-reciprocal plot of 1/υ versus 1/[S] 
usually yields overlaying straight lines in a pattern that is characteristic of the inhibition 
type. As shown in Figure 1.20, for competitive inhibitors, the straight lines intersect at 
their y intercepts (A); for noncompetitive inhibitors, lines intersect at x intercepts (B); for 
uncompetitive inhibitors, plot appears as a series of parallel lines (C) and mixed 
inhibitors, lines intersect above or below x axis dependent on the binding affinity to free 
enzyme and enzyme complex(D). 
Alternatively, a combination of Dixon plot
68
 (1/υ versus [I] at several fixed [S]) and 
Cornish-Bowden plot
69,70,71 
( [S]/υ versus [I] at several fixed [S])  can conveniently give 
the inhibition constant Ki (dissociation constant for enzyme-inhibitor (EI) complex) and 
inhibition type. As shown in Figure 1.21, for a competitive inhibitor, a Dixon plot gives 
directly the value of Kic, while a Cornish-Bowden plot appears as parallel lines (A); for a 
mixed inhibitor (noncompetitive inhibitor is a special case of mixed inhibitor), although a 
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Dixon plot appears the same as for a competitive inhibitor, a Cornish-Bowden plot shows 
intersecting lines. In addition, the two plots give value of Kic and Kiu respectively (B); for 
uncompetitive inhibitor, a Dixon plot shows parallel lines and  a Cornish-Bowden plot 
appears as intersecting lines. In short, a combination of Dixon and Cornish-Bowden plots 
provide a straightforward method to graphically determine inhibition type and inhibition 
constants, therefore this approach also has wide application in the kinetic study of 
enzyme inhibition.  
 
[I] decrease1/
1/[S]
[I] decrease
1/
1/[S]
(A) Competitive inhibitor
[I] decrease
1/
1/[S]
(B) Noncompetitive inhibitor
[I] decrease
1/
1/[S]
(C) Uncompetitive inhibitor (D) Mixed inhibitor  
Figure 1.20: Inhibition patterns of lines in Lineweaver-Burk plots. (A) Competitive inhibitor; (B) 
noncompetitive inhibitor; (C) uncompetitive inhibitor; (D) mixed inhibitor. 
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[S] increase1/
[S] decrease
[S]/
[I] [I]
Dixon plot, competitive Cornish-Bowden  plot, competitive
-Kic
1/Vm
[S] increase
1/
[I]
Dixon plot, mixed Cornish-Bowden  plot, mixed
-Kic
1/Vm
[S]/
[I]
-Kiu
(A)
(C)
[S] decrease
[S] increase
1/
[I]
(B)
Dixon plot, uncompetitive
[I]
-Kiu
[S]/
[S] decrease
Cornish-Bowden  plot, uncompetitive  
Figure 1.21: Dixon plot and Cornish-Bowden plot for diagnosing inhibition type. 
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1.9 Kinetic mechanism of bireactant biproduct (bi bi) reaction  
 
A general nomenclature is utilized to depict the number of substrates and products 
in an enzyme-catalyzed reaction. For example, a reaction utilizing two substrates and 
producing two products is referred to as bi bi reaction; bi uni reaction means two 
substrates react, producing a single product.  
 
 
Figure 1.22: Bi bi reaction mechanisms. (A) Random ordered; (B) compulsory ordered; (C) ping-pong 
mechanism. 
 
In the study of multisubstrate and multiproduct enzymatic reactions, the order in 
which substrates bind to the enzyme and products are released from the enzyme complex 
is of interest in that it is the reflection of reaction mechanism catalyzed by enzymes. In 
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the case of bi bi reaction ( Q   P  B A  ), there are basically two types of mechanism: 
ternary-complex and ping-pong. 
1) In a ternary-complex mechanism, two substrates bind to the enzyme in random 
order (random ordered bi bi reaction, Figure 1.22A) or in compulsory order (compulsory 
ordered bi bi reaction, Figure 1.22B). As illustrated in Figure 1.22, regardless of which 
substrate binds first, the ternary complex EAB is formed and turned over to product P and 
Q. The double reciprocal plots (Fig. Figure 1.23, 1/ versus [A] at several fixed [B], vice 
versa) for both ternary-complex mechanisms appear as intersecting set of lines, therefore 
one cannot distinguish random and compulsory ordered mechanisms by this method; 
2) Ping-pong bi bi reaction is also called double displacement reaction. As illustrated 
in Figure 1.22C, product P is released before second substrate B binds to the enzyme (i.e. 
substrate B cannot bind to free enzyme). According to the steady-state approach, the 
initial rate equation for a ping-pong bi bi reaction can be obtained (equation 1.4).    
                                                                                                      
]A][B[]B[]A[
]B][A[
A
m
B
m
m


KK
V
υ                      (1.4) 
 
where Km
A
 and Km
B
 are the Michaelis constants for substrate A and B respectively. The 
double reciprocal plot for ping-pong bi bi reaction yields a set of parallel lines when one 
substrate concentration is varied at several constant concentrations of the other substrate 
(Figure 1.23B), distinct from the pattern of intersecting lines for ternary-complex bi bi 
reaction. 
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[B] increase
1/
1/[A]
(A)
1/
[B] increase
1/[A]
(B)
 
Figure 1.23 Double reciprocal plots for bi bi reactions. (A) Ternary-complex mechanism; (B) ping-pong 
mechanism. 
 
As mentioned above, a double reciprocal plot cannot distinguish two different 
mechanisms involving ternary-complex. However, if there is product inhibition or dead-
end competitive inhibition of one substrate in the bi bi enzymatic reaction, specific 
inhibition patterns for different mechanisms can be observed from kinetic analysis when 
one substrtate concentration is varied and the other substrate is fixed at non-saturating 
concentration (~ apparent Km). The relationships in the case of inhibition patterns in the 
case of bi bi reaction were derived and summarized elsewhere (e.g. by Segel
67
) as Table 
1.1. According to Table 1.1, a dead-end competitive inhibitor can be used to not only 
distinguish compulsory and random ternary-complex mechanisms, but also determine the 
substrate binding order in a compulsory ordered reaction. Futhermore, a ping-pong 
mechanism has a specific inhibition pattern which allows the differentiation from ternary-
complex mechanism, supplementary to the aforementioned double reciprocal plot 
method. 
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Table 1.1: Inhibition patterns of dead-end competitive inhibitors for bi bi reaction ( Q  P  B  A  )
72
. 
Reaction mechanism 
Competitive 
inhibitor for 
substrate 
                   Inhibition pattern 
For varied [A] For varied [B] 
Random ordered 
A 
B 
Competitive 
Noncompetitive 
Noncompetitive 
Competitive 
Compulsory ordered 
(A binds first) 
A 
B 
Competitive 
Uncompetitive 
Noncompetitive 
Competitive 
Compulsory ordered 
(B binds first) 
A 
B 
Competitive 
Noncompetitive 
Uncompetitive 
Competitive 
Ping-pong 
(Double displacement) 
A 
B 
Competitive 
Uncompetitive 
Uncompetitive 
Competitive 
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1.10 Objectives of research 
 
      When this project was started, MenD was still described as a SHCHC synthase as the 
first committed enzyme in the classical biosynthesis of vitamin K2 (menaquinone)
14
. 
However, subsequent studies showed that MenD actually catalyzes the formation of 
SEPHCHC
5,6,15
 and the X-ray structures of apo- and holo-MenD from E. coli also 
appeared in the literature
31,33
. These reports represent a revolutionary advance in the 
enzymological research of MenD. However, the mechanism of the MenD-catalyzed 
reaction remains hypothetical; the systematic kinetics and structure-function relationships 
have not been explored.  
       In order to elucidate the enzymatic mechanism of MenD and confirm the suggestion 
that MenD is an SEPHCHC synthase, and on the basis of speculation as shown in Figure 
1.5, some mechanistic probes were designed as structural analogues of the substrates and 
used to investigate the kinetics of the MenD reaction. Futhermore, point mutations of 
relevant residues in active site could be conducted on the basis of the published X-ray 
structure and sequence alignments with homologous enzymes. The kinetic studies of a 
series of MenD mutants in comparison with wild type enzyme could reveal the roles of 
specific residues and will lead to improving our understanding of the structure-function 
relationships within this enzyme. 
In summary, the specific objectives of this work were as follows: 
1) Validation of the method for kinetic assay of the MenD-catalyzed reaction using 
spectrophotometric measurement and HPLC analysis;  
2) Determination of the steady-state kinetics of the MenD-catalyzed reaction; 
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3) Synthesis of succinyl phosphonate analogues of 2-KG and determination of 
inhibition constants; 
4) Synthesis of ISC analogues and investigation of the MenD-catalyzed reaction 
using the analogues; 
5) Investigation of the kinetic mechanism of the MenD-catalyzed reaction using the 
analogues of 2-KG and ISC; 
6) Point mutation of the active site residues of MenD and determination of the 
kinetics of the MenD mutants. 
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2. EXPERIMENTAL 
 
2.1 Chemical synthesis 
 
Experiments that required anhydrous conditions were performed under an inert 
atmosphere of either dry argon or nitrogen gas.  Glassware was dried overnight in an 
oven set at 120 C and assembled under a stream of inert gas.  All reagents were obtained 
from commercial suppliers (Sigma-Aldrich, Alfa-Aesar, VWR and TCI) and used 
without further purification unless indicated otherwise. Dichloromethane and acetonitrile 
were freshly distilled from calcium hydride. Thin layer chromatography (TLC) was 
performed on precoated silica gel plates (Merck Kieselgel 60F254, 0.25 mm thickness) 
and visualized with phosphomolybdic acid-cerium sulfate reagent (solution prepared as: 
conc. H2SO4 (9 ml), phosphomolybdic acid (10 g), Ce(SO4)2 (2.5 g) and water (added up 
to 250 ml)), iodine vapors, ninhydrin (1.5 % w/v solution in tert-butanol) or ultraviolet 
light at 254 nm. Flash chromatography was performed using Merck silica gel 60 (230-
400 mesh).  All NMR spectra for 
1
HNMR, 
13
CNMR, COSY, HMBC, HMQC, and JMOD 
were acquired using a Bruker 500 MHz spectrometer with samples dissolved in the 
appropriate deuterated solvents. Chemical shifts for 
1
HNMR and 
13
CNMR were reported 
in ppm downfield from tetramethylsilane and determined by the residual solvent proton 
signal; chemical shifts of 
31
PNMR were reported in ppm downfield from 85% phosphoric 
acid as standard. Mass spectrometry was performed on a mass spectrometer API Qstar 
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XL pulsar hybrid LC/MS/MS system with Agilent 1100 series HPLC or an integrated 
syringe pump. Melting points were measured on a Gallencamp melting point apparatus 
and are not corrected.  The NMR and high-resolution mass spectrometry were determined 
in the Saskatchewan Structural Sciences Centre (http://www.usask.ca/sssc/). Specific 
rotations ([]D) are the average of 5 determinations for one solution at ambient 
temperature using a 1 ml, 10 cm cell; the units are deg dm
-1
cm
3
g
-1
, the concentrations (c) 
are reported in g/100 ml, and the values are rounded to reflect the accuracy of the 
measured concentrations (the major source of error). 
 
2.1.1 Succinic acid monobenzyl ester 
 
 
 
     This compound was prepared as described in the literature
73
. Succinic anhydride (6.0 
g, 60 mmol), benzyl alcohol (5.4 g, 50 mmol) and DMAP (0.3 g, 2.5 mmol) were 
refluxed in anhydrous THF (30 ml) under argon overnight. White powder was 
recrystallized from ethyl acetate and hexane (9.1 g, yield: 87%). The 
1
HNMR and 
13
CNMR spectra are consistent with that of the literature. 
 
1
H NMR (CDCl3):  2.71 (m, 4H), 5.16 (s, 2H), 7.36 (m, 5H);  
13
C NMR (CDCl3):  28.9, 28.9, 66.7, 128.2, 128.3, 128.6, 135.7, 171.8, 171.2. 
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2.1.2 Benzyl alkyl diester of succinyl phosphonate  
 
 
 
      At 0 C, succinic acid monobenzyl ester (6.25 g, 30.0 mmol) was suspended in 25 ml 
dry CH2Cl2 containing 1 drop of DMF. Oxalyl chloride (16.5 ml, 2.0 M in DCM, 33.0 
mmol) was added dropwise under argon atmosphere. After stirring at ambient 
temperature for 1 hour, the reaction mixture became a clear solution. After 30 minutes, 
the volatiles were rotary evaporated (40 C) to yield a brown oily residue (6.80 g, ca. 
100%). This residue was used without further purification. To 3.50 g (15.4 mmol) of the 
residue was added trimethyl phosphite (1.82 ml, 15.4 mmol) slowly at 0 C; bubbles 
evolved immediately. After stirring at ambient temperature for 2 hours, the mixture was 
concentrated in vacuo to give brown oil (2a, 4.63 g, ca. 100%). The product was used 
next without further purification.  
 
1
H NMR (CDCl3, 500MHz):  2.69 (t, J = 6.0 Hz, 2 H) 3.15 (td, J = 6.5 Hz, 2.0 Hz, 2 H), 
3.84 (d, J = 10.5 Hz, 3H), 3.86 (d, J = 10.5 Hz, 3H), 5.11 (s, 2 H), 7.33 (m, 5 H); 
31
P NMR (CDCl3, 200 MHz):  -1.0;
  
HRMS (ESI
+
): calcd for C13H18O6P 301.0835, found 301.0840 ([M+H]
+
); calcd for 
C13H17O6NaP 323.0654, found 323.0656 ([M+Na]
+
).  
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Benzyl diethyl ester of succinyl phosphonate (2b) was prepared as 2a in ca. 100% yield. 
 
2b: 
1
H NMR (CDCl3, 500 MHz):  1.36 (m, 6 H), 2.68 (t, J = 6.5 Hz, 2 H), 3.17 (td, J = 
6.5 Hz, 2.3 Hz, 2 H), 4.21 (m, 4 H), 5.11 (s, 2 H), 7.34 (m, 5 H);  
31
P NMR (CDCl3, 200 MHz):  -1.5; 
HRMS (ESI
+
): calcd for C15H22O6P 329.1148, found 329.1141([M+H]
+
). 
 
Benzyl diisopropyl ester of succinyl phosphonate (2c) were prepared as 2a in ca. 100% 
yield 
 
2c: 
1
H NMR (CDCl3, 500 MHz):  1.36 (m, 12 H), 2.67 (t, J = 6.5 Hz, 2 H), 3.18 (td, J = 
6.5 Hz, 2.5 Hz, 2 H), 4.77(m, 2 H), 5.13 (s, 2 H), 7.34 (m, 5 H);  
31
P NMR (CDCl3, 200MHz):  -4.5;  
HRMS (ESI
+
): calcd for C17H26O6P 357.1461, found 357.1469 ([M+H]
+
). 
 
2.1.3 Benzyl monoester succinyl phosphonate  
 
 
 
The preparation followed the literature method with slight modification
74
. Triester 2a 
(2.60 g, 8.66 mmol) was dissolved in dry acetonitrile (11 ml), and then the solution was 
stirred with anhydrous LiBr (0.75 g, 8.66 mmol). The resulting yellow solution was 
heated to 70 C (oil bath) under argon atmosphere. A white precipitate formed within 10 
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minutes and was vacuum filtered after 20 hours, then washed with dry acetonitrile and 
anhydrous diethyl ether. White powder was obtained (benzyl monomethyl succinyl 
phosphonate, BMMP, 3a, 2.10 g, 83%). 
 
1
H NMR (D2O, 500 MHz):  2.69 (t, J = 6.0 Hz, 2 H), 3.16 (td, J = 6.0 Hz, 2.0 Hz, 2 H), 
3.55 (d, J = 10.5 Hz, 3 H), 5.16 (s, 2 H), 7.43 (m, 5 H);  
13
C NMR (D2O, 125 MHz):  27.4 (d, Jc-p = 4.5 Hz), 38.5 (d, Jc-p = 49.0 Hz), 53.3 (d, Jc-p 
= 6.0 Hz), 67.5, 128.6, 129.0, 129.2, 129.5, 135.9, 175.1, 219.2 (d, Jc-p = 165.5 Hz);  
31
P NMR (D2O, 200 MHz):  -0.5; 
HRMS(ESI
-
): calcd for C12H14O6P 285.0533, found 285.0531 ([M-Li]
-
); (ESI
+
):  calcd for 
C12H14LiO6PK 331.0319, found 331.0327 ([M+K]
+
). 
 
Benzyl monoethyl succinyl phosphonate (BMEP, 3b) was prepared as 3a from 2b. 
 
3b (yield: 70%): 
1
H NMR (D2O, 500 MHz):  1.21 (t, J = 7.1 Hz, 3 H), 2.67 (t, J = 6.2 
Hz, 2 H), 3.17 (td, J = 6.0 Hz, 2.0 Hz, 2 H), 3.87 (m, 2 H), 5.16 (s, 2 H), 7.43 (m, 5 H); 
13
C NMR (D2O, 125 MHz):  16.3 (d, Jc-p = 5.5 Hz), 27.5 (d, Jc-p = 4.5 Hz), 38.4 (d, Jc-p = 
49.0 Hz), 63.0 (d, Jc-p = 6.0 Hz), 67.5, 128.6, 129.0, 129.2, 135.9, 175.2, 219.6 (d, Jc-p = 
166.0 Hz); 
31
P NMR (D2O, 200 MHz):  -1.5;  
HRMS(ESI
-
): calcd for C13H16O6P 299.0690, found 299.0688([M-Li]
-
).  
 
Benzyl monoisopropyl succinyl phosphonate (BMIP, 3c) was prepared as 3a from 2c. 
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3c (yield: 62%): 
1
H NMR (CDCl3, 500 MHz):  1.21 (d, J = 6.0 Hz, 6 H), 2.67 (t, J = 6.5 
Hz, 2 H), 3.18 (d, J = 6.5 Hz, 2 H), 4.39 (m, 1 H), 5.16 (s, 2 H), 7.43 (m, 5 H); 
13
C NMR (CDCl3, 125 MHz): 23.7, 23.8, 27.5 (d, Jc-p = 4.5 Hz), 38.4 (d, Jc-p = 
49.0Hz), 67.5, 71.5 (d, Jc-p = 6.0 Hz), 128.6, 128.6, 128.9, 129.2, 136.0, 175.2, 219.9 (d, 
Jc-p = 167.5 Hz); 
31
P NMR (CDCl3, 200 MHz):  -3.0.  
HRMS(ESI
+
): calcd for C14H19LiO6P 321.1073, found 321.1082 ([M+H]
+
). 
 
2.1.4 Monoester succinyl phosphonate 
 
 
 
Compound 3a (0.50g, 1.7 mmol) was dissolved in a mixture of EtOAc (10 ml) and 
formic acid (3 ml) and was hydrogenated with 10% Pd/C (50 mg) using a balloon 
technique. After 16 h, the reaction mixture was vacuum filtered through celite and the 
filter cake was washed with EtOAc and water. The filtrate was evaporated to give pale 
yellow oil (0.41 g). This material was dissolved in water (1-2 ml) and passed through a 
column of Dowex 50W-X8 (Na
+
) by eluting with deionized water. The desired fractions 
were pooled and evaporated (40 C) in vacuo to give pale yellow oily residue. The 
residue was triturated in acetone and dried in vacuo. Pale yellow powder was obtained 
(monomethyl succinyl phosphonate, MMSP, 4a, 0.35 g, 85%). 
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1
H NMR (D2O, 500 MHz):  2.44 (t, J = 6.5 Hz, 2H), 3.08 (t, J = 6.5 Hz, 2H), 3.63 (d, J 
=10.5 Hz, 3H);  
31
P NMR (D2O, 200 MHz):  0.0;  
HRMS(ESI
+
): calcd for C5H8O6Na2P 240.9848, found 240.9853([M+H]
+
) 
 
Monoethyl succinyl phosphonate (MESP, 4b) was prepared as 4a from 4b. 
 
4b (yield: 60%): 
1
H NMR (D2O, 500 MHz):  1.26 (t, J = 7.0 Hz, 3 H), 2.66 (t, J = 6.1 
Hz, 2 H), 3.17 (td, J = 6.2 Hz, 1.7 Hz, 2 H), 4.0 (m, 2 H);  
31
P NMR (D2O, 200 MHz): -1.5; 
HRMS(ESI
+
): calcd for C6H10O6Na2P 255.0010, found 255.0010([M+H]
+
) 
 
Monoisopropyl succinyl phosphonate (MISP, 4c) were prepared as 4a from 4c. 
 
4c (yield: 87%): 
1
H NMR (D2O, 500 MHz);  1.26 (d, J = 7.0 Hz, 6 H), 2.40 (t, J = 6.0 
Hz, 2 H), 3.09 (t, J = 6.0 Hz, 2 H), 4.46 (q, J = 7.0 Hz, 1 H); 
31
P NMR (D2O, 200 MHz):  -2.47; 
HRMS(ESI
+
): calcd for C7H12O6Na2P 269.0161, found 269.0163 ([M+H]
+
); calcd for 
C7H13O6NaP 247.0341, found 247.0321([M-Na+2H]
 +
). 
 
2.1.5 Succinylphosphonate 
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Compound 2a (4.63 g, 15.4 mmol) and LiBr (2.94 g, 33.9 mmol) were dissolved in 
dry acetonitrile (30 ml), and the reaction mixture was heated to reflux under argon for 72 
hours. The precipitate was filtered and washed with dry acetonitrile and anhydrous ether. 
White powder was yielded (5, 4.16 g, 95%). Compound 6 (succinylphosphonate, SP) was 
then prepared from 5 as 4a-c. 
 
5 (yield: 95%): 
1
H NMR (D2O, 500 MHz):  2.61 (t, J = 6.3 Hz, 2 H), 3.16 (td, J = 5.9 
Hz, 1.2 Hz, 2 H), 5.17 (s, 2 H), 7.43 (m, 5 H);  
13
C NMR (D2O, 125 MHz):  27.8 (d, Jc-p = 3.6 Hz), 38.1 (d, Jc-p = 44.0 Hz), 67.4, 128.7, 
128.9, 129.2, 136.1, 176.0, 226.4 (d, Jc-p = 158.4 Hz); 
31
P NMR (D2O, 200 MHz):  -0.59. 
 
6 (yield: 85%): 
1
H NMR (D2O, 500 MHz):  2.35 (t, J = 7.1 Hz, 2 H), 3.01 (td, J = 7.2, 
1.1 Hz);  
HRMS(ESI
-
):  Calcd for C4H6O6P 180.9907, found 180.9911([M-3Na+2H]
-
). 
 
2.1.6 Methyl monomethyl succinylphosphonate and ethyl monomethyl 
succinylphosphonate 
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Methyl monomethyl succinylphosphonate (MMMP, 9a) was prepared from 7a
75
 and 
trimethyl phosphite via 8a as 3a-c. 
 
9a (yield: ):
1
H NMR (D2O, 500 MHz):  2.66 (t, J = 6.0 Hz, 2 H), 3.14 (t, J = 6.0 Hz, 2 
H), 3.60 (d, J = 10.5 Hz, 3 H), 3.68 (s, 3 H); 
13
C NMR (D2O, 125 MHz):  27.1 (d, Jc-p = 4.0 Hz), 38.4 (d, Jc-p = 49.0 Hz), 52.7, 53.3 
(d, Jc-p = 6.0 Hz), 176.0, 219.4 (d, Jc-p = 165.7 Hz) 
31
P NMR (D2O, 200 MHz):  -0.45; 
HRMS(ESI
-
):  Calcd for C6H10O6P 209.0221, found 209.0215 ([M-Li]
-
). 
 
Ethyl monomethyl succinylphosphonate (EMMP, 9b) was prepared as 9a. 
 
9b (yield: ):
 1
H NMR (D2O, 500 MHz): 1.23 (t, J = 7.0 Hz, 3 H), 2.64 (t, J = 6.0 Hz, 2 
H), 3.15 (t, J = 6.0 Hz, 2 H), 3.61 (d, J = 10.5 Hz, 3 H), 4.14 (q, J = 7.0 Hz, 2 H); 
13
C NMR (D2O, 125 MHz):  13.6, 27.5 (d, Jc-p = 4.5 Hz), 38.5 (d, Jc-p = 36 Hz), 53.3 (d, 
Jc-p = 6.0 Hz), 62.3, 175.6, 219.4 (d, Jc-p = 165.7 Hz); 
31
P NMR (D2O, 200 MHz):  -0.47. 
HRMS(ESI
-
):  Calcd for C7H12O6P 223.0377, found 223.0367 ([M-Li]
-
). 
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2.1.7 Methyl acetylphosphonate and monomethyl butyrylphosphonate 
 
 
 
Methyl acetylphosphonate (MAP, 10a) was prepared from acetyl chloride as 
described in the literature
74
.  
 
10a: 
1
H NMR (D2O, 500 MHz):  2.43 (d, J = 5.0 Hz, 3 H), 3.62 (d, J = 10.5 Hz, 3 H). 
 
 
 
Monomethyl butyrylphosphonate (MMBP, 10b) was prepared from butyryl chloride 
as described in literature
74
.  
 
10b: 
1
H NMR (D2O, 500 MHz):  0.89 (t, J = 7.5 Hz, 3 H), 1.60 (m, 2 H), 2.80 (d, J = 
7.5 Hz, 2 H), 3.62 (d, J = 10.0 Hz, 3 H); 
13
C NMR (D2O, 125 MHz):  13.2, 16.4 (d, Jc-p = 3.0 Hz), 45.4 (d, Jc-p = 45.5 Hz), 53.2 
(d, Jc-p = 6.0 Hz), 222.6 (d, Jc-p = 160.3 Hz); 
31
P NMR (D2O, 200 MHz):  0.16; 
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HRMS (ESI
-
):  Calcd for C5H10O4P 165.0322, found 165.0362 ([M-Li]
-
). 
 
2.1.8 -Benzoylpropionic acid and 1-phenyl-1,4-butanediol 
 
 
-Benzoylpropionic acid (compound 11) was prepared as described in the 
literature
76,77
. The mixture of succinic anhydride (6.8 g, 68 mmol) and anhydrous AlCl3 
(20.0 g, 0.15 mol) in dry benzene (30 ml) was heated up to reflux for 30 min. After 
cooled to room temperature, the reaction mixture was poured in a mixture of conc. HCl 
(10 ml) and ice (100 g). White precipitate was formed with stirring and collected by 
filtration. The product cake was washed with cold water and petroleum ether. After dried 
under high vacuum, white powder was obtained (11.5 g, Yield: 95%). The 
1
HNMR 
spectrum is consistent with that of the literature. 
 
1
H NMR (CDCl3):  2.82 (t, 2H, J = 6.51 Hz, CH2CO2H), 3.32 (t, 2H, J = 6.51 Hz,  
COCH2), 7.47 (t, 2H, J = 7.66 Hz,Ph-H), 7.59 (t, 1H, J = 7.22 Hz,Ph-H), 7.99 (d, 2H, J = 
7.88 Hz, Ph-H).  
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1-Phenyl-1,4-butanediol (12) was prepared as described in literature with a modified 
work-up and purification
78
. The resulting white powder (crude product) was washed with 
CHCl3 on a filter and the collected filtrate was evaporated to give yellow oily residue. 
The residue was purified with dry-column flash chromatography (30-100% ethyl 
acetate/hexane) to give 12 as a colorless liquid (yield: 85%, lit. 93%). 
 
1
H NMR (CDCl3):  1.66 (m, 2H, CH2), 1.84 (m, 2H, CH2), 2.76 (br, 2H, 2OH), 3.65 (m, 
2H, CH2OH), 4.70 (td, J = 6.28, 2.16 Hz, 1H, CHOH), 7.24-7.35 (m, 5H, Ph-H).  
 
2.1.9 4-Oxo-4-phenylbutanal 
 
 
 
The compound 13 was prepared with a modified literature method (change 
temperature control)
79
. At -78 
o
C under argon, to a solution of oxalyl chloride (56 ml, 112 
mmol, 2M in dichloromethane) and dry dichloromethane (150 ml) was slowly added 
anhydrous DMSO (13.6 ml). After stirring for 10 min, a solution of 1-phenyl-1,4-
butanediol (4.0 g, 24 mmol) in 60 ml dichloromethane was added over 20 min. The 
mixture was kept at -78 
o
C for 40 min and then Et3N (80 ml) was added slowly. After 
stirring at -78 
o
C for 20 min, the reaction mixture was warmed up to room temperature 
50 
and then passed through a silica gel pad (ca. 5 cm high). Dichloromethane was used to 
wash the pad. The collected brown solution was evaporated to give yellow residue. The 
residue was purified by flash column with 15% EtOAc in hexane to give 13 (3.73g, yield: 
96%, lit. 80%) as a yellow-brown liquid (Rf = 0.29, 40% EtOAc in hexane). 
 
1
H NMR (CDCl3):  2.93 (t, J = 6.31 Hz, 2H, CH2), 3.33 (t, J = 6.32 Hz, 2H, CH2), 7.47 
(m, 2H, Ph-H), 7.57 (m, 1H, Ph-H), 7.98 (m, 2H, Ph-H), 9.90 (s, 1H, CHO); 
13
C NMR(CDCl3): 31.0, 37.7, 128.4, 130.0, 133.4, 136.5, 197.9, 200.7..  
 
2.1.10 Dimethyl 1-hydroxy-4-oxo-4-phenyl-butylphosphonate 
 
 
 
The compound 14 was prepared according to the literature method
80
. The crude 
product (green oily residue) was purified by flash column with 100% EtOAc to afford 14 
as a white solid (yield: 74%, mp. 88-90 
o
C).  
 
1
H NMR (CDCl3): 2.14 (m, 1H of CH2CHOH), 2.27 (m, 1H of CH2CHOH), 3.28 (m, 
2H, CH2CO), 3.81 (2d, 6H, JHP = 10.32 Hz, 2P-OCH3), 4.04 (m, 1H, CHOH), 7.45 (m, 
2H, Ph-H), 7.56 (m, 1H, Ph-H),7.97 (m, 2H, Ph-H);  
31
P NMR (CDCl3): 26.80; 
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13
C NMR (CDCl3): 25.9 (d, 
3
JCP = 2.0 Hz, CH2CO), 34.7 (d, 
2
JCP = 13.5 Hz, 
CH2CH(OH)P), 53.5 (d & d, 
2
JCP = 6.3, 7.1 Hz, 2P-OCH3), 67.1(d, JCP = 162.3 Hz, 
CHOH), 128.1, 128.6, 133.2, 136.9, 200.2.  
 
2.1.11 Lithium monomethyl-(1-hydroxy-4-oxo-4-phenyl-butyl)-phosphonate 
 
 
 
A solution of dimethyl 1-hydroxy-4-oxo-4-phenyl-butylphosphonate (14, 0.14 g, 0.50 
mmol) and lithium bromide (43 mg, 0.50 mmol) in acetonitrile (4 ml) was heated to 70 
o
C (oil bath) under argon overnight. The white precipitate was collected by vacuum 
filtration and washed with acetonitrile and diethyl ether to give 5 (0.10 g, yield: 76%) as a 
white powder. 
 
1
H NMR (D2O): 1.99 (m, 1H of CH2CHOH), 2.17 (m, 1H of CH2CHOH), 3.31 (m, 1H 
of COCH2), 3.25 (m, 1H of COCH2), 3.61 (d, 3H, J = 9.9 Hz, P-OCH3), 3.84 (m, 1H, 
CHOH), 7.55 (m, 2H, Ph-H), 7.68 (m, 1H, Ph-H), 8.00 (m, 2H, Ph-H); 
31
P NMR (D2O): 22.29; 
13
C NMR (D2O): 27.1 (d, 
3
JCP = 3.3 Hz, CH2CO), 35.7 (d, 
2
JCP = 12.7Hz, 
CH2CH(OH)P), 52.5 (d, 
2
JCP = 6.2 Hz, P-OCH3), 67.6 (d, JCP = 158.5 Hz, CHOH), 128.7, 
129.3, 134.42, 136.9, 205.8. 
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2.1.12 Benzyl 4-(dimethoxyphosphoryl)-4-hydroxybutanoate 
 
 
 
The compound 16 was prepared from 2a according to the literature
81
. Crude product 
(yellow oil) was purified by flash column with 70-100% EtOAc in hexane to give 2 
(yield: 69%) as a colorless liquid (Rf = 0.1, 70% EtOAc in hexane).  
 
1
H NMR (CDCl3): 2.10 & 2.01 (2m, 2H, CH2CH2CH), 2.62 (m, 2H, COCH2), 3.77 & 
3.76 (d & d, JHP = 10.2 Hz, 6H, 2POCH3), 3.97 (m, 1H, CHOH), 5.11 (d, J = 1.75 Hz, 
2H, PhCH2), 7.24 (m, 5H, Ph-H).  
 
2.1.13 Benzyl 4-acetoxy-4-(dimethoxyphosphoryl)butanoate 
 
 
 
At 0 
o
C, to a solution of compound 16 (3.12 g, 10.4 mmol) in pyridine (10 ml) was 
added acetic anhydride (2.0 ml, 21.2 mmol, ca. 2 equiv.) under argon atmosphere. The 
reaction mixture was stirred at room temperature overnight. Pyridine was removed by 
coevaporation with toluene and the brown oily residue was taken with EtOAc (50 ml), 
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washed with 1N HCl (15 ml x 3), water (10 ml) and brine (10 ml) and dried over Na2SO4. 
After concentration in vacuo, benzyl 4-acetoxy-4-(dimethoxyphosphoryl) butanoate (17) 
was given as a pale yellow liquid (3.38 g, yield: 94%). The product was used for next 
step without further purification. 
 
1
H NMR (CDCl3): 2.10 (s, 3H, CH3CO), 2.15 (m, 1H, one H of CH2CHOH), 2.26 (m, 
1H, one H of CH2CHOH), 2.47 (m, 2H, COCH2), 3.78 (2d, JHP = 10.5, 11.0 Hz, 6H, 2P-
OCH3), 5.11 (s, 2H, PhCH2), 5.33 (m, 1H, CHOAc),7.34 (m, 5H, Ph-H); 
31
P NMR (D2O): 22.53; 
13
C NMR (D2O): 20.7, 24.9, 30.4 (d, 
2
JCP = 12.0 Hz, CH2CH), 53.5, 66.7, 66.6 (d, JCP 
= 169.1 Hz, CH-P), 128.4, 128.7, 135.9, 169.8, 172.2.  
 
2.1.14 4-Acetoxy-4-(dimethoxyphosphoryl)butanoic acid 
 
 
 
Compound 17 (3.0 g, 8.7 mmol) in EtOAc (25 ml) was hydrogenated with 10% Pd/C 
(0.5 g) using a balloon technique. After overnight, the reaction mixture was vacuum 
filtered through celite. The filtrate was evaporated in vacuo to give 4-acetoxy-4-
(dimethoxyphosphoryl)butanoic acid (18) as a colorless liquid (2.20 g, yield: ca. 100%). 
The product was used for next step without further purification. 
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1
H NMR (CDCl3): 2.11 (br, 4H, CH3CO and one H of CH2CHOAc), 2.22 (m, 1H, one 
H of CH2CHOAc), 2.43 (m, 2H, COCH2), 3.78 (m, 6H, 3P-OCH3), 5.33 (m, 1H, 
CHOAc); 
31
P NMR (D2O): 22.66; 
13
C NMR (D2O): 20.6, 24.7, 30.0 (d, 
2
JCP = 12.1 Hz, CH2CH), 53.6, 53.7, 66.5 (d, JCP 
= 169.2 Hz, CH-P), 169.8, 176.7. 
 
2.1.15 4-(Benzylamino)-1-(dimethoxyphosphoryl)-4-oxobutyl acetate  
 
 
 
At 0 
o
C, to a solution of compound 18 (1.08 g, 4.25 mmol) in dry dichloromethane (5 
ml) was added 1 drop of DMF under argon protection. Oxalyl chloride (2.33 ml, 2.0 M in 
dichloromethane) was added slowly. The reaction mixture was allowed to stir at room 
temperature and volatiles were evaporated after 1.5 hours. The resultant residue was 
taken with dichloromethane (30 ml) and cooled to 0 
o
C, to which Et3N (0.65 ml, 4.67 
mmol) and benzylamine (0.51 ml, 4.67 mmol) were added slowly. The mixture stirred at 
room temperature overnight and then concentrated in vacuo. The residue was partitioned 
in HCl (1N, 15 ml) and EtOAc (50 ml). The organic layer was separated and washed 
twice with HCl (1N, 15 ml), then sat. NaHCO3 (15 ml) and brine (10 ml), and dried over 
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Na2SO4. The solvent was removed in vacuo to give the crude product (0.64 g) as a pale 
yellow liquid. The crude product was purified by flash column with 5% MeOH in 
dichloromethane to give compound 19 (0.48 g, yield: 33%) as a colorless liquid (Rf = 
0.35, MeOH in dichloromethane, visualized with I2). 
1
H NMR showed that the product 
was still with some impurity and the product was used for next step without further 
purification.  
 
1
H NMR (CDCl3): 2.05 (s, 3H, CH3CO), 2.21 & 2.12 (2m, 2H, CH2CHOH), 2.62 & 
2.45 (2m, 2H, COCH2), 3.70 (m, 6H, 2 P-OCH3), 4.40 (t, J = 2.6 Hz, 2H, PhCH2), 5.26 
(m, 1H, CHOAc), 6.52 (br, 1H, CONH), 7.25 (m, 5H, Ph-H).  
 
2.1.16 Dimethyl 4-(benzylamino)-1-hydroxy-4-oxobutylphosphonate 
 
 
 
A mixture of compound 19 (0.47 g, 1.37 mmol) and Et3N (0.29 ml, 2.08 mmol) in 
MeOH (30 ml) was stirred at room temperature. The reaction was monitored by TLC (Rf 
= 0.24, 10% MeOH in dichloromethane, visualized with I2). After 16 hours, the reaction 
mixture was partitioned in EtOAC and HCl solution. The organic layer was separated and 
the aqueous layer was extracted with EtOAc (x 3). The combined organic layer was dried 
over Na2SO4 and evaporated in vacuo to give a pale yellow liquid (0.34 g), which was 
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eluted with 5% MeOH in dichloromethane to give compound 6 (0.15 g, yield: 36%) as a 
colorless liquid. 
 
1
H NMR (CDCl3): 2.15 & 2.07 (2m, 2H, CH2CH), 2.60 & 2.52 (2m, 2H, COCH2), 3.81 
(2d, JHP = 10.3, 10.3 Hz, 6H, 2P-OCH3), 4.01 (m, 1H, CHOH), 4.44 (t, J = 2.6 Hz, 2H, 
PhCH2), 6.29 (br, 1H, CONH), 7.33 (m, 5H, Ph-H);  
31
P NMR (D2O): 26.55;
13
C NMR (D2O): 27.4, 33.3 (d, 
2
JCP = 13.5 Hz, CH2CH), 44.2, 53.7 (2d, 
2
JCP = 6.3, 7.1 
Hz, 2P-OCH3), 67.8 (d, JCP = 163.5 Hz, CH-P), 128.0, 128.2, 129.1, 138.4, 173.4.  
 
2.1.17 Lithium methyl 4-(benzylamino)-1-hydroxy-4-oxobutylphosphonate  
 
 
 
 A solution of compound 20 (0.15 g, 0.50 mmol) and lithium bromide (43 mg, 0.50 
mmol) in acetonitrile (4 ml) was heated to 70 
o
C (oil bath) under argon overnight. The 
precipitate was collected by vacuum filtration and washed with acetonitrile and diethyl 
ether to give 21 (0.10 g, yield: 68%, m.p. 223-225 
o
C) as a pale yellow powder.  
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1
H NMR (CDCl3): 2.10 & 1.93 (2m, 2H, CH2CH), 2.55 & 2.47 (2m, 2H, 2 COCH2), 
3.62 (d, JHP = 10.0 Hz, 3H, P-OCH3), 3.77 (m, 1H, CHOH), 4.42 (s, 2H, PhCH2),7.44 (m, 
5H, Ph-H) ; 
31
P NMR (D2O): 22.05; 
13
C NMR (D2O): 28.4, 33.1 (d, 
2
JCP = 13.1 Hz, CH2CH(OH)P), 43.5, 52.5 (d, 
2
JCP = 6.3 
Hz, 2P-OCH3), 68.5 (d, JCP = 158.3 Hz, CH-P), 127.8, 127.9, 129.3, 138.6, 176.5.  
 
2.1.18 Methyl 2-tert-butyldimethylsilyloxycyclohexa-3,5-diene-1-carboxylate 
 
 
 
1-[(tert-Butyl-dimethylsilyl)oxy]1,3-butadiene (22) was prepared as oily residue from 
crotonaldehyde according to the literature method (yield: 72%, lit. 84%)
82
. The HNMR 
specctrum is consistent with that of the literature. 
 
1
H NMR (CDCl3):  0.16 (s, 6H), 0.92 (s, 9H), 4.81 (t, 1H, J = 10.0 Hz), 4.98 (t, 1H, J = 
17.0 Hz), 5.73 (t, 1H, J = 11.5 Hz), 6.22 (dt, 1H, J = 17.0, 10.5 Hz), 6.57 (d, 1H, J = 12.0 
Hz). 
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Methyl 2-tert-butyldimethylsilyloxycyclohexa-3,5-diene-1-carboxylate (compound 
23) was prepared from 22 and methyl propiolate according to literature method (yield: 
60%, lit. 71%, Rf = 0.26 in 5% EtOAc/hexane)
83
. The HNMR and CNMR spectra are 
consistent with that of the literature. 
 
1
H NMR (CDCl3):  0.94 (s, 3H), 0.12 (s, 3H), 0.86 (s, 9H), 2.84 (m, 2H), 3.76 (s, 3H), 
5.07 (m, 1H), 5.87 (appar. d, 2H, J = 1.5 Hz),7.01 (t, 1H, J = 3.0 Hz);  
13
C NMR (CDCl3):  -4.3, -4.0, 18.2, 26.0, 27.5, 51.6, 61.7, 124.9, 128.3, 131.8, 137.8, 
167.4.  
 
2.1.19 Methyl 2-(tert-butyldimethylsilyloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-
carboxylate 
 
 
 
Methyl 2-(tert-butyldimethylsilyloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate  
(compound 24) was prepared with modified literature method
83
. A solution of m-CPBA 
(ca. 65%, 20.0 g, 75.3 mmol) in CH2Cl2 (150 ml) was washed with brine in 500 ml 
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separatory funnel. The organic layer was separated and dried over anhydrous MgSO4. 
The MgSO4 was filtered off to obtain dry m-CPBA solution in  CH2Cl2. Diene 23 (10.13 
g, 37.7 mmol), NaHCO3 (9.50 g, 113.1 mmol) and CH2Cl2 (250 ml) were mixed and 
heated to reflux in a 1L three-necked round-bottom flask equipped with a condenser and 
a dropping funnel under nitrogen gas protection. The dried m-CPBA solution in CH2Cl2 
was added to the mixture through the dropping funnel over 30 min. The resulting mixture 
was then heated to reflux for additional 4 hours, then cooled to room temperature and 
stirred overnight. The reaction mixture was filtered through celite and the filtrate was 
washed with sat. Na2S2O5 solution (140 ml x 3), sat. NaHCO3 solution (100 ml x 2), H2O 
(100 ml) and brine (100 ml), dried over Na2SO4, and then evaporated in vacuo to give 
oily residue. The residue was purified by flash chromatography using 5-10% 
EtOAc/hexane to give product as a colorless liquid (7.60 g, yield: 71%, Rf = 0.18 in 15% 
EtOAc/Hexane). 
 
1
H NMR (CDCl3):  0.09 (s, 3H), 0.18 (s, 3H), 0.87 (s, 9H), 2.73 (m, 2H), 3.25 (m, 1H), 
3.32 (m, 1H), 3.73 (s, 3H), 5.03 (s, 1H), 6.74 (m, 1H).  
13
C NMR (CDCl3):  -4.5, -4.5, 18.2, 25.9, 26.0, 49.4, 51.7, 54.4, 63.0, 129.4, 
135.6,166.7.  
 
2.1.20 Methyl 6-(tert-butyldimethylsilyloxy)-5-hydroxycyclohexa-1,3-diene-
carboxylate 
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Epoxide 24 (1.95 g, 6.86 mmol) and 1,8-diazabicuclo[5.4.0]undec-7-ene (5.21 g, 
34.22 mmol) were dissolved in CH2Cl2 (60 ml) and stirred under argon at room 
temperature overnight. The solvent was removed in vacuo and the residue was taken with 
EtOAc (50 ml). Then the resulting solution was washed with sat. NaHCO3 solution (15 
ml x 3) and brine (15 ml), dried over Na2SO4 and evaporated in vacuo to give a brown 
oily residue. The residue was purified with a flash chromatography using 25% 
EtOAc/hexane to give methyl 6-(tert-butyldimethylsilyloxy)-5-hydroxycyclohexa-1,3-
diene-carboxylate (25) as a colorless liquid (1.65g, yield: 85%, Rf = 0.17 in 25% 
EtOAc/hexane). 
 
1
H NMR (CDCl3):  0.1 (s, 3H), 0.2 (s, 3H), 0.82 (s, 9H), 1.44 (d, 1H, J = 7.5 Hz, OH), 
4.13 (m, 1H), 4.68 (s, 1H), 6.26 (dd, 1H, J = 9.0, 5.5 Hz), 6.32 (dd, 1H, J = 9.0, 5.5 
Hz),7.11 (d, 1H, J = 5.5 Hz) . 
13
C NMR (CDCl3):  -4.8, 4.5, 18.1, 25.7, 51.7, 67.7, 69.3, 124.5, 129.6, 132.5, 132.5, 
167.1; 
HRMS (CI
+
): calcd for C14H25O4Si 285.1522, found 285.1528 ([M+1]
+
) 
 
2.1.21 Methyl 6-(tert-butyldimethylsilyloxy)-5-(2-ethoxy-2-oxoethoxy)cyclohexa-1,3-
dienecarboxylate 
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To a solution of diene alcohol 25 (1.14 g, 4.01 mmol) in dry CH2Cl2 (2 ml) was added 
rhodium (II) acetate dimer (8.8 mg, 1 mol %). A solution of ethyl diazoacetate 
(containing 15% CH2Cl2, 0.27 g, 2.01 mmol) in CH2Cl2 (1 ml) was added under argon at 
room temperature over 1 hour. After stirring for additional 1 hour, the reaction mixture 
was concentrated in vacuo and purified with flash chromatography using 10-50% 
EtOAc/hexane to give the unreacted diene alcohol 25 (0.60 g) and methyl 6-(tert-
butyldimethylsilyloxy)-5-(2-ethoxy-2-oxoethoxy)cyclohexa-1,3-dienecarboxylate (26) as 
a colorless liquid (0.50 g, yield: 71% based on consumed starting material, Rf = 0.32 in 
25% EtOAc/hexane).  
 
1
H NMR (CDCl3):  0.06 (s, 3H), 0.16 (s, 3H), 0.80 (s, 9H), 1.27 (t, 3H, J = 7.0 Hz), 3.76 
(s, 3H), 4.06 (m, 3H, CHOCH2), 4.20 (q, 2H, J = 7.0 Hz), 4.75 (s, 1H), 6.26 (dd, 1H, J = 
9.5, 5.0 Hz), 6.35 (dd, 1H, J = 9.5, 5.5 Hz), .7.10 (d, 1H, J = 5.5 Hz); 
13
C NMR (CDCl3):  -4.7, -4.4, 14.3, 18.1, 25.0, 51.8, 61.1, 65.1, 65.4, 76.4, 126.3, 
129.3, 130.1, 132.8, 170.0, 170.4; 
HRMS (EI
+
): calcd for C18H30O6Si 370.1812, found 370.1820 ([M]
+
). 
 
2.1.22 Methyl  5-(2-ethoxy-2-oxoethoxy)-6-hydroxycyclohexa-1,3-diene carboxylate 
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Compound 26 (0.43 g, 1.11 mmol) was mixed with AcOH (9 ml) and H2O (6 ml), and 
the mixture was stirred at room temperature overnight. The reaction mixture was 
evaporated to dryness in vacuo to give a pale yellow oily residue. The residue was 
purified with a flash chromatography using 40% EtOAc/hexane to give product methyl  
5-(2-ethoxy-2-oxoethoxy)-6-hydroxycyclohexa-1,3-diene carboxylate (27) as a colorless 
liquid (0.25 g, yield: 84%, Rf = 0.18 in 40% EtOAc/hexane).  
 
1
H NMR (CDCl3):  1.28 (t, 3H, J = 7.0 Hz), 3.43 (s, 1H), 3.80 (s, 3H), 4.21 (q, 2H, J = 
7.0 Hz), 4.28 (s, 2H), 4.34 (ddd, 1H, J =6.5, 3.0, 1.5 Hz), 4.88 (d, 1H, J = 6.5 Hz), 6.16 
(ddd, 1H, J = 9.5, 5.5, 1.5Hz), 6.30 (dd, 1H, J = 9.0, 3.0 Hz), 7.01 (d, 1H, J = 5.5 Hz); . 
13
C NMR (CDCl3):  14.3, 52.2, 61.1, 67.0, 69.5, 79.6, 123.9, 129.6, 132.8, 133.0, 167.5, 
170.7.. 
HRMS (EI
+
): calcd for C12H16O6 256.0947, found 256.0942 ([M]
+
). 
 
2.1.23 5-(Carboxymethoxy)-6-hydroxycyclohexa-1,3-diene carboxylate (CHCD) 
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1.) Acid form of CHCD 
At 0 
o
C, to the mixture of di-ester 27 (0.64 g, 3.9 mmol) in THF/H2O (24 ml/6 ml) 
was added LiOH.H2O (982 mg, 23.4 mmol). The mixture was stirred at room temperature 
for 24 hours. Volatiles were removed in vacuo below 30 
o
C, and the residue was diluted 
to 2.0 ml with deionized water and passed through Dowex 50WX8-100 [H
+
] column. 
Fractions with pH < 3 (or monitored by the UV absorbance at 280 nm) were lyophilized 
and checked by 
1
HNMR. The pure product ((±)-CHCD, 28) was pale brown powder. 
 
1
H NMR (D2O):  4.19 (dd, 1H, J = 5.0, 1.5 Hz), 4.70 (s, 1H), 4.24 (s, 2H), 6.37 (dd, 1H, 
J = 9.5, 5.0 Hz), 6.46 (dd, 1H, J = 10.5, 5.5 Hz), 7.24 (d, 1H, J = 5.5 Hz).. 
 
2.) Lithium salt of CHCD 
The preparation is the same as the acid form, but the crude product was loaded to the 
Dowex 1X8-100 [Cl
-
] column. After washed with deionized water, the column was eluted 
with LiCl solution (0~1.0 M). Fractions were monitored by the UV absorbance at 280 
nm. Appropriate fractions were lyophilized and checked by 
1
HNMR. The lyophilized 
residues with good purity were triturated for several times with a mixture of acetone and 
methanol (v/v 10:1). White powder was collected by vacuum filtration and dried under 
oil pump. 
 
1
H NMR (D2O):  3.95 (s, 2H), 4.11 (m, 1H), 4.70 (d, 1H, J = 3.0 Hz), 6.19 (dd, 1H, J = 
9.5, 5.0 Hz), 6.32 (dd, 1H, J = 10.5, 5.5 Hz), 6.82 (d, 1H, J = 5.5 Hz);. 
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13
C NMR (D2O):  65.9, 66.9, 76.6, 126.5, 127.5, 130.0, 134.0, 174.4, 177.9; 
HRMS(ESI
-
):  calcd for C9H8LiO6 219.0486, found 219.0490 ([M-Li]
-
). 
 
2.1.24 5-Carboxymethoxy-6-hydroxy-cyclohexa-1,3-dienecarboxylic acid methyl 
ester (CHCDMe) 
 
 
 
At room temperature, diester 27 was mixed with acetonitrile (2 ml) and H2O (2 ml). 
To the mixture was added Novozyme 435 (104 mg, Candida antarctica Lipase B 
immobilized on acrylic resin, Sigma). The mixture was stirred for 2.5 hours at room 
temperature and filtered through a cotton plug in glass pipette, washed with a mixture of 
acetonitrile and H2O (v/v 1:1). The collected filtrate was rotary evaporated and 
lyophilized to yield pale yellow residue ((±)-CHCDMe, 29). 
 
1
H NMR (D2O):  3.68 (s, 3H), 4.07 (s, 1H, J = 5.0 Hz), 4.61 (s, 1H), 4.09 (s, 2H), 6.26 
(dd, 1H, J = 9.5, 5.0 Hz), 6.34 (dd, 1H, J = 9.5, 6.0 Hz), 7.13 (d, 1H, J = 6.0 Hz).  
 
2.1.25 Methyl 2-methoxy-3-(1-methoxy-1-oxopropan-2-yloxy)benzoate 
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Methyl 3-hydroxy-2-methoxybenzoate (30) was prepared starting from 2,3-di-
hydroxybenzoic acid according to the literature method
84
.  
 
1
H NMR (CDCl3): 3.91 (s, 3H), 3.92 (s, 3H), 6.02 (s, 1H, OH), 7.04 (appar. t, 1H, J = 8 
Hz), 7.14 (dd, 1H, J = 8, 1.5 Hz), 7.38 (dd, 1H, J = 8, 1.5 Hz).  
 
The mixture of compound 30 (0.73 g, 4.0 mmol), NaI (0.12 g, 20 mol %), anhydrous 
K2CO3 (1.10 g, 2.0 equiv.) methyl 2-bromopropionate (0.58 ml, 1.3 equiv.) and MeCN 
(40 ml) was refluxed under argon overnight. The reaction was monitored with TLC (5% 
MeOH in CH2Cl2). After removal of solvent in vacuo, the residue was taken with CH2Cl2 
(20 ml) and H2O (10 ml). The aqueous layer was separated and extracted with CH2Cl2 
(10 ml x 2). The organic layers were combined and dried over MgSO4. After removal of 
solvent, the residue was purified with a flash chromatography using 2% MeOH/CH2Cl2 
to give methyl 2-methoxy-3-(1-methoxy-1-oxopropan-2-yloxy)benzoate (31) as a 
colorless liquid (0.83 g, yield: 77%).  
 
1
H NMR (CDCl3): 1.64 (d, 3H, J = 7.0 Hz), 3.73 (s, 3H), 3.89 (s, 3H), 3.94 (s, 3H), 
4.79 (q, 1H, J = 7.0 Hz), 7.01 (m, 2H), 7.37 (dd, 1H, J = 7.0, 2.5 Hz); 
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13
C NMR (CDCl3): 18.6, 52.1, 52.2, 61.6, 74.1, 119.8, 123.7, 124.0, 126.6, 150.3, 
151.5, 166.5, 172.2. ,. 
 
2.1.26 3-(1-Carboxyethoxy)-2-methoxybenzoic acid 
 
 
 
Compound 31 (0.33 g, 1.23 mmol) was mixed with LiOH.H2O (0.21 g, 5.01 mmol, 
4.0 equiv.) in a mixture of THF (4 ml) and H2O (2 ml), and stirred at room temperature 
overnight. THF was removed in vacuo and to the solution was added H2O (ca. 5 ml). The 
resulting aqueous solution was then washed with EtOAc (7 ml) and acidified to pH = 1-2 
with aq. HCl (5 M), then extracted with EtOAc (15 ml x 2). The combined organic phase 
was washed with brine (10 ml) and dried over MgSO4, and evaporated in vacuo to give 3-
(1-carboxyethoxy)-2-methoxybenzoic acid (32) as pale yellow liquid. After 
recrystallization from EtOAc/hexane (v/v 1:1), a white solid was obtained (0.25 g, yield: 
83%, m.p. 135-137 
o
C). 
 
1
H NMR (CDCl3):  1.75 (d, 3H, J = 7.0 Hz), 4.14 (s, 3H), 4.89 (q, 1H, J = 7.0 Hz), 7.09 
(dd, 1H, J = 8.0, 1.5 Hz), 7.16 (appar. t, 1H, J = 8.0 Hz), 7.76 (dd, 1H, J = 8.0, 1.5 Hz); 
13
C NMR (CDCl3): 18.6, 62.7, 73.4, 120.0, 123.1, 125.0, 125.7, 149.3, 150.2, 166.1, 
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175.7. 
 
2.1.27 Methyl 2-hydroxy-3-(1-methoxy-1-oxopropan-2-yloxy)benzoate 
 
 
 
To a solution of compound 31 (0.39 g, 1.45 mmol) in dry CH2Cl2 (15 ml) at -78 
o
C 
was added BBr3 (1.0 M solution in CH2Cl2, 2.90 ml, 2.90 mmol) under argon. The 
reaction mixture was stirred for 40 min at -78 
o
C and H2O (2.0 ml) was added slowly, 
then warmed up to room temperature, H2O (10 ml) was added. The aqueous phase was 
separated and extracted with CH2Cl2 (15 ml x 3). The combined organic phase was dried 
over Na2SO4 and evaporated to give colorless oily residue. The residue was purified by 
flash chromatography using 0.5% MeOH/ CH2Cl2 to give methyl 2-hydroxy-3-(1-
methoxy-1-oxopropan-2-yloxy)benzoate  as oily residue (33) (0.26 g, yield: 70%). 
 
1
H NMR (CDCl3):  1.66 (d, 3H, J = 7.0 Hz), 3.74 (s, 3H), 3.94 (s, 3H), 4.84 (q, 1H, J = 
7.0 Hz), 6.77 (appar. t, 1H, J = 8.0 Hz), 7.09 (dd, 1H, J =8.0, 1.0 Hz), 7.51 (dd, 1H, J = 
8.0, 1.5 Hz),10.99 (s, 1H); . 
13
C NMR (CDCl3):  18.7, 52.3, 52.5, 74.7, 113.6, 118.6, 123.1, 123.6, 146.4, 153.4, 
170.8, 172.6. 
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2.1.28 3-(1-Carboxyethoxy)-2-hydroxybenzoic acid 
 
 
 
Compound 33 (0.13 g, 0.51 mmol) was mixed with LiOH.H2O (86 mg, 2.05 mmol, 
4.0 equiv.) in a mixture of THF (3 ml) and H2O (1.5 ml), and stirred at room temperature 
for 2 days. THF was removed in vacuo and to the solution was added H2O (ca. 5 ml). The 
resulting aqueous solution was then washed with EtOAc (5 ml x 3) and acidified to pH = 
1-2 with aq. HCl (5 M), then extracted with EtOAc (15 ml x 2). Combined organic phase 
was washed with brine (10 ml) and dried over MgSO4, evaporated in vacuo to give white 
solid. The white solid was recrystallized from CHCl3 to yield 3-(1-carboxyethoxy)-2-
hydroxybenzoic acid (34) as white powder (65 mg, yield: 56%, m.p. 158-160 
o
C). 
 
1
H NMR (CDCl3/CD3OD (1 drop)):  1.65 (d, 3H, J = 7.0 Hz), 4.76 (q, 1H, J = 7.0 Hz), 
6.79 (appar. t, J = 8.0 Hz), 7.09 (dd, 1H, J = 8.0, 1.5 Hz), 7.56 (dd, 1H, J = 8.0, 1.5 Hz). 
(Consistent with the literature
66
) 
 
2.1.29 Methyl 3-(2-methoxy-2-oxoethoxy)benzoate and methyl 3-(1-methoxy-1-
oxopropan-2-yloxy)benzoate 
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The mixture of methyl 3-hydroxybenzoate (0.60 g, 4.0 mmol), NaI (0.12 g, 20mol%), 
anhydrous K2CO3 (1.10 g, 2.0 equiv.), methyl bromoacetate or methyl 2-
bromopropionate (5.2 mmol, 1.3 equiv.) and MeCN (40 ml) was refluxed under argon 
overnight. The reaction was monitored with TLC (2% MeOH/CH2Cl2). After removal of 
the solvent in vacuo, the residue was taken with EtOAc (30 ml) and H2O (15 ml). The 
organic layer was separated and extracted with brine (10 ml x 2). The organic layer was 
dried over MgSO4 and evaporated in vacuo to dryness. After removal of solvent, the 
residue was eluted with 2% MeOH in CH2Cl2 to give methyl 3-(2-methoxy-2-
oxoethoxy)benzoate (35a)  and methyl 3-(1-methoxy-1-oxopropan-2-yloxy)benzoate 
(35b) (
1
HNMR indicated the only impurity was excess methyl bromoacete or methyl 2-
bromopropionate, yield: ca.100%) as pale yellow liquid. The products were used for next 
step without further purification. 
 
35a 
1
H NMR (CDCl3):  3.81 (s, 3H), 3.91 (s, 3H), 4.69 (s, 2H), 7.14 (ddd, 1H, J = 8.0, 
2.5, 0.5 Hz), 7.36 (appar. t, 1H, J = 8.0 Hz), 7.54 (dd, 1H, J = 2.5, 1.5 Hz), 7.69 (d, 1H, J 
= 7.5 Hz); 
35b 
1
H NMR (CDCl3):  1.64 (d, 3H, J = 7.0 Hz), 3.76 (s, 3H), 3.90 (s, 3H), 4.84 (q, 1H, 
J = 7.0 Hz), 7.09 (dd, 1H, J = 8.0, 2.5 Hz), 7.34 (appar. t, 1H, J = 8.0 Hz), 7.53 (dd, 1H, J 
= 2.5, 1.5 Hz), 7.69 (d, 1H, J = 7.5 Hz). . 
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2.1.30 3-(Carboxymethoxy)benzoic acid and 3-(1-carboxyethoxy)benzoic acid 
 
 
 
Compound 35a or 35b (ca. 4.0 mmol) was mixed with LiOH.H2O (0.67 g, 16.0 
mmol, 4.0 equiv.) in a mixture of THF (5 ml) and H2O (5 ml), and stirred at room 
temperature overnight. THF was removed in vacuo and to the solution was diluted with 
H2O (ca. 10 ml). The resulting aqueous solution was then washed with CH2Cl2 (15 ml) 
and acidified to pH = 1-2 with aq. HCl (5 M), then extracted with EtOAc (15 ml x 2). 
Combined organic phase was washed with brine (10 ml) and dried over MgSO4, 
evaporated in vacuo to give crude product (36a 0.87 g, pale yellow solid; 36b 0.70 g, pale 
yellow solid). After recrystallization from EtOAc/hexane, white solid was obtained (36a 
0.72 g, yield: 82%, m.p. 213-215 
o
C; 36b 0.60 g, yield: 76%, m.p. 184-186 
o
C). 
 
36a 
1
H NMR (CD3OD):  4.72 (s, 2H), 7.18 (dd, 1H, J = 8.0, 2.0 Hz), 7.39 (appar. t, 1H, 
J = 8.0 Hz), 7.55 (s, 1H), 7.63 (d, 1H, J = 7.5Hz),
 
13
C NMR (CDCl3):  65.9, 116.3, 120.7, 123.8, 130.6, 133.3, 159.5, 169.4, 172.4.. 
 
36b 
1
H NMR (CD3OD):  1.61 (d, 3H, , J = 7.0 Hz), 4.86 (q, 1H, dd, 1H, J = 7.0 Hz), 
7.13 (dd, 1H, J = 8.0, 2.5 Hz), 7.37 (appar. t, 1H, J = 8.0 Hz), 7.51 (s, 1H), 7.62 (d, 1H, J 
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= 7.5 Hz);. 
13
C NMR (CDCl3):  17.4, 72.1, 115.3, 119.7, 122.3, 129.2, 131.9, 157.8, 168.0, 174.1.. 
 
2.2 Enzymology experimental 
 
Chemicals including buffers, 2-ketoglutarate (2-KG), ThDP, ampicillin, IPTG etc. 
were purchased from Sigma-Aldrich, VWR, EMD and were Molecular Biology Grade or 
were of the highest grade available. Centrifugation was performed using a Beckman J2-
HS refrigerated centrifuge with a F500 or JA-25.50 rotor or Beckman Coulter microfuge 
18 and 22R centrifuge. UV-visible spectrophotometry was performed using DU-640 
spectrophotometer with a circulating bath-controlled temperature block. Bradford assay 
kit was obtained from Bio-Rad. The centrifugal filter used was Nanosep centrifugal 
device with 30 kDa cut-off from Pall Life Science. The cultures were lysed using 
Virosonic 600 ultrasonic cell disrupter. The purification of His-tagged proteins were 
routinely performed on BIOCAD 700E Perfusion Chromatography Workstation of 
Applied Biosystems using a Hitrap Chelating HP column from GE Health (1.0 ml) or a 
NTA Superflow Cartridge (1.0 ml) from QIAGEN. DNA primers were purchased from 
Alpha DNA. The pfu DNA polymerase and the QuickChange mutagenesis kit were 
obtained from Stratagene. PCR amplification were performed using PXE 0.2 Thermal 
Cycler of Thermo Electron Corporation. The isolation of isochorismate or CHCD was 
performed with the AKTAhplc in a refrigerated chamber using Lichropep RP-18 column 
from Merck. HPLC analysis or isolation was carried out on Agilent 1100 series with 
diode array multi-wavelength detector and G1313A autosampler using Zorbax SB-C18 
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(4.6 × 250 mm) analytical column or Zorbax SB-C18 (9.4 × 250 mm) semi-preparative 
column. DNA sequencings were performed at the DNA Technologies Unit, National 
Research Council (NRC), Plant Biology Institute (PBI), Saskatoon, SK, Canada. The 
competent cells of E. coli XL1-Blue and BL21-Gold were prepared following Macova's 
protocol
41
.  
 
2.2.1 Mutagenesis   
 
The plasmid containing the wild type menD gene was obtained from Dan Toogood
85
. 
Mutageneses for R107K, K292Q, R293K and R413K were performed using the 
QuickChange kit from Stratagene according to the manufacturer’s manual. The primers 
for site-directed mutagenesis (ordered from Alpha DNA, QC, Canada) are shown as 
below (Table 2.1).  
Table 2.1: List of MenD mutagenic primers. The underlined sequences indicate the codon for new amino 
acids. R107K (change 5'-C319GC-3' to 5'-AAG-3'); K292Q (change 5'-A874AA-3' to 5'-CAA-3'); R293K 
(change 5'-C877GG-3' to 5'-AAG-3'); R413K (change 5'-C1237GT-3' to 5'-AAG-3'). 
Mutants Sequence of primers 
R107K 
5' to 3'    C TTA ACC GCC GAT AAG CCG CCG GAG CTA ATT GAC TGC  (Forward) 
5' to 3'    GCA GTC AAT TAG CTC CGG CGG CTT ATC GGC GGT TAA G (Reverse) 
K292Q 
5' to 3'    C CTG ACG GGG CAA CGG CTC CTG CAA TG  (Forward) 
5' to 3'    CA TTG CAG GAG CCG TTG CCC CGT CAG G   (Reverse) 
R293K 
5' to 3'    C CTG ACG GGG AAA AAG CTC CTG CAA TGG CAG G  (Forward) 
5' to 3'
  
  C CTG CCA TTG CAG GAG CTT TTT CCC CGT CAG G   (Reverse) 
R413K 
5' to 3'    CG GTG TAC AGC AAC AAG GGG GCC AGC GGT ATC G (Forward) 
5' to 3'
  
   C GAT ACC GCT GGC CCC CTT GTT GCT GTA CAC CG  (Reverse) 
 
The DNA template pMD14 (pET-14b plasmid containing menD was called as 
pMD14 in our lab, obtained from Andrea Macova
41
) was isolated from the XL1-blue host 
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according to the protocol in the QIAprep spin miniprep kit manual. The PCR experiments 
were performed with 50 l total reaction volume in 0.5 ml PCR tube as follows: 
Molecular biology water (added first), 38.5 l  
Template DNA (pMD14, 37 ng/l),   1.5 l 
Primer (forward, 100 ng/l, Alpha DNA), 1.5 l 
Primer (reverse, 100 ng/l, Alpha DNA), 1.5 l 
10X pfuUltra buffer (Stratagene) 5 l 
dNTPs (10 mmol, Stratagene) 1 l 
pfuUltra polymerase (2.5 U/l, Stratagene, added last) 1 l 
 
The thermocycler was programmed as follows: 
Step1: 95 
o
C   30 seconds 
Step2: 95 
o
C   30 seconds 
           55 
o
C 1 min 
           72 
o
C     ca. 14 min 
After 18 cycles were performed for the amplification, the reaction mixtures were 
cooled to 4 
o
C. To each amplification product was added 1 l DpnI (restriction enzyme, 
20 U/l, New England Biolabs), and the resulting mixture was thoroughly mixed and 
incubated for 1 hour at 37 
o
C to digest the parental pMD14.  
The DpnI-treated DNA (4 l) was added to XL1-blue competent cell (100 l) in 0.5 
ml PCR tube and cooled on ice for 30 min. Once heated at 42 
o
C for 40 seconds, the 
mixture in PCR tube was added to a 0.9 ml pre-heated LB media in a sterile 14 ml 
polypropylene Falcon tube. After 1 hour incubation at 37 
o
C with shaking at 250 rpm, 50 
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l of the culture was plated on a LB-agar plate containing 50 g/ml of ampicillin and 
incubated at 37 
o
C. A few colonies from each plate appeared after overnight incubation. 
Several of the colonies (usually 3) were picked out and used to inoculate LB media (6 ml) 
containing 50 g/ml ampicillin at 37 oC with 250 rpm overnight. Each of the grown 
cultures was harvested to isolate plasmid using QIAprep spin miniprep kit. The plasmids 
were sequenced to confirm the mutation results. 
 
2.2.2 Gene overexpression and protein purification  
 
 The vectors containing targeted mutant genes were transformed into E. coli BL21-
Gold competent cells with the same procedure of transformation to XL1-Blue cell 
described above. One colony of the transformed BL21-Gold cell was used to inoculate 
LB media (5 ml) containing 50 g/ml ampicillin at 37 oC with 250 rpm for 4 hours. The 
grown culture was inoculated to 250 ml LB with 250 l ampicillin (50 mg/ml), which 
was shaken at 37 
o
C with 250 rpm. When the OD600 of the culture reached 0.6 - 0.8 
(about 3.5 hours), 100 l IPTG solution (1.0 M) was added to the culture with a final 
concentration of 0.4 mM. The IPTG-induced culture was then shaken at 25 
o
C with 250 
rpm overnight (~16 hours). The culture was harvested and protein was purified according 
to the established protocol
41
. The fractions containing MenD or mutants were pooled and 
dialyzed against MenD dialysis buffer (50 ml Tris (100 mM, pH 7.4; 500 ml glycerol; 
450 ml deionized water) for 18-20 hours at 4 
o
C. The concentrations of proteins were 
determined by Bradford Assay using BSA as standard. The proteins were separated into 
0.4 ml aliquot, frozen in liquid nitrogen and stored at -80 
o
C. 
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2.2.3 Preparation of isochorismate (ISC) 
 
 
 
Chorismic acid was prepared biosynthetically from glucose using Klebsiella 
pneumonia 62-1. The preparation of isochorismate from chorismate using EntC was 
similar to previous procedure with some modification
41
. In a 14 ml polypropylene round-
bottom Falcon tube,  the solution of chorismic acid (140 mg) in deionized water (2 ml) in 
a 10 ml was adjusted to pH = ca.7 with NaOH (1 M). To the pH-adjusted solution were 
added the Tris buffer (0.6 ml, pH 8.0, 1 M) and MgCl2 (0.18 ml, 1 M). After the addition 
of EntC (0.5 ml), the reaction mixture was incubated at 30 
o
C for 1.5-2 hours. After the 
mixture was cooled on ice, MeOH (2 ml) was added and then acidified to pH < 2 with 
HCl (5 M). The white precipitate was removed using centrifuge and the supernatant was 
filtered through a 0.45 m syringe filter into a round-bottom flask. The filtrate was 
concentrated in vacuo to ca. 2 ml. The solution was loaded to the Lichropep RP-18 
column from Merck on the AKTAhplc in a refrigerated chamber. The elution of the 
column and isolation of isochorismate are the same as previous procedure
41
.  
 
2.2.4 Isolation of (-)-5-(carboxylatomethoxy)-6-hydroxycyclohexa-1,3-diene 
carboxylate ((-)-CHCD) 
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The lithium salt of (±)-CHCD (40 mg), 2-KG (30 mg), ThDP (2 mg) were dissolved 
in deionized water (1 ml). The resulting mixture was adjusted to pH = 7-8 with NaOH (1 
M) to form a clear solution. To the solution were added 0.2 ml Tris buffer (7.4, 1 M) and 
0.16 ml MenD (28 M), water was then added to obtain a ca. 2 ml reaction mixture 
which was shaken at room temperature until the UV absorbance at 280 nm (5 l of 
reaction mixture was diluted with 1 ml deionized water) stopped decreasing (ca.12 
hours). MeOH (0.5 ml) was added and drops of HCl (5 M) were added to acidify the 
reaction mixture pH < 2. After filtered through 0.45 m syringe filter, the solution was 
loaded to the Lichropep RP-18 column from Merck on the AKTAhplc in a refrigerated 
chamber. Typically, the MeOH/0.1% TFA solution gradient elution procedure was as 
follows: 0-10% MeOH over 40 min, stay with 10% MeOH until (-)-CHCD peak was 
eluted. The fractions of (-)-CHCD was monitored at 280 nm and/or using UV scan with a 
maximal UV absorbance at 278-280 nm. The appropriate fractions were pooled and 
concentrated in vacuo at room temperature. The concentrated solution was frozen and 
lyophilized to achieve pale brown solid. The 
1
HNMR of the product is identical to 
racemic CHCD. The specific rotation of (-)-CHCD was determined as 25][ D  = -170 ± 10 
(c 0.24, H2O).  
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2.2.5 Isolation of 5-carboxymethoxy-2-(3-carboxy-propionyl)-6-hydroxy-cyclohex-2-
enecarboxylate (CCHC) 
 
 
 
The lithium salt of (±)-CHCD (232 mg), 2-KG (160 mg), ThDP (10 mg) were 
dissolved in 3 ml deionized water. The resulting mixture was adjusted to pH = 7-8 with 
NaOH (1 M) to form a clear solution. To the solution were added 0.4 ml Tris buffer (7.4, 
1 M) and 0.1 ml MenD (65 M), water was then added to obtain ca. 4 ml reaction 
mixture which was shaken at room temperature until the UV absorbance at 280 nm (1 l 
of reaction mixture was diluted with 1 ml deionized water) stopped decreasing (ca.35 
hours). The reaction mixture was adjusted to pH = 4 with ca. 100 l formic acid (96%). 
MenD was removed by Nanosep centrifugal device with 30 kDa cut-off. The resulting 
filtrate was isolated with HPLC using a Zorbax SB-C18 (9.4 × 250 mm) semi-preparative 
column. The column was eluted with an isocratic eluent combination of 5% acetonitrile 
and 95% formic acid (0.1%). (-)-CHCD was eluted at ca. 23.5 min and CCHC at ca. 37.5 
min. The collected eluents were evaporated in vacuo to remove volatiles, the resulting 
solutions were lyophilized to yield (-)-CHCD (
1
HNMR showed the same result as 
authentic CHCD) as pale brown solid and CCHC as white solid. The component 
characterized by NMR as Diels-Alder product of CHCD was also isolated (eluted at ca. 
42.3 min).  
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25][ D  = -50 ± 10 (c 0.12, H2O)
 
CCHC:   
1
H NMR (CD3OD):  2.40 & 2.35 (m, m, 1H), 2.49 (t, 1H, dd, 1H, J = 6.0 Hz), 
2.75 & 2.71 (m, m, 1H), 3.03 (m, 1H) & 2.93 (m, 1H), 3.33 (d, 1H, J = 6.0 Hz), 3.62 (m, 
1H), 4.10 (m, 3H), 7.11 (br, 1H); . 
13
C NMR (CDCl3):  27.9, 29.6, 31.8, 47.5, 66.9, 70.2, 76.5, 133.8, 142.1, 174.7, 176.5, 
177.4, 201.3; 
HRMS(ESI
-
):  calcd for C9H15O9 315.0722, found 315.0741 ([M-H]
-
). 
 
2.2.6 Continuous assay of MenD- or mutant-catalyzed reactions using UV 
spectrophotometer 
 
The stock solutions of buffer and substrates were prepared as follows: Tris buffer was 
prepared by dissolving Tris in deionized water. The pH value was adjusted with HCl and 
determined with pH meter (100 mM, pH 7.4); ThDP and 2-KG were dissolved in Tris 
buffer and adjusted to pH = 7.4 with NaOH (1M). The typical stock solution for ThDP 
and 2-KG are 20 mM and good for kinetic assay within a month if stored at -20 
o
C. The 
MgCl2 solution was prepared as described for ThDP and 2-KG solution to obtain 1.0 M 
solution at pH 7.4. The typical enzyme concentrations were 5-20 M. The ISC or (±)-
CHCD solution was prepared and their concentrations were calibrated (refer to 2.2.7) and 
good for days. The assay stock solutions of ThDP, 2-KG, ISC or (±)-CHCD solution 
were stored at -20 
o
C and cooled on ice when the kinetic assay was being done. 
All assays were carried out at 25 
o
C in 1.4-ml quartz cuvettes with 1.0 cm path length 
using a Beckman Coulter DU 600/700 spectrophotometer and were performed in a 1 ml 
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(or 0.6 ml) total volume. Usually the reaction mixture containing components except ISC 
was pre-incubated for 5 min and then blanked before initiated with ISC. The reaction rate 
was determined by continuously monitoring the absorbance change at 278 nm or 300 nm. 
The initial rate was calculated on the basis of the extinction coefficients of the substrates 
(at 278 nm,  (ISC)= 8300 M-1.cm-1,86  ((±)-CHCD)= 4700 M-1.cm-1; at 300 nm,  
(ISC) = 3600 M
-1
.cm
-1
,  ((±)-CHCD)= 1700 M-1.cm-1;) by the equation 2.1:  
 
(2.1)      Min)/M(  
εΔt
10ΔA
   υ
6



  
 
Typically, the reaction mixture has a final concentration of 100 mM Tris-HCl (buffer, 
pH 7.4), 5 mM MgCl2, 50 M ThDP, 100 M 2-KG, 20 M ISC and appropriate 
concentrations of MenD or mutants (10, 30, 60 nM or higher for the low activity 
mutants).  All data points represent the average of at least two experiments. 
 
2.2.7 Determination of the concentrations of ISC and (±)-CHCD  
 
At first the concentration of ISC can be roughly determined. We assumed the ISC 
solution was pure and containing only ISC. The UV absorbance of 4 l ISC solution 
diluted in 596 l Tris buffer (100 mM, pH 7.4) was measured against the buffer at 278 
nm. The apparent concentration was then given according to Beer’s law A = lc.  
The more accurate concentration of ISC was then determined by the absorbance at 
278 nm by using  = 8300 M-1cm-1 as described below. To a 0.6 ml reaction mixture 
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containing 100 mM Tris (pH 7.4), 100 M 2-KG, 5 mM MgCl2, 50 M ThDP and 100 
nM MenD was added ISC (30 M, apparent conc. determined as described above) to 
initiate the reaction. The complete depletion of ISC monitored at 278 nm was related to 
the amount of ISC and therefore the concentration of ISC can be determined according to 
the ISC solution volume added and Beer’s law A = lc. 
The concentration of (±)-CHCD was determined in the same way using  = 4700 
M
-1
.cm
-1
 which was determined from the standard (±)-CHCD solutions prepared in 
volumetric flasks. 
 
2.2.8 HPLC analysis of the MenD reaction 
 
The reaction was performed at 25 
o
C in a 4 ml solution with a final concentration of 
100 mM Tris (pH 7.4), 2 mM MgCl2, 100 M 2-KG, 50 M ThDP, 60 nM MenD, 20 
M 3,4-dihydroxybenzene (3,4-DHB, as internal standard). From the reaction mixture, 1 
ml solution was transferred to a cuvette as blank solution for UV monitoring. After 
incubation for 5 min, the reaction was initiated by adding 7.5 l ISC (6.4 mM, final conc. 
16 M) to the 3 ml reaction mixture. From the 3 ml solution, 1 ml solution was 
transferred to a cuvette which was monitored on UV spectrophotometer with the blank 
solution at 278 nm. At the same time, every 3 min, 150 l of the solution was taken out 
from the remaining 2 ml reaction solution and quenched with 1 l formic acid solution 
(v/v, 10%) to pH = ca. 4. These quenched fractions were filtered through Nanosep 
centrifugal device with 30 kDa cut-off and cooled on ice prior to HPLC analysis. The 
HPLC analysis condition is as follows: Zorbax SB-C18 (4.6 × 250 mm) analytical RP 
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column, isocratic elution with 10% acetonitrile out of 0.1% formic acid (v/v), 25 
o
C, 1 
ml/min flow rate, injection of 50 l sample. All components were identified by 
comparison with authentic compounds. The 3,4-DHB and ISC were eluted at 7.3 min and 
8.0 min respectively. The concentration of ISC was quantified based on the ratio of 
integral area of 3,4-DHB and ISC peaks according to the response factor between the two 
compounds which was determined under the same conditions.  
 
2.2.9 Determination of a
mK  and 
a
maxV of the MenD reaction  
 
The MenD reaction was assayed as described in 2.2.6. The kinetic constants of the 
MenD reaction for individual substrate (2-KG and ISC) or cofactor (ThDP and Mg
2+
) 
were determined with the varied concentrations at the saturating concentrations of the 
other substrates or cofactors. The reaction was usually initiated with various 
concentrations of ISC. Kinetic constants were determined using the program Leonora
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by nonlinear least-squares fitting of the data to Michaelis-Menten equations 2.2 (vs. 
[S]). In the cases where the initial rates at the full range of substrate concentrations for 
saturation curve were not achievable experimentally, the kinetic parameters were 
estimated by the Hanes-Woolf plot ([S]/ vs. [S]) according to the equation 2.3. 
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where [S] represents the concentration of substrate, Km is Michaelis constant, Vmax is 
the maximal rate. 
     The same procedure was applied to the kinetic assay using CHCD as substrate instead 
of ISC. Since only (+)-enantiomer of racemic CHCD can react in the reaction, the actual 
working concentration of CHCD is a half of the concentration of the racemic CHCD 
solution. 
 
2.2.10 Inhibition study of 2-KG phosphonate analogues with respect to 2-KG 
     
The reaction mixture contained all components and appropriate inhibitors except 2-
KG. MenD with a final concentration of 60 nM was used and [ISC] was fixed at 20 M 
for the assay. After pre-incubation at 25 
o
C for 5 minutes, the reaction was initiated by 
addition of 2-KG with various concentrations (10, 15, 20, 40 M) at 5 fixed 
concentrations of each inhibitors. The inhibition type and the inhibition constants were 
determined graphically by a Dixon plot
68
 (1/ vs. [inhibitor] at four different [2-KG]) and 
Cornish-Bowden plot (plot [2-KG]/ vs. [inhibitor] at four different [2-KG]), based on 
the equation 2.4. 
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where [I] is the inhibitor concentration, iK is the inhibitor constant, S is the substrate 
2-KG. 
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2.2.11 Determination of the reversibility of the 2-KG phosphonate inhibition 
 
A fast dilution method was performed to test the reversibility of MMSP inhibition. 
Three parallel continuous assays were conducted: (1) to a 1 ml reaction mixture with 100 
mM Tris (pH 7.4), 5 mM MgCl2, 50 M ThDP and 10 M MMSP was added 60 nM 
MenD. The mixture was pre-incubated at 25 
o
C and finally initiated by 20 M 2-KG; (2) 
Same as (1) except that there is no MMSP added and MenD was pre-incubated with 
water (30 l MenD (28 M) was mixed with 10 l water) for 30 min before added to the 
reaction mixture, the final concentration of MenD is still 60 nM; (3) Same as (2), but 
MenD was pre-incubated with MMSP instead of water (30 l MenD (28 M) was mixed 
with 10 l MMSP (40 M)) for 30 min before added to the reaction mixture; the final 
concentration of MenD is still 60 nM.  
 
2.2.12 Kinetic mechanism study of the MenD reaction using CHCD 
 
The reaction rate was determined with 30 nM MenD, 100 mM Tris (pH 7.4), 5 mM 
MgCl2 and 50 M ThDP by varying the concentrations of 2-KG (4, 8, 16, 32, 64 M) 
with the constant concentration of CHCD at 5, 10, 20, 50 M respectively. The pattern of 
kinetic mechanism was distinguished as ping-pong bi bi enzymatic reaction by the double 
reciprocal plots (1/ vs. [2-KG] or [CHCD]). Kinetic constants were determined using 
the program Leonora by non-linear least-squares fitting of data to the rate equation as 2.5, 
which describes the initial rate in the absence of products for a ping-pong bi bi enzymatic 
reaction: 
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where [A] is the concentration of the substrate (2-KG) that first binds to MenD, [B] is 
the concentration of the second substrate (ISC or CHCD), A
mK  and 
B
mK  are the respective 
Michaelis constants for substrate A and B, and 
maxV  is the maximal velocity when both 
substrates are at saturating concentrations. 
 The dead-end competitive inhibitor monomethyl succinylphosphonate                                                                                                               
(MMSP) was used as a mechanistic tool to investigate the kinetic mechanism of MenD 
reaction with CHCD as an alternative substrate and substrate 2-KG was at the fixed non-
saturating concentration (~ a
mK ). The inhibition of MMSP with respect to CHCD was 
similarly determined by a Dixon plot (1/ against [inhibitor] at four different [CHCD]) 
and Cornish-Bowden plot ([CHCD]/ against [inhibitor] at four different [CHCD]). The 
reaction rate was determined with 60 nM MenD, 100 mM Tris (pH 7.4), 5 mM MgCl2, 50 
M ThDP.  [2-KG] was fixed at 6 M and [CHCD] was at 3 M, 6 M, 9 M, 18 M. 
[MMSP] was varied at 10 M, 20 M, 30 M and 40 M. 
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3. RESULTS AND DISCUSSION 
 
3.1 Chemical synthesis 
 
3.1.1 Chemical synthesis of phosphonate analogues of 2-KG  
 
 At the begining of synthesis of phosphonate analogues of 2-ketoglutarate (2-KG), a 
synthetic route which is coincidentally the same as reported by Bunik et al. later
59
, was 
explored. However, in our hands, the condition for the saponification of the carboxylate 
ester with NaOH or conc. HCl solution caused cleavage of the C-P bond to yield succinic 
acid.  
Fortunately, a modified route to the phosphonate analogues of 2-KG was developed 
successfully (Scheme 3.1). Succinic acid monobenzyl ester (1), prepared from succinic 
anhydride and benzyl alcohol according to the literature method
73
, was cleanly converted 
to the reactive acid chloride using oxalyl choride in the presence of a catalytic amount of 
DMF. The resulting acid chloride, in no need of further purification, readily reacted with 
trialkyl phosphite to yield the benzyl diester of succinyl phosphonate (2a-c) 
quantitatively from 1. The specific removal of one alkyl group from the phosphonate 
diester with 1.0 equivalent of  LiBr turned out to be very effective and the resulting 
lithium salt product was easy to isolate as a white precipitate (3a-c).  
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Scheme 3.1: Synthesis of phosphonate analogues of 2-KG. Reagents and conditions: a) benzyl alcohol, 
DMAP (cat.), anhydrous THF, reflux 12 h; (b) (1) oxalyl chloride (2 M in DCM), DMF (cat.), DCM, 1.5h; 
(2) trialkyl phosphite, 2 h; (c) LiBr (1.0 equiv.), acetonitrile; (d) EtOAc, formic acid, H2, Pd/C; Dowex 
[Na
+
]; (e)LiBr (2.2 equiv.), acetonitrile; (f) EtOAc, formic acid, H2, Pd/C; Dowex [Na
+
]; (g) trimethyl 
phosphite, 2 h; (h) LiBr (1.0 equiv.), acetonitrile; (i) 10a: NaI (1.0 equiv.), acetonitrile; 10b: LiBr (1.0 
equiv.), acetonitrile. 
 
An initial attempt to hydrogenolyse the benzyl group with Pd/C in methanol was not 
successful possibly due to poor solubility of the lithium salts (3a-c) in organic solvents. 
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The removal of the benzyl group was successfully achieved by adding formic acid, which 
helped solubilize lithium salts and facilitate hydrogenolysis as well, but the yielded 
product was found to be the phosphonate methyl ester resulting from acid-catalyzed 
esterification with methanol. This problem was then overcome by using a combination of 
formic acid and ethyl acetate. It turned out that formic acid and ethyl acetate worked very 
well to achieve the hydrogenolysis of benzyl ester in 3a-c without affecting the 
phosphonate ester. Crude products of 4a-c were purified with Dowex cation exchange 
resin to yield the pure sodium salt of 4a-c. Excess LiBr realized complete hydrolysis of 
the phosphonate diester to prepare compound 5. In the same way, the hydrogenolysis of 5 
in formic acid and ethyl acetate yielded succinyl phosphonate 6.  
For compounds 4a-c and 6, a fast H/D exchange of the 3-position ( to 2-keto) in 
D2O was observed on 
1
HNMR spectra. The signal due to H-3 gradually dissapeared in 
hours. As a consequence, the 
13
CNMR signal of the 3-carbon of compounds 4a-c and 6 
was not detected due to the deuterium coupling. These lithium salts are not soluble in 
common deuterated solvents including DMSO-d6. However, H/D exchange was not 
observed for compounds containing 4-carboxylic esters such as 3a-c. Therefore, the fast 
H/D exchange seems to be due to the 4-carboxylate group of 4a-c and 6, which facilitates 
the exchange at the 3-position. 
Compound 9a-b and 10a-b were prepared using the same strategy. All the 
phosphonate analogues including 3a-c, 4a-c, 6, 9a-b and 10a-b were chemically 
synthesized with good purity (>95%, NMR) in salt form, which are all water soluble and 
therefore convenient for the kinetic assay of MenD enzyme. As a result, our approaches 
88 
represent a versatile synthesis for an array of acylphosphonate analogues with varied 
carboxylate and phosphonate moieties. 
The 2-KG phosphonate analogues with a 2-hydroxyl group in place of the ketone 
were also synthesized, for instance, as compound 15 and 21 (Scheme 3.2 and Scheme 
3.3). In compound 15, the carboxyl group was also substituted with a phenyl ketone; in 
compound 16, the carboxyl group was changed to an amide. Starting from benzene and 
succinic anhydride, aldehyde 13 was prepared by LiAlH4 reduction and Swern oxidation 
via 11 and 12. The reaction of aldehyde 13 and dimethyl phosphite yielded compound 14, 
which was treated with 1.0 equiv. LiBr to afford 2-hydroxy monoester phosphonate 15.  
 
 
Scheme 3.2: Synthesis of phosphonate analogue 15. Reagents and conditions: (a) AlCl3, lit.76
,
77, 95%; (b) 
LiAlH4, THF, lit.78, 85%; (c) Swern [O], -78 
o
C, 96%; (d) DBU, THF, lit.80, 74%; (e) 1.0 equiv. LiBr, 
acetonitrile, 70 
o
C, 76%. 
 
Reduction of benzyl dimethyl phosphonate 2a by NaBH4 afforded the 2-hydroxyl 
product 16 (Scheme 3.3), which was then acetylated to protect the 2-hydroxyl group. 
89 
Hydrogenolysis of 17 freed the carboxyl group and got ready for forming amide 19, 
which was then deprotected to regenerate the alcohol. The phosphonate monoester 21 
was readily prepared using 1.0 equiv. LiBr. 
2-Hydroxyl phosphonates 15 and 21 are both water-soluble lithium salts and provide 
structural variety for the aforementioned 2-keto phosphonates, adding to a library of 
phosphonate analogues available for inhibition screening of MenD enzyme. 
 
 
Scheme 3.3: Synthesis of phosphonate analogues 21. Reagents and conditions: a) NaBH4, KH2PO4, H2O, 
69%; b) Ac2O, pyridine, 96%; c) H2, Pd/C, EtOAc, ca. 100%; d) Oxalyl chloride, DMF (cat.), CH2Cl2, 
benzylamine, Et3N, 33%; e)  Et3N, MeOH, 36%; f) LiBr, acetonitrile, 70 
o
C, 68%. 
 
3.1.2 Chemical synthesis of the analogues of ISC  
 
The synthesis of ISC analogues (±)-CHCD (28) started with the formation of the 
Diels-Alder product 23, which reacted with meta-chloroperoxybenzoic acid (m-CPBA) to 
afford epoxide 24 (Scheme 3.4).  
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Scheme 3.4: Synthesis of (±)-CHCD. Reagents and conditions: (a) Et3N, t-butyldimethylsilyl chloride, NaI, 
acetonitrile, 72%; (b) methyl propiolate, 60%; (c) m-CPBA, NaHCO3, CH2Cl2, 71%; (d) DBU (5.0 equiv.), 
CH2Cl2, 85%; (e) N2CHCOEt, Rh2(OAc)4, CH2Cl2, 71%; (f) AcOH/H2O (v/v 3:2), 84%; (g) LiOH (6 
equiv.), THF/H2O (v/v 4:1), Dowex [H
+
] or anion exchange resin, LiCl.   
 
Commercially available m-CPBA usually contains water as stabilizer and was found 
to cause low yield (ca. 10-15%). The yield was remarkably improved to 71% using dried 
m-CPBA that was prepared by dissolving wet m-CPBA in CH2Cl2 and drying over 
anhydrous Na2SO4 before use. Opening of the epoxide ring in 24 by DBU formed the 
cyclohexadiene isomer 25 at toom temperature. Introduction of the side chain was 
achieved by the Rh-catalyzed reaction with ethyl diazoacetate. The resulting compound 
26 was then deprotected by removing the t-butyldimethylsilyl group under acidic 
conditions, and hydrolyzed by excess LiOH in a mixture of THF and water to yield crude 
(±)-CHCD 28. The purification with a cation exchange resin column or anion exchange 
resin column afforded the acid form or lithium salt of CHCD, which are both water-
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soluble and convenient for kinetic assay. The ion exchange resin method enables a simple 
and scalable purification of usually unstable ISC analogues, eliminating tedious HPLC 
isolation. It was observed that (±)-CHCD demonstrated higher stability than ISC. 
Furthermore, this new CHCD synthetic strategy could be adapted to prepare different 
isochorismate analogues with a 1,3-dienebenzoate structure, for instance, trans-2,3-
dihydroxy-2,3-dihydrobenzoate or 3-hydroxy-2,3-dihydrobenzoate
65
. 
 
 
Scheme 3.5: Synthesis of (±)-CHCD methyl ester ((±)-CHCDMe). Reagents and conditions: Candida 
antarctica Lipase B, acetonitrile/H2O. 
 
Initially, Candida antarctica Lipase B was tried in order to develop a mild condition 
to hydrolyze compound 27 to prepare (±)-CHCD (28), or the optically active compound. 
However, the experimental results showed that the product was the methyl ester (±)-
CHCDMe (29, Scheme 3.5). Steric hindrance may be accountable for selective hydrolysis 
of esters by lipase. (±)-CHCDMe is water-soluble and was also tested in a kinetic assay 
of MenD enzyme as an ISC analogue. 
Several ISC analogues bearing a benzene core were prepared from the compound 30 
which was reported by Coleman et al. (Scheme 3.6)
84
. Methyl 2-bromopropanoate and 
methyl bromoacetate were used to introduce a side chain to the benzene core. Hydrolysis 
of compounds 31, 33 and 35a-b resulted in the carboxylic acid compounds 32, 34 and 
36a-b respectively. The removal of the methyl group from compound 31 was achieved 
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using BBr3 at -78 
o
C. These analogues were prepared as pure acid compounds that are 
soluble in the buffers for MenD assay and therefore could be tested as inhibitors or 
alternative substrates in the MenD reaction. 
 
 
Scheme 3.6: Synthesis of ISC analogues with benzene core. Reagents and conditions: a) 3084, NaI, K2CO3, 
MeCN, reflux, 77%; (b) LiOH, THF/H2O (v/v 2:1), 83%; (c) BBr3, CH2Cl2, -78 
o
C, 70%; (d) LiOH, 
THF/H2O (v/v 2:1), 56%; (e) NaI, K2CO3, MeCN, reflux, ca. 100%; (f) LiOH, THF/H2O (v/v 1:1). 36a: 
82%; 36b: 76%. 
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3.2 Mutagenesis and protein expression 
 
The wild type MenD and some mutants including S32A, S32D, R33K, R33Q, E55D, 
Q118E, S391A, R395A, R395K, and I418L were prepared previously in our lab, the 
plasmids (pMD14) harboring the genes for MenD and mutants were stored in XL1-Blue 
cell at -80 
o
C. MenD and mutants were all prepared by overexpression of individual 
plasmids (refer to 2.2.2). Four new mutants R107K, K293Q, R293K and R413K were 
prepared in the same PCR thermocyclic program (refer to 2.2.1) and the corresponding 
gene sequences were determined. The determined sequences were aligned with the wild 
type menD to identify the desired plasmids. All the four new mutants were confirmed as 
expected and the plasmids containing mutant genes were transformed to E. coli BL21-
Gold cell and overexpressed with IPTG induction. The plasmids containing the desired 
mutants were all successfully expressed and purified with Ni-affinity columns to 
homogeneous solution (refer to 2.2.2). 
 
Figure 3.1: SDS-PAGE gel of purified MenD mutants: 1. S32A; 2. S32D; 3. R33K; 4. R33Q; 5. E55D; 6. 
R107K; 7. Q118E; 8. R293K; 9. S391A; 10. S395A; 11. R395K; 12. R413K; 13. I418L; 14. K292Q; 
Ladder (Sigma-Aldrich). 
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 These four new mutants, together with freshly prepared mutants S32A, S32D, R33K, 
R33Q, E55D, Q118E, S391A, R395A, R395K and I418L from the stored plasmids in our 
lab were shown in one SDS-PAGE gel (Figure 3.1) with a MW= ca. 64 kDa (the wt-
MenD has 556 residues with MW= 61367 Da, plus N-terminal his-tag residues, the 
molecular weights of the enzymes used in all experiments amount to ca. 64 kDa.).  
 
3.3 Preparation of isochorismate (ISC) 
 
Although the preparation of isochorismate from chorismate catalyzed by EntC was 
performed previously in our lab, the scale of the reaction and purification seemed to have 
room for further optimization. In the step of acidification with HCl (refer to 2.2.3), it was 
found that the desired acid form of ISC might form a precipitate that would be removed 
by subsequent filtration. This could cause considerable loss of the desired ISC. Therefore, 
MeOH was added to dissolve more ISC so that all the ISC in the crude mixture could 
escape the filtration prior to FPLC purification. The yield was improved from 10-15% to 
40-45%. Because the conversion of chorismic acid to ISC by EntC is a thermodynamic 
equilibrium, the isolation yield is very satisfactory. 
 
3.4 Isochorismate analogues were tested for the MenD reaction  
 
In attempts to design inhibitors structurally analogous to isochorismate, trans-(±)-5-
carboxymethoxy-6-hydroxy-cyclohexa-1,3-dienecarboxylate ((±)-CHCD, 28) was 
synthesized as a racemic mixture (refer to 3.1.2). Experimental results indicated that (±)-
CHCD is not an inhibitor, but is recognized as a substrate by MenD. In Figure 3.2A, it is 
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shown that the drop of UV absorbance at 278 nm (the maximal UV absorbance 
wavelength of CHCD) corresponds to half of the quantity of CHCD used (A = 
1/2×30×10
-6
 M×1 cm×4700 M
-1
.cm
-1
) and remains substantially constant after the 
progress curve levels off; HPLC analysis clearly indicated that half the quantity of CHCD 
was consumed and the other half was unreactive (Figure 3.2B and Figure 3.2C).  
This apparently suggests that only one enantiomer of the racemic mixture was 
involved in the reaction, consistent with the high stereospecificity of enzyme reactions. In 
order to prove this assumption, unreacted CHCD was isolated with a preparative HPLC 
column (see 2.2.4) and its specific rotation was measured as 
D]α[  = -170 ± 10 (c 0.24, 
H2O), while for the synthetic racemic CHCD, D]α[  = -2 ± 2 (c 0.24, H2O) and for 
physiological substrate ISC, 
D]α[  = 220 ± 10 (c 0.18, H2O) as determined in our lab. 
These results strongly support that trans-(+)-CHCD is the substrate species involved in 
the MenD-catalyzed reaction, and thus acts as alternative substrate. Naturally, our interest 
turned to the kinetics of trans-(+)-CHCD transformation by MenD reaction and whether 
the unrecognized trans-(-)-CHCD inhibits the MenD reaction. Fortunately, it turned out 
that (-)-CHCD made no difference to MenD activity in the presence of ISC, thus racemic 
CHCD can be used in MenD reactions. As shown in Figure 3.2A, the reaction progress 
curve of the MenD reaction utilizing racemic CHCD (UV absorbance at 278 nm of 
CHCD over time in minutes) is essentially the same as using ISC, therefore kinetics of 
the MenD reaction utilizing CHCD can be determined as a regular MenD assay, i.e. 
monitoring the depletion of CHCD over time by UV spectrophotometer (refer to 2.2.6). 
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Figure 3.2: Comparison of HPLC and spectrophotometric analysis of the MenD reaction utilizing trans-(±)-
CHCD. The reaction was performed with 60 nM MenD, 100 mM Tris (pH 7.4), 5 mM MgCl2, 50 M 
ThDP, 100 M 2-KG and 30 M (±)-CHCD. The HPLC elution buffer was 5% ACN, 95% formic acid 
solution (0.1%, v/v) and the detection wavelength was 278 nM. (A) A progress curve detected 
spetrophotometrically at 278 nM. ▲ Blank reaction mixture containing all components but 2-KG; ■ 
reaction mixture initiated with 2-KG; (B) reaction mixture before initiation with 2-KG, the area of CHCD 
(retention time: 7.28 min) was 379.5 mAU*s; (C) reaction mixture quenched at 30 min after the initiation 
with 2-KG, the area of CHCD was 188.6 mAU*s. 
 
 
  The methyl ester of trans-(±)-CHCD (i.e. CHCDMe, compound 29, refer to 2.1.2) 
was tested as a substrate of MenD. In contrast to CHCD, CHCDMe was found not to be 
accepted by MenD; no change in UV absorbance was detected. The methyl ester of the 
side chain is probably not compatible with the basic residues surrounding where 
carboxylates of ISC presumably locate in the active site of MenD (Figure 1.13). This 
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suggests the involvement of unsaturated carboxylic moiety of ISC in the enzyme-
substrate interaction. 
Several isochorismate analogues with a benzene ring core (compound 32, 34, and 
36a&b, refer to 3.1.2) were also tested as inhibitors of the MenD reaction. Unlike the 
inhibitory efficacy they (or close analogues) exhibited for salicylate synthase or 
isochorismatase
64,66
, compounds 32, 34, 36a and 36b were neither substrate nor inhibitor 
for MenD. This suggests that the active site of MenD is unable to accommodate the flat 
benzene core. 
 
3.5 Characterization and analysis of CCHC   
 
 
Figure 3.3: HPLC chromatogram of MenD reaction mixture using CHCD as substrate. Conditions: detector 
wavelength at 210 nm; Zorbax SB-C18 (9.4 × 250 mm) semi-preparative column; isocratic elution with 5% 
acetonitrile and 95% formic acid (0.1%). 
 
As noted above, trans-(+)-CHCD is recognized as an alternative substrate by MenD, 
therefore it is reasonable to assume the formation of an SEPHCHC-like product from the 
reaction. However, 
1
HNMR analysis of the MenD reaction mixture using CHCD failed to 
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detect the signal of predicted SEPHCHC-like product; HPLC isolation with semi-
preparative column was not successful either, although several unexpected peaks were 
found in the chromatogram (Figure 3.3). The peak with a retention time 23.5 min was 
attributed to unreacted (-)-CHCD by comparison with a sample spiked with authentic 
CHCD. The fractions at 37.5 min, 42.2 min and 66.8 min were unknown and were 
collected. The fractions at both 37.5 min and 42.2 min yielded white solids after 
lyophilization.  
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Figure 3.4: The product from fraction at 37.5 min (refer to Figure 3.3). a) SEPHCHC and analogue 37; b) 
UV scan of the product. 
 
The UV scan of the product from the fraction at 37.5 min revealed a maximal 
absorbance at 228 nm with an extinction coefficient of 12000 M
-1
.cm
-1
, suggesting a 
conjugated structure different from the expected SEPHCHC-like product (compound 37, 
Figure 3.4), which is expected to be  UV inactive, as observed for SEPHCHC, due to the 
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absence of a conjugated π-system. Extensive analysis using NMR was then conducted to 
determine the chemical structure of the compound. Structural analysis including 
1
HNMR, 
COSY, Jmod-
13
CNMR and HMQC as shown below (Figure 3.5, Figure 3.6, Figure 3.7 
and Figure 3.8) clearly suggest that the compound is actually 5-carboxylmethoxyl-2-(3-
carboxypropionyl)-6-hydroxy-cyclohex-2-enecarboxylate (CCHC). Its configuration was 
assumed to be the same as that of SEPCHC, in accordance with the specific nature of 
enzyme reactions
15
. Furthermore, high resolution mass spectrometry also supported this 
assignment (see 2.2.5).   
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Figure 3.5: 
1
HNMR spectroscopy of CCHC. 
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Figure 3.6: Jmod-
13
CNMR spectroscopy of CCHC. 
 
 
Figure 3.7: H-H COSY spectroscopy of CCHC. 
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Figure 3.8: HMQC spectroscopy of CCHC. 
 
 
Figure 3.9: Proposed Diels-Alder product of CHCD. The fraction at 42.2 min (refer to Figure 3.3 ). 
 
The fraction at 42.2 min as shown in Figure 3.3 is identified as the Diels-Alder 
product of two CHCD molecules according to the NMR analysis (NMR spectra were 
attached in Appendix), but the relative configuration was not fully determined (Figure 
3.9). This finding could account for the instablility of a CHCD stock solution and why 
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the freshly prepared solution must be calibrated in concentration by full MenD-catalyzed 
conversion before the kinetic assay. 
In conclusion, CCHC was isolated as the product from the MenD-catalzyed reaction 
using CHCD as substrate and its structure was well characterized on the basis of NMR 
and MS in good agreement with its UV scan. 
  
 
Figure 3.10: Proposed mechanism of CCHC formation. 
 
Questions arose here why the isolated product is CCHC but not compound 37 when 
CHCD was used in the MenD reaction. A plausible answer is that CCHC comes from 37 
by allyl isomerization (Figure 3.10). As noted earlier (refer to 1.2), MenD was long 
annonated as SHCHC synthase until Guo et al. suggested that the real product is 
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SEPHCHC and SHCHC is formed by spontaneous elimination or upon catalysis of 
enzyme MenH from SEPHCHC
13,14,15
. This might be due to the fact that SEPHCHC is a 
base-labile compound and elusive from UV detection. Following this idea, a mechanism 
for CCHC formation was proposed (Figure 3.10). As with the formation of SEPHCHC 
from ISC, the SEPHCHC-like analogue 37 is supposed to be produced from CHCD by 
MenD, but due to the acidic -proton of the ketone, this analogue readily enolizes to 
facilitate subsequent elimination and therefore lead to CCHC or even SHCHC. In the 
case of SEPHCHC, the formation of SHCHC is thermodynamically favored because of  
the superior leaving inclination of the enolpyruvyl side chain in SEPHCHC, but in the 
case of compound 37, the formation of CCHC becomes favored.  
In order to confirm our assumption, MenD reaction mixtures using racemic CHCD as 
the substrate were analyzed by HPLC. As shown in Figure 3.11, identical volumes from 
the same reaction mixture taken immediately after the reaction finished, and 16 hours 
later, were analyzed by HPLC. In the upper chromatogram, unreacted (-)-CHCD and very 
small CCHC peaks can be seen, while over 16 hours (lower chromatogram) CHCD peak 
remained the same but the CCHC peak significantly increased, i.e. thermodynamically 
more stable CCHC was formed from the undetected intermediate slowly and 
spontaneously. The undetected intermediate is proposed to be compound 37. Similarly, in 
the case of MenD reaction utilizing ISC, Guo et al. indicated asynchronous substrate 
comsuption and SHCHC formation
6
. Furthermore, when isolated pure CCHC was 
dissolved in pH 12-13 solution overnight on the bench, HPLC analysis clearly showed 
formation of SHCHC by this treatment (Figure 3.12, the upper chromatogram is pure 
CCHC solution, the lower is NaOH-treated CCHC solution).  
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Immediately after reaction
Wavelength 228 nm
16 hours after reaction
Wavelength 228 nm
 
 
Figure 3.11: HPLC analysis of MenD reaction using CHCD. Conditions: Zorbax SB-C18 analytical 
column; isocratic elution with 5% acetonitrile and 95% formic acid (0.1%); flow rate at 1.0 ml/min. 
 
 
CCHC
CCHC
SHCHC
Wavelength 230 nm
Wavelength 293 nm
 
 
Figure 3.12: HPLC analysis of CCHC solution at pH 12-13. Conditions: Zorbax SB-C18 analytical column; 
isocratic elution with 5% acetonitrile and 95% formic acid (0.1%); flow rate at 1.0 ml/min. 
105 
As a result, these evidences strongly support the proposed conversion mechanism of 
compound 37 to CCHC and SHCHC (Figure 3.10). Interestingly, after we finished 
studies of CHCD-utilized MenD reaction, similar work by Müller et al. emerged in the 
literature and a CCHC-like product was reported
65
. MenD was found to turn over 
(2S,3S)-2,3-dihydroxy-2,3-dihydrobenzoate (2,3-CHD), a simple compound lacking the 
side chain of CHCD or ISC. The authors successfully observed SEPHCHC-like product 
and slowly formed CCHC-like stable compound by NMR spectroscopy (Figure 3.13).  
Moreover, according to this report MenD has a much broader substrate scope than 
expected. Considering racemic trans-CHD and trans-CHCD can be prepared using our 
CHCD synthetic route in large lab scale, the combination of MenD and CHCD synthesis 
strategy is of great interest in chemoenzymatic synthesis of certain optically pure 
molecules. For example, it is certain that MenD can be used in preparing optically pure 
trans-(-)-CHCD and (2R,3R)-2,3-CHD from their racemates.  
 
 
 
Figure 3.13: (2S,3S)-2,3-dihydroxy-dihydrobenzoate (2,3-CHD)-utilized MenD reaction
65
. 
 
 
3.6 The continuous and HPLC assay of the MenD reaction using ISC 
 
When MenD was considered an SHCHC synthase, kinetic assay was performed in a 
coupled assay by determing NADH depletion rate in conversion of concomitantly formed 
pyruvate to lactic acid by lactate dehydrogenase (LDH)
14
. When MenD was demonstrated 
to be an SEPHCHC synthase producing SEPHCHC and carbon dioxide, Guo et al. 
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conducted kinetic assays by monitoring UV absorbance of substrate ISC at 278 nm
6
. This 
assay method is very attractive due to features of being handy and not disturbing reaction 
mixture. To ensure the validation of the continous assay by UV spectrophotometer, and 
to confirm the new functional assignment of MenD, the MenD reaction was carefully 
evaluated by UV spectroscopy and HPLC analysis.  
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Figure 3.14: The MenD-catalyzed reaction progress curve monitored at 278 nm by UV spectrophotometer. 
Conditions: 100 mM Tris buffer (pH 7.4), 5 mM MgCl2, 50 M ThDP, 100 M 2-KG and 8 M ISC, at 25 
o
C. The concentrations of MenD were 90 nM, 60 nM and 30 nM respectively. 
 
In continuous assays, the time-dependent depletion of ISC was monitored by 
observing the UV absorbance at 278 nm. Unlike the usual exponential progress curve for 
first-order reactions, the disappearance of substrate proceeds in a linear fashion as shown 
in Figure 3.14, suggesting a zero-order dependence on this substrate, perhaps due to the 
very small saturating concentration for ISC. After the depletion of ISC, the progress 
curve levels off sharply, then increases slowly, interpreted to represent a slow and 
spontaneous formation of SHCHC
6
.  
107 
 
Retention time / min
0 min
3 min
18 min
30 min
60 min
22 hours
3,4-DHB
ISC
SHCHC
5 6 7 8 9
Reaction time
A
2
9
3
/ 
m
A
U
30
30
30
30
30
40
0
4
A
 
Figure 3.15: HPLC analysis of the MenD reaction using ISC. Conditions: refer to 2.2.8, the detection 
wavelength for HPLC was 293 nm. 
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Figure 3.16: Comparison of UV and HPLC-observed progress curve of the MenD reaction using ISC. 
Conditions: refer to 2.2.8, the detection wavelength for HPLC was 293 nm. 
 
In order to validate the continuous assay by a UV spectrophotometer, concentrations 
of ISC during the process of reaction were determined by HPLC analysis. Aliquots of the 
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reaction mixture were quenched by formic acid to pH = ca. 4-5 at certain intervals and 
then analyzed in parallel by HPLC under the same conditions. Quenching the reaction 
mixture aliquots with formic acid to pH = ca. 4-5 did not decompose ISC within the 
analysis time period, or else faster ISC depletion would be mistakenly observed in 
comparison with UV detection. The internal standard 3,4-dihydroxy-benzoic acid (3,4-
DHB) was used to quantify the concentration of ISC (Figure 3.15). It was observed that 
the ISC peak was decreasing during the reaction process, while SHCHC was formed 
slowly, obviously asynchronous to the ISC depletion. After ISC was depleted completely 
at ca. 30 min, SHCHC still slowly accumulated over 22 hours. This observation is 
consistent with Guo’s proposal that SHCHC forms from UV-inactive SEPHCHC 
irrelevant of MenD catalysis under assay conditions, and the progress curve after ISC 
depletion moves up because of SHCHC accumulation
6
. The parallel experiments (Figure 
3.15 and Figure 3.16) demonstrate the same rates of ISC consumption, which was 
represented by the slope of linear dropping progress curves. These results clearly indicate 
that the UV absorbance change at 278 nm of MenD reaction mixture is due to ISC 
consumption and the slope of this line represents MenD-catalyzed activity. 
In the presence of saturating 2-KG, MgCl2 and ThDP, the MenD reaction can be 
considered a pseudo-first-order reaction, according to rate = kcat[E], reaction rates should 
be proportional to enzyme concentrations. Figure 3.14 indeed demonstrates the slopes of 
the dropping linear part are proportional to the enzyme concentrations (slope ratio = -
0.0019: -0.0042: -0.0059 = 1:2:3, concentration ratio = 30 nM: 60 nM: 90 nM = 1:2:3), 
supporting the validation of using ISC consumption rate to represent turnover rate.  
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In conclusion, UV absorbance change of the MenD-catalyzed reaction mixture at 278 
nm as a function of time was confirmed to be the rate of ISC consumption; SHCHC is not 
the direct turnover product of MenD catalysis. In section 3.4, trans-(+)-CHCD was found 
to be an alternative substrate of MenD. Considering that trans-(+)-CHCD has almost the 
same UV absorbance spectroscopy as ISC, the continous assay of MenD reaction using 
ISC can be expanded to the case of MenD-catalyzed CHCD consumption. 
 
3.7 Determining concentration and 300 of ISC and (±)-CHCD  
 
Because ISC and (±)-CHCD are not stable in solution, it is necessary to use freshly 
prepared solutions to determine accurate kinetic constants. Initially, the ISC solution 
concentration was calibrated by determining its absorbance at 278 nm, but this method 
proved to be problematic. As shown in Figure 3.14 and Figure 3.16, referring to blank 
solution containing all components but ISC, after full consumption of ISC the UV-
observed progress curve should reach the X-axis as HPLC-observed curve shows. But the 
UV absorbance does not drop to zero in the spectrophotometric assays. The use of fresh 
ISC solution reduced but could not eliminate this problem. Therefore it was reasoned that 
the absorbance of ISC solution at 278 nm could not be attributed solely to ISC. 
In order to determine accurate concentrations of ISC and (±)-CHCD, full enzymatic 
conversion of MenD in the presence of excess 2-KG is a suitable strategy
86
. By using 278 
= 8300 M
-1
.cm
-1
 for ISC
86
 and 278 = 4700 M
-1
.cm
-1
 for (±)-CHCD (refer to 2.2.7), UV 
absorbance drops measured from reactions can be used to determine substrate 
concentrations.  
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In the cases of assaying some mutants, higher concentrations of enzyme, ThDP or 
substrates were needed. These species have moderate or high absorbance at 278 nm, 
causing too high background noise of the reaction mixture to determine the absorbance 
decrease due to ISC or CHCD consumption; hence the absorbance at 300 nm was usually 
measured to circumvent the problem. Thus, it was required to determine the extinction 
coefficients of ISC and CHCD at 300 nm. Since the 278 of ISC and CHCD were already 
known, the experiment as follows was designed: in a 1.4 ml quartz cuvette, 0.6 ml total 
volume reaction mixture containing 100 mM Tris buffer (pH 7.4), 5.0 mM MgCl2, 50 M 
ThDP, 100 M 2-KG, 150 nM MenD and 10 M ISC was scanned 
spectrophotometerically in a range of 240-320 nm at an interval time of 1 min (Figure 
3.17). In Figure 3.17A, it shows that the UV absorbance of the enzymatic reaction 
mixture decreased due to the ISC depletion and stopped at ca. 7 min. The UV 
absorbances at 278 nm and 300 nm were extracted from each scan and plotted with 
respect to time, as shown in Figure 3.17B. The results clearly indicate that the monitoring 
at 278 nm and 300 nm is representing ISC depletion at the same pace and therefore it is 
valid to assay the reaction monitoring UV absorbance at 300 nm. Furthermore, because 
the absorbance decrease of the full enzymatic conversion of ISC at 278 nm represents the 
same amount, the 300 of ISC could be derived according to 8300
278
300 


A
A
(M
-1
.cm
-1
). 
From three repetitions of the experiments as above, the average 300 of ISC was 
determined as 3600 M
-1 
cm
-1
. The value was used in all the kinetic assays when 
applicable. 
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Figure 3.17: Determination of the extinction coefficient of ISC at 300 nm. A) Time-dependent UV scans of 
MenD reaction mixture using ISC as substrate; B) UV absorbance decreases at 278 nm and 300 nm using 
the data extracted from A. 
 
Similar experiments were also conducted for enzymatic conversion of (±)-CHCD, 
and the same conclusion was drawn. The 300 for (±)-CHCD was determined to be 1700  
M
-1
.cm
-1
 (Figure 3.18). Recall, because only one enantiomer of CHCD is reactive in 
MenD-catalyzed (or some mutants) reactions, reactive concentrations of CHCD are half 
of the racemic CHCD solution used for assays.  
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Figure 3.18: Determination of the extinction coefficient of ISC at 300 nm. A) Time-dependent UV scans of 
MenD reaction using (±)-CHCD as substrate; B) UV absorbance decrease at 278 nm and 300 nm using the 
data extracted from A. 
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3.8 Activity assays of MenD and mutants 
 
Although the MenD-catalyzed reaction is a bi-substrate reaction, it becomes a pseudo 
uni-substrate reaction when all the other substrates and cofactors are at saturating 
concentrations. The activities of MenD and mutants were assayed using continuous UV 
monitoring of the consumption of ISC and (±)-CHCD at 278 nm or 300 nm. All the 
apparent kinetic parameters including
a
mK ,
a
catk , 
a
m
a
cat Kk /  were derived from the saturation 
curves or Hanes-Woolf plots of the substrates (2-KG, ISC and CHCD) and cofactors 
(MgCl2 and ThDP).  
The very small saturating concentration or 
a
mK  
observed for ISC makes it easy to 
obtain a linear ISC depletion curve (refer to Figure 3.14), but almost impossible to 
determine the initial rate at a very low concentration of ISC due to the short time period 
allowed for measurement and the background absorbance noise (applied to MenD and 
most but not all mutants studied). Guo et al. reported 
a
mK  
value of ISC measured for wt-
MenD is 0.053 ± 0.003 M, corresponding to < 0.00083 AU UV absorbance6. This small 
value precludes accurate measurement of initial rates with varied ISC concentrations 
below 
a
mK  of ISC, which is required to obtain saturation curve of ISC. For the mutants 
having a very large saturation concentration for ISC or CHCD, the UV absorbance is too 
high to measure with a UV spectrophotometer. The apparent kinetic parameters were 
hence unable to be determined. In such cases, kinetic constants were estimated from 
Hanes-Woolf plot.  
The saturation curves for 2-KG, ThDP and Mg
2+ 
of wild type MenD reaction, typical 
of Michaelis-Menten kinetics, are shown in Figure 3.19 and kinetic constants were 
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derived from them. The kinetic parameters of mutant S32A, S32D, R33K, R33Q, E55D, 
R107K, K292Q, R293K, S391A, S395A, S395K, R413K, and I418L were measured in 
the same way. 
 
 
Figure 3.19: Saturation curves of the MenD-catalyzed reaction. (A) 2-KG Saturation curve of MenD. The 
reaction rate was determined with 10 nM MenD, 100 mM Tris (pH 7.4), 5 mM MgCl2, 50 M ThDP and 
16 M ISC; (B) ThDP Saturation curve of MenD. The reaction rate was determined with 10 nM MenD, 
100 mM Tris (pH 7.4), 5 mM MgCl2, 16 M ISC and 100 M 2-KG; (C) MgCl2 Saturation curve of MenD. 
The reaction rate was determined with 10 nM MenD, 100 mM Tris (pH 7.4), 50 M ThDP, 16 M ISC and 
100 M 2-KG. 
 
3.9 Inhibition of the MenD-catalyzed reaction with phosphonate analogues of 2-KG 
 
In line with pioneering work by Kluger and Pike using a phosphonate analogue of 
puruvate (MAP, refer to section 1.7.1) to study pyruvate dehydrogenase (PDH-E1)
51
, 2-
keto phosphonate analogues, which are close steric analogues of 2-KG, were surmised to 
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behave as inhibitors of MenD. Eleven 2-keto phosphonate compounds were synthesized 
and assayed as inhibitors of the MenD reaction. As expected, it was found that these 
phosphonates demonstrate inhibition of MenD with varied efficiencies. 
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Figure 3.20: Graphic determination of MMSP inhibition of the MenD-catalyzed reaction. (A) Dixon plot 
(1/rate vs. [MMSP]); (B) Cornish-Bowden plot ([2-KG]/rate vs. [MMSP]). The reaction rate was 
determined with 60 nM MenD, 100 mM Tris (pH 7.4), 5 mM MgCl2, 50 M ThDP and 16 M ISC. [2-
KG] was at 10 M (▲), 15 M (Δ), 20 M (■), 40 M (□). 
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Inhibition type and inhibition constants were determined graphically by a 
combination of Dixon plot (1/ vs. [inhibitor] at four different [2-KG]) and Cornish-
Bowden plot ([2-KG]/ vs. [inhibitor] at four different [2-KG]). For instance, the Dixon 
plot and Cornish-Bowden plot as shown in Figure 3.20 suggest that monomethyl succinyl 
phosphonate (MMSP) is a reversible, competitive inhibitor with respect to 2-KG in the 
MenD reaction (refer to section 1.8). The inhibition constant ( iK ) of MMSP is 0.7 ± 0.1 
M as indicated in Figure 3.20A, showing very potent inhibition in terms of Michaelis 
constant of 2-KG (9.9 ± 0.6 M, Table 3.1).  
The structures of the 2-KG phosphonates tested and the inhibition results are 
summarized in Table 3.1. Among these phosphonates, succinylphosphonate (SP) was 
determined as an inhibitor with Ki of 150 ± 10 M. Careful inspection of the HNMR 
spectrum of SP revealed the presence of residual MMSP (ca. 0.5%). Since SP has one 
more negative charge than 2-KG, very likely the observed inhibition is due to a small 
amount of the potent MMSP. The same observation was reported by Kluger and Pike in 
their inhibition study of PDH using acetyl phospohnate (AP)
51
.  
Following the successful example of MMSP as inhibitor, phosphonates with varied 
phosphonate ester and carboxyl groups were tested (Table 3.1). Compounds MMSP, 
MESP and MISP, bearing same number of charges as 2-KG, demonstrate varied potency 
of inhibition. Increasing the size of the phosphonate monoester causes one order of 
magnitude dropping of inhibition potency. Steric hindrance appears to be accountable for 
weaker binding affinity between MenD and inhibitor, implying close recognition of the 
1-carboxylate of 2-KG (the counterpart of the phosphonate monoester moiety) by the 
active site.  
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Table 3.1: Inhibition constants of 2-KG phosphonate analogues for MenD reaction. * ca. 0.5% MMSP 
contained.       
Compounds Structure 
iK  (M) 
 
Monomethyl succinylphosphonate                                                                                                               
(MMSP) 
 
-O
O
P
O
O
OMe
O-
 
0.7 ± 0.1 
 
Monoethyl succinylphosphonate 
(MESP) 
 
-O
O
P
O
O
OEt
O-
 
16 ± 1 
 
Monoisopropyl succinylphosphonate                                                                                                           
(MISP) 
 
-O
O
P
O
O
OiPr
O-
 
170 ± 10 
 
Methyl monomethyl succinylphosphonate 
(MMMP) 
 
MeO
O
P
O
O
OMe
O-
 
240 ± 20 
 
Ethyl monomethyl succinylphosphonate 
(EMMP) 
 
EtO
O
P
O
O
OMe
O-
 
1630 ± 90 
 
Benzyl monomethyl succinylphosphonate 
(BMMP) 
BnO
O
P
O
O
OMe
O-
 
160 ± 10 
 
Benzyl monoethyl succinylphosphonate 
(BMEP) 
BnO
O
P
O
O
OEt
O-
 
1320 ± 60 
 
Benzyl monoisopropyl succinylphosphonate 
(BMIP) 
BnO
O
P
O
O
OiPr
O-
 
6700 ± 400 
 
            Monomethyl butyrylphosphonate 
(MMBP) 
 
P
O
O
OMe
O-
 
- 
 
           Methyl acetylphosphonate 
(MAP) 
 
P
O
O
OMe
O-
 
- 
 
Succinylphosphonate
 
(SP) 
 
-O
O
P
O
O
O-
O-
 
150 ± 10
*
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Surprisingly, the phosphonates bearing a carboxylic ester as MMMP, EMMP, 
BMMP, BMEP and BMIP also inhibit MenD with appreciable potency. It appears that 
the active site of MenD allows flexibility for recognizing the 4-carboxylate anion of 2-
KG, tolerant of neutral carboxylic esters. In order to study the role of the carboxyl group 
in inhibition, analogues MMBP and MAP, which lack a carboxyl moiety, were prepared 
and tested as inhibitors. It was found that neither of the two analogues inhibits the MenD 
reaction at concentrations up to 10 mM, implying that the 4-carbonyl group is necessary 
for binding.  
BMMP, BMEP and BMIP demonstrate the same trend as MMSP, MESP and MISP: 
inhibition constants increase with increasing size of the alkyl group of the phosphonate 
esters. Unexpectedly, although BMMP has a benzyl ester, which is bulkier than the 
methyl ester of MMMP and the ethyl ester of EMMP, BMMP exhibits a slightly lower 
inhibition constant than MMMP and a 10-fold lower inhibition constant than EMMP.  
Structural analysis of 2-keto acid-utilizing ThDP-dependent enzymes with bound 
intermediates or intermediate phosphonate analogues revealed a common three-centered 
binding mode for 2-keto acid substrates, including the interactions specific for leaving 
group (1-carboxylate), 2-carbonyl/carbinol and substrate substituents
55,56,87
. In POX, the 
methyl substituent of LThDP is located in a hydrophobic pocket formed by V394, F121, 
W479 and isoalloxazine of FAD, whereas, for BFDC and BAL, the larger substituents of 
their substrates are accommodated in a wider pocket consisting of several aromatic 
residues
39,52,53
. In contrast, the solved MenD structure indicated that the possible binding 
pocket for the carboxyethyl substituent of 2-KG consists of basic residues such as 
arginines and lysines. Stabilization of π-π stacking or cation-π interaction, between the 
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phenyl group of BMMP and the binding pocket as shown in MenD structure
31
, may 
account for the inhibition enhancement. In conclusion, inhibition results of the 2-KG 
phosphonates indicated that appreciable variation is allowed by the 2-KG substituent 
binding pocket, implying a broad scope of accepted substrates. This is consistent with the 
report that MenD catalyzed unphysiologically C-C forming reaction for a variety of 2-
keto acids
65
. Undoubtedly, an X-ray structure of MenD with a trapped ThDP-
phosphonate adduct will reveal more information about this binding pocket. This kind of 
study will be greatly instructive not only for understanding catalysis mechanism, but also 
for identification and modification of the relevant residues in order to favorably alter 
MenD’s substrate specificity. 
Both compound 15 and 21, different from the 2-keto phosphonate analogues above 
(refer to section 3.1.1),  are 2-hydroxy phosphonate monoesters. The former has a phenyl 
ketone and the latter has a benzyl amide. Inhibition assays indicated that neither of them 
inhibited the MenD reaction although they have very similar structures as the inhibitory 
2-keto phosphonates. This outcome may be rationalized by the underlying principle that 
2-keto analogues form a covalent adduct with ThDP, and the 2-keto function is necessary 
for this.  
MenD is a proposed drug target, particularly for antituberculosis drugs
4,
Error! 
Bookmark not defined.. The inhibitory phosphonate analogues mentioned above are the 
first reported inhibitors of MenD, therefore these compounds were tested for inhibition of 
mycobacterial growth. Unfortunately, these inhibitors did not show significant inhibition 
of M. tuberculosis growth in vitro under aerobic and hypoxic conditions
88
. 
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3.10 Reversibility of the inhibition by 2-KG phosphonate 
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Figure 3.21: Progress curves of MenD reaction for test of inhibition reversibility.  Assay conditions: at 25 
o
C, Tris (pH 7.4) 100 mM, MgCl2 5 mM, ThDP 50 M, ISC 10 M and MenD 60 nM. (▲) reaction 
mixture containing 10 M MMSP was initiated with 2-KG; (□) MenD was pre-incubated with water for 30 
min, reaction mixture was initiated with 2-KG; (■) MenD was pre-incubated with MMSP for 30 min, 
reaction was initiated with 2-KG. 
 
Kinetic analysis of the MenD reaction indicated graphically that 
succinylphosphonates are inhibitors of MenD in a reversible, competitive manner. In 
order to further investigate the reversibility of the inhibitions, MenD pre-equilibrated 
with MMSP was diluted as described in section 2.2.11. In the experiment, MenD (30 L 
MenD (28 M)) was preincubated with MMSP (10 L MMSP (40 M)) over 30 min at 
room temperature, so in the mixture, [MenD] = 21 M and [MMSP] =10 M; then 6.29 
L of the mixture was added to a reaction mixture of 2200 L, so the actual [MMSP] in 
the final reaction mixture was 0.029 M (only 4% of Ki 0.7 M of MMSP). As shown in 
Figure 3.21, MenD pre-incubated with only water (□) and with MMSP (■) were 
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compared. Progress curves indicated the same reaction rate within experimental error, 
suggesting that the activity of MenD pre-incubated with MMSP was recovered quickly 
due to dilution of inhibitor. In contrast, obvious inhibition was observed with 10 M of 
MMSP (▲). Thus, the dilution method demonstrated that MMSP binds reversibly to 
MenD. 
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Figure 3.22: Test for time-dependence of MMSP inhibition. Reaction conditions: at 25 
o
C, Tris (pH 7.4) 
100 mM, MgCl2 5 mM, ThDP 50 M, ISC 20 M and MenD 60 nM. (A) Reactions were initiated with 2-
KG after 5 min incubation of MenD and MMSP. (B) Reactions were initiated with MenD after 5 min 
incubation of all reagents but MenD. (■) [MMSP] 400 M; (▲) [MMSP] 100 M; (Δ) [MMSP] 0 M. 
 
In order to test time-dependence of inhibition, parallel experiments of kinetic assay 
in the presence and the absence of MMSP were performed. As shown in Figure 3.22, 
when [MMSP] = 100 or 400 M in the presence of saturating [2-KG], almost full 
inhibition of MenD activity was observed equally regardless of 2-KG or ISC initiation. 
All the progress curves are linear without time-dependent increase of inhibition within 
the steady-state assay time period. In addition, no time lag was observed with MenD 
initiation, ruling out significant time-dependent inhibition caused by slow binding 
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between MMSP and MenD. This observation is consistent with previous studies in 
PDH
23,51
 and BFDC
52
.   
In summary, the kinetic analysis, including the dilution method and alteration of 
initiation order of substrates, suggests that these phosphonates inhibit MenD by 
establishing a rapid, reversible equilibrium with the ThDP-MenD complex. 
 
3.11 Kinetic mechanism of the MenD reaction 
 
In the proposed mechanism of the MenD-catalyzed reaction (Figure 1.5), a ping-pong 
bi bi mechanism was surmised. It seems to be very likely that 2-KG must bind to MenD 
first, and only after carbon dioxide is released, and the resulting post-decarboxylation 
product can subsequently react with isochorismate. Usually, the double reciprocal plot for 
ping-pong bi bi reaction results in a set of parallel lines when one substrate concentration 
is varied at several constant concentrations of the other substrate (Figure 1.23B). 
For the MenD-catalyzed reaction of CHCD, it was found that the 
a
mK  of (+)-CHCD 
(12.0 ± 0.6 M, Table 3.2), in contrast to that of ISC, is a spectrophotometrically 
measurable value. This value allows determination of reaction rate at several different 
concentrations of (+)-CHCD below value of 
a
mK , so that an accurate value can be 
determined.  
As shown in Figure 3.23, when both [2-KG] and [CHCD] are varied around their 
individual 
a
mK  
values, the double reciprocal plots of either 1/rate vs. 1/[2-KG] or 1/rate 
vs. 1/[CHCD] exhibited parallel lines.This demonstrated kinetically for the first time that 
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the reaction catalyzed by MenD follows a ping-pong bi bi mechanism if 2-KG was 
assumed to bind to MenD first based on the proposed mechanism. 
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Figure 3.23:  Double reciprocal plots of the MenD-catalyzed reaction of CHCD. For reaction conditions, 
refer to section 2.2.12. (A) Double reciprocal plot (1/rate vs. 1/[2-KG]). Concentrations of 2-KG (4 M, 8 
M, 16 M, 32 M, 64 M) varied at each concentration of CHCD (5 M (▲), 10 M (Δ), 20 M (■), 50 
M (□)). (B) Double reciprocal plot (1/rate vs. 1/[CHCD]). Concentrations of 2-KG (4 M (▲), 8 M (Δ), 
16 M (■), 32 M (□), 64 M (+)) varied at each concentration of CHCD (5 M, 10 M, 20 M, 50 M).  
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Furthermore, these plots can also give the real (not apparent) kinetic constants such 
as
mK , maxV  and catk according to equation 2.5. The apparent and real kinetic constants 
for the CHCD-utilizing MenD reaction were summarized in Table 3.2.  
  
Table 3.2: Kinetic constants of the CHCD-utilizing MenD reaction. Noted that (±)-CHCD was used, but 
only half amount of [(±)-CHCD] was used for deriving kinetic constants. 
Substrate 
a
mK  (µM) 
a
maxV   (µM/min) 
a
catk  (min
-1
) mK (µM) maxV (µM/min) catk (min
-1
) 
2-KG 2.8 ± 0.4 0.68 ± 0.03 23 ± 1 3.8 ± 0.2 
0.80 ± 0.02 27 ± 1 
CHCD 12.0 ± 0.6 0.74 ± 0.02 25 ± 1 9.1 ± 0.4 
 
By analogy, the 2-KG phosphonates are assumed to be competitive inhibitors with 
respect to 2-KG when CHCD is utilized as alternative substrate of MenD, given that 
these analogues, in mimicking of 2-KG, compete for the binding site of 2-KG, not ISC. 
From the phosphonates tested for the ISC-utilizing MenD reaction, the most potent 
inhibitor MMSP was chosen to test for this. The Dixon and Cornish-Bowden plots 
(Figure 3.24) demonstrate that MMSP is still a reversible, competitive inhibitor with 
respect to 2-KG, with iK = 1.3 ± 0.1 M, comparable to the iK value determined from the 
ISC-utilizing reaction.  
As discussed above, (+)-CHCD is accepted as an alternative substrate by MenD and 
the apparent Michaelis constant is 12.0 ± 0.6 M. Moreover, the potent inhibitor MMSP 
exhibited reversible, competitive inhibiton with respect to 2-KG in the MenD-catalyzed 
reaction of CHCD (Figure 3.24). These findings enable the use of MMSP as a 
mechanistic probe to investigate the kinetic mechanism of the reaction (refer to Table 
1.1). Plausibly, the MenD-catalyzed reaction of CHCD should share the exact reaction 
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mechanism as the ISC-utilizing reaction. Thus, the results of kinetic mechanism probed 
by MMSP for CHCD-utilizing reaction can be assumed to represent the naturally 
occurring MenD reaction. 
 
-2.0
-1.0
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
-6.0 -4.0 -2.0 0.0 2.0 4.0 6.0 8.0 10.0 12.0
[MMSP] (M)
1
/r
a
te
 (
M
in
/

M
)
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
-6.0 -4.0 -2.0 0.0 2.0 4.0 6.0 8.0 10.0 12.0
[MMSP] (M)
[2
-K
G
]/
ra
te
 (
M
in
)
A
B
 
Figure 3.24: Graphic determination of MMSP inhibition with respect to 2-KG in the MenD-catalyzed 
reaction of CHCD. (A) Dixon plot (1/rate vs. [MMSP]); (B) Cornish-Bowden plot ([2-KG]/rate vs. 
[MMSP]). The reaction rate was determined with 60 nM MenD, 100 mM Tris (pH 7.4), 5 mM MgCl2, 50 
M ThDP and 50 M (+)-CHCD (100M (±)-CHCD). [2-KG] was at 4 M (▲), 8 M (Δ), 16 M (■), 32 
M (□). 
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Figure 3.25: Graphic determination of MMSP inhibition with respect to CHCD in the MenD-catalyzed 
reaction of CHCD. Reaction conditions refer to 2.2.12. (A) Dixon plot (1/rate vs. [MMSP]); (B) Cornish-
Bowden plot ([CHCD]/rate vs. [MMSP]) for MenD reaction with CHCD as substrate. [2-KG] was fixed at 
6 M and [CHCD] was at 3 M (▲), 6 M (Δ), 9 M (■), 18 M (□). 
 
 Following this idea, [2-KG] was fixed at 6 M and [(+)-CHCD] was varied around 
its Michaelis constant, and the MenD reaction was determined kinetically in the presence 
of MMSP. As indicated in Figure 3.24, MMSP was determined graphically as a 
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reversible, competitive inhibitor with respect to 2-KG, while the pattern of Dixon plot 
and Cornish-Bowden plot in Figure 3.25 showed that MMSP is an uncompetitive 
inhibitor (
iuK  = 4.1 ± 0.3 M) with respect to CHCD (refer to section 1.8). Given that 2-
KG was proposed bind first, the results agree with the pattern for ping-pong bi bi 
reaction, as suggested by Segel (Table 1.1)
67
.  
Encouraged from the application of MMSP in probing the kinetic mechanism of 
MenD, it was certainly expected that this compound will gain great attention in studies of 
2-KG-utilizing enzymes, especially ThDP-dependent ones, as widely used as methyl 
acetylphosphonate (MAP). 
In summary, for the first time, the kinetic mechanism of the MenD reaction was 
demonstrated to be ping-pong bi bi, by two different approaches. This conclusion is an 
important step towards elucidation of the MenD reaction mechanism.  
 
3.12 Kinetic analysis of MenD and mutants 
 
In order to investigate catalytically important residues in the active site of MenD, 14 
mutants (S32A, S32D, R33K, R33Q, E55D, R107K, Q118E, K292Q, R293K, S391A, 
R395A, R395K, R413K, and I418L) were designed based on sequence alignment and 
structural analogy between MenD and homologous enzymes. The potential functions of 
these mutants were already briefly reviewed and predicted in section 1.5. Activity assays 
of these mutants and comparison of their kinetic parameters with that of the wild type 
MenD were expected to be informative for elucidation of the interaction between 
substrate, cofactors and active site. 
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At first, the MenD-catalyzed reaction was assayed using ISC as substrate (Table 3.3). 
The amK  of ISC was so small that the measurement of UV absorbance at [ISC] varied 
around amK  became effectively impossible due to the low signal noise ratio, i.e. the 
saturation curve of ISC could not be obtained. Therefore, amK  of ISC was denoted as < 2 
M in Table 3.3. For the same reason, acatk   of ISC was not determined and  
a
m
a
cat Kk /  
was 
denoted as > 9 min
-1
.M-1. 
 
Table 3.3: Kinetic constants of wt-MenD. ND: not determined. 
Enzymes Substrate 
a
mK (M) 
a
catk  
 (Min
-1
) 
a
m
a
cat Kk /  
(Min
-1
.M-1) 
Wt-MenD 
2-KG 9.9 ± 0.6 
17 ± 2 
1.7 ± 0.1 
ThDP 8 ± 1 2.13 ± 0.02 
MgCl2 44.4 ± 0.3 0.38 ± 0.04 
ISC < 2 ND > 9 
(+)-CHCD 12.0 ± 0.6 25 ± 1 2.08 ± 0.02 
 
When (+)-CHCD was used as an alternative substrate for the MenD-catalyzed 
reaction instead of ISC, steady-state kinetics can be readily determined using a 
continuous assay. It was found that the 
a
catk  of the MenD-catalyzed reaction of CHCD is 
higher than that of the ISC-utilizing reaction, but the catalytic specificity 
a
m
a
cat Kk /  is 
appreciably lower.  
All the mutants (S32A, S32D, R33K, R33Q, E55D, R107K, Q118E, K292Q, 
R293K, S391A, R395A, R395K, R413K, and I418L) were assayed using ISC and CHCD 
as wild type MenD. The results and discussion of the kinetics are as follows. 
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3.12.1 Residues interacting with ThDP 
 
Table 3.4: Kinetic constants of I418L, E55D and S391A. ND: not determined. 
Enzymes Substrate 
a
mK (M) 
a
catk  
 (Min
-1
) 
a
m
a
cat Kk /  
(Min
-1
.M-1) 
I418L 
2-KG 200 ± 30 
12.5 ± 0.7 
0.063 ± 0.006 
ThDP 600 ± 100 0.021 ± 0.002 
MgCl2 400 ±  80 0.031 ± 0.005 
ISC < 2 ND > 6 
(+)-CHCD 27 ± 3 23 ± 1 0.85 ± 0.06 
E55D 
2-KG 12 ± 2 
12.8 ± 0.7 
1.1 ± 0.1 
ThDP 24 ± 4 0.53 ± 0.06 
MgCl2 8 ± 2 1.6 ± 0.3 
ISC < 2 ND > 6 
(+)-CHCD 2.5 ± 0.5 22 ± 1 9 ± 1 
S391A 
2-KG
 
13 ± 1 
17.6 ± 0.5 
1.35 ± 0.07 
ThDP 17 ± 1 1.04 ± 0.03 
MgCl2 13 ± 2 1.4 ± 0.2 
ISC < 2 ND > 9 
(+)-CHCD 36 ± 3 12.5 ± 0.5 0.35 ± 0.02 
 
As is well known for ThDP-dependent enzymes, tautomerization and ionization of 
ThDP occurs by a conserved mechanism
18,21
. Enzyme-bound ThDP is commonly 
oriented to the unfavored V-shape conformation with the aid of active site residues so as 
to facilitate proximity of 4'-NH2 and C2-H (Figure 1.12). Frank et al.
36
 reported that 
residue I415 in PDC from S. cerevisiae located under ThDP and substitutions to 
methionine or leucine caused a great reduction in the 
a
catk value. Computational studies 
further indicated the large side chain of I415 reduces the flexibility of ThDP. For this 
purpose, methionine is used in ThDP-dependent POX and leucine is used in 
transketolase. 
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 As shown in Figure 1.11, residue I418 in MenD is located near ThDP with its 
uncharged side chain inserting between the aminopyrimidine ring and the thiazolium 
ring.  It was therefore predicted that I418 in MenD plays the same role as I415 in PDC. 
Therefore, mutant I418L was prepared and assayed (Table 3.4). Changing this isoleucine 
to leucine caused a 20-fold decrease in amK  
of 2-KG, a 10-fold in amK  
of Mg
2+
 and a 75-
fold in 
a
mK  
of ThDP. Unlike the only ca. 3% residual activity observed for PDC I415L
36
, 
MenD I418L exhibited very close activity in both cases of the ISC-utilizing and CHCD-
utilizing MenD reactions when compared to wild type. The observation that catalytic 
specificity of ThDP was lowered up to 100-fold strongly supports that this highly 
conserved residue is important for cofactor binding and activation in MenD, as expected. 
Since I418 was considered an important residue assisting V-conformation of ThDP in 
facilitation of C2-H proton abstraction, kinetic results that 
a
mK  
of CHCD was almost 
unchanged and mutant activity was only slightly reduced imply that ThDP activation or 
aminopyridine proton relay should not be rate-limiting and is independent of binding and 
turnover of the second substrate. In the future, systematic substitution of I418 in MenD, 
for instance, to valine, alanine and glycine, may provide more information to understand 
its role in catalysis. 
Before the solved MenD structure was reported, the glutamate residue (E55) was 
predicted to be important for highly conserved glutamate-aided tautomerization in ThDP-
dependent enzymes
14
. In our lab, E55Q was found to be essentially inactive as assayed by 
SHCHC formation. In the widely accepted mechanism for ThDP activation, it is the 
glutamic acid that interacts with N1' of aminopyrimidine giving rise to abstraction of the 
C2-H proton
37
. Herein, MenD E55D was designed to investigate the function of this 
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residue (Table 3.4). The conservative exchange of glutamate to aspartate that has been 
used for several different ThDP-dependent enzymes is advantageous over activity-
abolishing mutation, as indicated by Tittmann et al., by which the differences of pKa and 
distance may shed light on individual catalytic steps
89
. Unlike the significant reduction of 
catalytic activity observed for IPDC E52D mutant
89
, mutant E55D showed only slightly 
reduced activity, but the catalytic specificity of ThDP is 4-fold smaller. This result 
supports the proposed role of E55 in the activation with ThDP. However, the catalytic 
specificity of Mg
2+
 is also 4-fold smaller, implying that the disturbance of the interaction 
with ThDP also affects the binding of Mg
2+
. Furthermore, it appears that the role of 
residue E55 solely focuses on ThDP binding, since the kinetic constants with respect to 
2-KG, ISC or CHCD are virtually unchanged. 
Although a structural comparison indicated that S391 of MenD is analogous to H260 
of homologous ThDP-dependent 2-KG dehydrogenase E1 subunit from E. coli (KGDH 
E1)
88
, quite different functions were proposed for the two residues. H260 in KGDH E1 
has potential recognition with the distal carboxylate (i.e. 4-carboxylate of 2-KG). In 
contrast, the hydroxyl of S391 in MenD is within hydrogen bonding distance of the 
diphosphate and sulfur atom of ThDP. MenD mutant S391A has activity comparable to 
wild type and the mutation exhibits little influence on kinetic constants (Table 3.4). 
Similar to S32A (discussed below), mutant S391A may also play a structural role 
dependent on the backbone amide, or a water molecule may act to rescue the function of 
the deleted hydroxyl group
88
. 
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3.12.2 Residues interacting with 2-KG-ThDP adduct 
 
Table 3.5: Kinetic constants of S32A, S32D and Q118E. ND: not determined; a, the kinetic parameters 
were derived from Hanes-Woolf equation plot. 
Enzymes Substrate 
a
mK (M) 
a
catk  
 (Min
-1
) 
a
m
a
cat Kk /  
(Min
-1
.M-1) 
S32A 
2-KG 9.92 ± 0.08 
13.6 ± 0.3 
1.37 ± 0.02 
ThDP 4.3 ± 0.3 3.2 ± 0.2 
MgCl2 80 ± 10 0.17 ± 0.02 
ISC < 2 ND > 7 
(+)-CHCD 42 ± 2 14.5 ± 0.5 0.35 ± 0.01 
S32D
 
2-KG ND ND ND 
ThDP ND ND ND 
MgCl2 ND ND ND 
ISC
a
 263 2.5 0.0095 
(+)-CHCD No (or trace) activity 
Q118E No activity 
 
In analogy to S26 in BFDC, S32 in MenD was in our lab predicted as catalytically 
important residue by sequence aligment
41
. Later, the solved structures of BFDC with (R)-
mandelate and methyl benzoylphosphonate (MBP) were published
42,52,53
. Commonly, 
S26 in BFDC was found to form potential hydrogen bonds to the carboxylate anion of 
mandelate and the phosphonate moiety of the ThDP-MBP adduct with its main chain and 
side chains. Notably, benzoylphosphonic acid was proved to covalently modify S26 by 
phosphorylation in BFDC
43
. These studies indicated clearly that S26 is found near the 1-
carboxylate of benzoylformate (the leaving group
87
) in BFDC. The X-ray structure of 
MenD with a 2-KG-ThDP adduct has not been published yet, but S32 in MenD seems to 
occupy a similar position to S26 in BFDC. Therefore, MenD S32A and S32D were 
designed to test the importance of this residue (Table 3.5).  
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S32A showed slightly reduced catalytic activity with almost unchanged catalytic 
specificity with respect to 2-KG, ThDP and Mg
2+
, whereas the catalytic specificity 
towards (+)-CHCD was lowered ca. 6-fold with the Michaelis constant increasing 
approximately 4-fold. The results suggest that the removal of S32 hydroxyl is tolerated in 
MenD, although it affects CHCD binding. The tolerance of a hydrophobic amino acid at 
the S26 position in BFDC was also observed, but to a lesser extent, in extensive 
mutagenesis experiments
90
. Maybe ISC binding is also compromised although steady-
state kinetics failed to demonstrate it due to the extremely small Michaelis constant of 
ISC.  
However, MenD S32D showed significant alteration of kinetic constants when 
compared to wild type MenD. The Michaelis constant of ISC drastically increased to 263 
M from less than 2 M for the wild type MenD so that catalytic specificity towards ISC 
decreased at least 10
4
 times; catalytic activity of this mutant decreased to ca. 15% of wild 
type, while no activity was detected when CHCD was used. For this mutant, because the 
extremely high saturating values of ISC have an absorbance beyond the limit of the 
spectrophotometer, a kinetic assay determining UV absorbance at full range of 
concentrations of ISC could not be conducted experimentally. Therefore, the kinetic 
constants of 2-KG, ThDP and Mg
2+
 were not determined, and the Michaelis constant of 
ISC was estimated by Hanes-Woolf plot (refer to section 1.8). As a result, substitution of 
the neutral hydroxyl group to a carboxylic acid subtantially impaired enzymatic turnover 
of MenD, maybe by sharply weakening the binding affinity of ISC and CHCD.  
The steady-state kinetic analysis of both mutants S32A and S32D showed effects on 
the interaction with ISC or CHCD. This appears very different from the well-accepted 
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assignments of the role of S26 in BFDC, where S26 was found to use its side chain 
hydroxyl and backbone to interact with 1-carboxylate anion of ThDP-subtrate 
adduct
42,43,52,53
. A plausible explanation is that in MenD, S32 plays a role mainly using 
the backbone amide. Due to its proximity to the catalytic center, subtitution of hydroxyl 
with carboxylate essentially interferes with subsequent carboligation between the 
incipient enamine/carbanion and ISC, or carboxylate anion of mutant S32D is structurally 
incompatible with ISC which bears negative charges. 
Q118 in MenD was speculated as the counterpart to H70 in BFDC and Q113 in 
BAL
30,52
. Those two residues were both revealed in X-ray structures to interact with 
C2-OH of ThDP adduct intermediate. In addition, Q113 in BAL participates in 
stabilization of 1-carboxylate of ThDP adduct via a water molecule. Furthermore, Q112 
in POX and H473 in TK are analogous to the residues of BFDC and BAL
87
. The side 
chain of glutamine can be either a hydrogen bond acceptor or donor. It was pointed out 
that the exchangeable properties of thiazolium-proximal glutamine and histidine in the 
context suggest that they are hydrogen bond acceptors rather than acid-base residues
30,91
. 
In the family of 2-keto acid-utilizing ThDP-dependent enzymes, addition of the ThDP 
nucleophilic carbene to the 2-keto group and formation of an enamine/carbanion 
intermediate is the universally conserved mechanism. Therefore, stabilizing the incipient 
addition product is supposed to be critical to subsequent catalytic steps. Unlike residues 
for substrate or cofactor binding as discussed above, Q118 in MenD, similar to its 
counterparts such as histidine in BFDC or TK and glutamine in BAL or POX, is 
predicted to have a large impact on enzymatic activity. It was found that substitution of 
Q118 to glutamate was catastrophic for MenD activity. This supports the proposal that 
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Q118 may play multifaceted roles such as orientation of 2-KG, the tetrahedral 2-KG-
ThDP adduct intermediate and even post-decarboxylation enamine/carbanion. In the 
future, systematic mutagenesis study of this residue, e.g. Q118A and Q118N etc, would 
certainly provide more information for elucidation of this critically important residue. 
 
3.12.3 Residues interacting with ISC  
 
According to the model proposed by Hunter et al. of MenD with bound substrates (2-
KG and ISC) (Figure 1.13), several basic residues (Arg33, Arg107, Lys292, Arg293, 
Arg395 and Arg413) surround the acidic side of ISC, consisting of two carboxylate 
anions and a hydroxyl, while the hydrophobic side of ISC is accommodated by a 
hydrophobic patch created by Ile474, Phe475 and Leu478 (Figure 1.13)
31
. These basic 
residues may also interact with other acidic species such as 2-KG or ThDP. Therefore, in 
order to confirm the model and provide insight into the roles these residues play in active 
site of MenD, mutants R33K, R33Q, R107K, K293Q, R293K, R395A, R395K and 
R413K were prepared and assayed kinetically. In summary, conservative exchanges as 
R33K, R107K and R395K result in significantly larger Michaelis constants of ISC up to 
measurable values (Table 3.6), while K292Q, R293K and R413K show little effect on 
that of ISC and CHCD. Commonly, these mutants exhibit unchanged or slightly reduced 
activity. 
R33 of MenD seems to be a more important residue for binding preference of ISC in 
that mutant R33K and R33Q show trace activity and ca. 10% residual activity by CHCD 
assays, repectively (Table 3.6). In Hunter's model, R33 is predicted to interact with the 
enolpyruvyl chain of ISC, where CHCD possesses a more flexible carboxylmethyl 
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moiety lacking planar conjugation. Presumably R33 participates in orienting the 
enolpyruvyl chain of ISC to facilitate enamine/carbanion's attack to ISC.  
 
Table 3.6: Kinetic constants of R33K, R33Q, R107K, R395A and R395K. ND: not determined; a, the 
kinetic parameters were derived from Hanes-Woolf equation plot; b, EDTA abolished the activity. 
Enzymes Substrate 
a
mK (M) 
a
catk  
 (Min
-1
) 
a
m
a
cat Kk /  
(Min
-1
.M-1) 
R33K 
2-KG ND ND ND 
ThDP ND ND ND 
MgCl2 ND ND ND 
ISC
a
 135 6.3 0.047 
(+)-CHCD No (or trace) activity 
R33Q 
2-KG
 
ND ND ND 
ThDP ND ND ND 
MgCl2 ND ND ND 
ISC
a
 54 7.3 0.14 
(+)-CHCD
a
 434 2.4 0.0055 
R107K 
2-KG
 
5.3 ± 0.9 
10.4 ± 0.4 
2.0 ± 0.3 
ThDP 4.8 ± 0.7 2.2 ± 0.2 
MgCl2 49 ± 8 0.21 ± 0.03 
ISC 7.5 ± 0.5 1.39 ± 0.04 
(+)-CHCD
a
 91 7.1 0.078 
R395A 
2-KG
 
ND ND ND 
ThDP ND ND ND 
MgCl2 ND ND ND 
ISC
a
 36 2.55 0.07 
(+)-CHCD
a
 393 2.4 0.006 
R395K 
2-KG 45 ± 3 
7.9 ± 0.3 
0.18 ± 0.01 
ThDP 2.2 ± 0.2 3.6 ± 0.2 
MgCl2
b
 < 2 > 4 
ISC
a
 5.3 ± 0.9 ND 1.5 ± 0.2 
(+)-CHCD
a
 109 10.9 0.10 
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According to Hunter's model, R395 is in proximity to unsaturated carboxylate and 
hydroxyl of bound ISC. Mutagenesis study of R395 for MenD is similar to that of R33 
(Table 3.6). Nonconservative mutant R395A has relatively lower activity than mutant 
R395K, suggesting that residue R395 has acid-base interaction with ISC. The two 
mutants exhibit greatly increased Michaelis constant with respect to ISC, reminding us 
the potential role that R395 may play in active site of MenD as a residue responsible for 
recognition of ISC, in addition to R33. 
 
Table 3.7: Kinetic constants of K292Q, R293K. ND: not determined; a, the kinetic parameters were derived 
from Hanes-Woolf equation plot; b, EDTA abolished the activity. 
Enzymes Substrate 
a
mK (M) 
a
catk  
 (Min
-1
) 
a
m
a
cat Kk /  
(Min
-1
.M-1) 
K292Q 
2-KG 2.6 ± 0.3 
11.9 ± 0.3 
4.6 ± 0.4 
ThDP 2.0 ± 0.2 6.0 ± 0.4 
MgCl2
b
 2.6 ± 0.7 5 ± 1 
ISC < 2 ND > 6 
(+)-CHCD 50 ± 1 17.2 ± 0.2 0.34 ± 0.01 
R293K 
2-KG 9.1 ± 0.8 
18 ± 1 
1.98 ± 0.06 
ThDP 4.7 ± 0.3 3.83 ± 0.03 
MgCl2 200 ± 100 0.09 ± 0.04 
ISC < 2 ND > 9 
(+)-CHCD 4.2 ± 0.7 24 ± 1 5.7 ± 0.7 
 
Relatively, mutant R107K shows only moderate 
a
mK  
increase for ISC and CHCD 
(Table 3.6). Maybe this is because R107 is not positioned properly to interact with the 
acidic moieties of ISC as R33 and R395 in MenD active site. 
K292 and R293 are more distant from C2 of ThDP (Figure 1.11), so maybe less 
relevant in subtrate binding and catalysis. MenD mutant K292Q and R293K show little 
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effect on activity, but puzzlingly alter Michaelis constants towards Mg
2+
 significantly 
(Table 3.7). In the case of K292Q, an extremely low Michaelis constant of Mg
2+
 was 
observed even with dialyzed mutant enzyme, whereas the Mg
2+
-dependent activity was 
abolished by EDTA. The same phenomenon was also found in the assay of mutant 
R395K. 
 
3.12.4 Residues interacting with 2-KG  
 
Table 3.8: Kinetic constants of R413K. ND: not determined. 
Enzymes Substrate 
a
mK (M) 
a
catk  
 (Min
-1
) 
a
m
a
cat Kk /  
(Min
-1
.M-1) 
R413K 
2-KG 220 ± 40 
6.1 ± 0.3 
0.028 ± 0.004 
ThDP 5 ± 1 1.2 ± 0.2 
MgCl2 10 ± 2 0.61 ± 0.09 
ISC < 2 ND > 3 
(+)-CHCD 10 ± 1 10.0 ± 0.2 1.0 ± 0.1 
 
Interestingly, MenD mutant R413K exhibits an apparent change of the kinetic 
constant of 2-KG exclusively among the basic mutants discussed (Table 3.8). Compared 
with wild type MenD, the Michaelis constant with respect to 2-KG increases 20-fold, 
accompanying a ca. 60-fold reduction of catalytic specificity. This result supports that 
R413 is reponsible for binding to 2-KG or a 2-KG derived intermediate. In Hunter's 
model, R413 seems to be oriented to such a conformation by which its guanidine group is 
able to potentially interact with either 2-KG or ISC. However, binding affinity of CHCD 
(
a
mK ) is same as for wild type MenD, and the
a
mK  of ISC remains very small. Therefore, 
R413 is identified as a residue interacting specifically with 2-KG, and is distinguished 
from other arginines discussed above.  
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Overall, the kinetic study of 14 mutants revealed constructive information for 
assignments of the roles of active site residues. Undoubtedly, X-ray structures of MenD 
with a trapped 2-KG-ThDP adduct intermediate or phosphonate analogue will clarify 
these hypotheses and delineate a more accurate map of active site residues in catalytic 
process. Based on combined knowledge learned from other extensive studies of ThDP-
dependent enzymes and kinetic analysis of MenD mutants herein, a diagram of binding 
mode for bound tetrahedral adduct intermediate and binding pocket of ISC can be 
putatively described as Figure 3.26. 
 
 
Figure 3.26: Proposed diagram of active site of MenD. (A) Binding mode for bound tetrahedral ThDP 
intermediate; (B) binding pocket of ISC.  
 
3.13 A recent report of a mutagenesis study of B. subtilis MenD 
 
On June 18, 2010, an online report (doi:10.1016/j.jmb.2010.06.025) about B. subtilis 
MenD (BsMenD) in the Journal of Molecular Biology appeared. In the paper, the 
medium-resolution X-ray structure of B. subtilis MenD with ThDP and Mn
2+
 was 
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reported, and a mutagenesis study of eight active site residues, such as R32, R106, K299, 
R409, R428, I489, F490 and L493, was performed.  
The sequence alignment of EcMenD and BsMenD demonstrates that, in EcMenD, the 
arginine residues such as R33, R107, R395, R413 are corresponding to R32, R106, R409, 
R428 respectively. It was indicated that, in BsMenD, R409 plays a significant role in 
binding with 2-KG and ISC, and R428 interacts with 2-KG while R32 and R106 are 
critical for the recognition of ISC. This is consistent with our findings for the assignment 
of roles for the four arginine residues in EcMenD. As the K292 in EcMenD, K299 in 
BsMenD showed little influence on the reaction. R293 in EcMenD is not conserved in 
BsMenD and our mutagenesis study showed that this residue has little influence too.  
In our project, the roles of the residues in EcMenD, which are corresponding to I489, 
F490 and L493 in BsMenD, were not explored by mutagenesis study, but it is predicted 
that the conserved I474, F475 and L478 in EcMenD may play the same roles in the 
binding of ISC and the stablization of ThDP. 
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4. CONCLUSIONS 
 
The main goal of this thesis was to elucidate the mechanism of the MenD-catalyzed 
reaction. MenD, a member of the ThDP-dependent enyzme superfamily, catalyzes the 
formation of SEPHCHC from ISC and 2-KG. MenD is currently annotated as SEPHCHC 
synthase after being called SHCHC synthase for many years.  
At first, the steady-state assay method was evaluated by spectrophotometric 
measurement and HPLC analysis. It was proved that the rate isochorismate consumption 
in the MenD-catalyzed reaction can be determined by measuring the UV absorbance 
change at 278 nm or 300 nm. 
Once the assay method was validated, the steady-state kinetic parameters of the 
MenD-catalyzed reaction were determined and other kinetic studies on this enzyme 
became possible. In order to find mechanistic probes to investigate MenD catalysis, 
phosphonate analogues of 2-KG were synthesized. It was found that the succinyl 
phosphonate analogues are potent competitive inhibitors against MenD with varied 
inhibition constants, but 2-hydroxyphosphonate analogues failed to inhibit MenD. 
Racemic CHCD and CHCDMe, the structural analogues of ISC, were synthesized 
and tested for the MenD reaction. (+)-CHCD was found to be the alternative substrate, 
whereas (-)-CHCD is not accepted by MenD and does not inhibit MenD; CCHC was 
isolated and the structure was determined, supporting that the compound is derived from 
CHCD turnover product. CHCDMe was not accepted by MenD. 
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The kinetic mechanism of the MenD-catalyzed reaction was explored by two 
different approaches. The double reciprocal plot of the CHCD-utilizing MenD reaction 
appeared as a parallel set of lines, suggesting a ping pong bi bi mechanism. Alternatively, 
the CHCD-utilizing MenD reaction was probed by phosphonate analogue MMSP. MMSP 
exhibited competitve inhibition with respect to 2-KG ( icK = 1.3 ± 0.1 M) and 
uncompetitve inhibition with respect to CHCD (
iuK  = 4.1 ± 0.3 M). These inhibition 
patterns against 2-KG and CHCD also support the conclusion of ping pong bi bi 
mechanism for the MenD-catalyzed reaction.  
Kinetic parameters of mutants S32A, S32D, R33K, R33Q, E55D, R107K, Q118E, 
K292Q, R293K, S391A, R395A, R395K, R413K, and I418L were determined and 
compared with that of wild type MenD. Ser32 shows influence on the interaction with 
ISC or CHCD, except for the predicted role of interacting with 1-carboxylate of ThDP-2-
KG adduct. Ile418 is apparently involved in assisting formation of V conformation of 
ThDP and Glu55 demonstrates the highly conserved role in the activation of ThDP. 
Ser391 may interact with ThDP via the backbone or a water molecule. Among the basic 
residues such as Arg33, Arg107, Lys292, Arg293, Arg395 and Arg413, Arg33 seems to 
interact with the enolypyruvyl side chain of ISC or CHCD and Arg107 is also relevant in 
the acid-base interaction with ISC or CHCD; Arg395 may mainly interact with the 1-
carboxylate anion of ISC or CHCD, whereas Arg413 is likely to recognize 2-KG. As in 
homologous ThDP-dependent enzymes, the thiazolium-proximal Gln118 plays a very 
important role in stabilizing ThDP-2-KG adduct by interacting with C2-OH. Moreover, 
this catalytically important residue may have other functions in MenD catalysis. 
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Relatively, Lys292 and Arg293 show less influence on ISC binding according to the 
kinetic results. 
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5. FUTURE WORK 
 
The steady-state kinetic assay of the MenD-catalyzed reaction has been established 
and several effective mechanistic probes are available, the future work of this project will 
certainly benefit from these progresses.  
At first, solving X-ray structures of MenD with 2-keto phosphonate analogues or 
ThDP-phosphonate covalent adducts will certainly provide rich information about the 
active site and further help the understanding of structure-function relationship in the 
MenD catalysis. Secondly, the spectroscopic study of ThDP-phosphonate covalent 
adduct, such as by circular dichroism, will enable the investigation of ThDP activation 
and probably all ThDP-related intermediates in the catalytic steps. 
The syntheses of novel substrate analogues and ThDP covalent complexes with 
substrates or analogues may develop useful probes for the MenD-catalyzed reaction. The 
pre-steady-state kinetics and 
1
HNMR detection of active intermediates have not been 
explored and need to be paid attention to. ThDP analogues have been proven to be 
effective mechanistic probe in the studies of the structures and mechanisms for many 
ThDP-dependent enzymes, thus the application of ThDP analogues in the MenD reaction 
will be promising to complement the exploitation of the substrate analogues. 
The results of mutations of some active site residues provide useful guidance for a 
systematic research on the residues of interest or other catalytically important residues in 
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MenD. Moreover, the inhibition studies of 2-KG phosphonate analogues against the 
mutants likely help identify the catalytic roles of certain residues. 
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6. APPENDIX 
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2
9
5
11
6
12
2&3
1HNMR/D2O
 
Appendix 1: 
1
HNMR of the isolated Diels-Alder product of CHCD (refer to Figure 3.3, fraction at 42.2 
min). 
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H-H COSY/D2O
 
Appendix 2: H-H COSY of the isolated Diels-Alder product of CHCD (refer to Figure 3.3, fraction at 42.2 
min). 
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13CNMR/D2O
 
Appendix 3: 
13
CNMR of the isolated Diels-Alder product of CHCD (refer to Figure 3.3, fraction at 42.2 
min). 
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JMOD-13CNMR/D2O
 
Appendix 4: JMOD-
13
CNMR of the isolated Diels-Alder product of CHCD (refer to Figure 3.3, fraction at 
42.2 min). 
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HMQC/D2O
 
Appendix 5: HMQC of of the isolated Diels-Alder product of CHCD (refer to Figure 3.3, fraction at 42.2 
min). 
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HMBC/D2O
 
Appendix 6: HMBC of of the isolated Diels-Alder product of CHCD (refer to Figure 3.3, fraction at 42.2 
min). 
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